

FILE COPY



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification n ⁵ : C12N	A2	(11) International Publication Number: WO 93/17093 (43) International Publication Date: 2 September 1993 (02.09.93)
<p>(21) International Application Number: PCT/FI93/00049</p> <p>(22) International Filing Date: 15 February 1993 (15.02.93)</p> <p>(30) Priority data: 07/836,021 14 February 1992 (14.02.92) US 07/841,997 28 February 1992 (28.02.92) US</p> <p>(71) Applicant (for all designated States except US): OY ALKO AB [FI/FI]; Salmisaarenranta 7, SF-00180 Helsinki (FI).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): LONDESBOROUGH, John [FI/FI]; Jääkärikatu 9 A 15, SF-00100 Helsinki (FI). VUORIO, Outi [FI/FI]; Neulastie 4 D 33, SF-00410 Helsinki (FI).</p>		<p>(74) Agent: SEPPO LAINE KY; Lönnrotinkatu 19 A, SF-00120 Helsinki (FI).</p> <p>(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: INCREASING THE TREHALOSE CONTENT OF ORGANISMS BY TRANSFORMING THEM WITH COMBINATIONS OF THE STRUCTURAL GENES FOR TREHALOSE SYNTHASE</p>		
<p>(57) Abstract</p> <p>Two nucleotide sequences encoding two different polypeptides found in yeast trehalose synthase have been isolated and cloned. A third polypeptide has been isolated from the enzyme and characterized, and a method is provided to isolate and clone the nucleotide sequence encoding this polypeptide. The coding sequences can be inserted into suitable vectors and used to transform host cells. The transformed cells will produce increased amounts of trehalose compared to the untransformed wild types and have increased tolerance to a variety of stresses, in particular to decreased availability of water. The invention may be used to improve the stress tolerance of organisms, to increase the storage life of foodstuffs and to produce trehalose economically on an industrial scale in an organism (e.g. baker's yeast) that is a traditional and safe foodstuff.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

INCREASING THE TREHALOSE CONTENT OF ORGANISMS BY TRANSFORMING THEM WITH COMBINATIONS OF THE STRUCTURAL GENES FOR TREHALOSE SYNTHASE.

5 FIELD OF INVENTION

10 This invention relates to the genetic engineering of the trehalose synthetic pathway of yeasts, such as baker's and distiller's yeasts, and to the transfer of this pathway by genetic engineering to other organisms. In particular, the present invention concerns trehalose synthase, novel genes encoding the trehalose synthase, novel vectors containing the novel genes, and host cells and organisms transformed with the novel vectors. The invention also relates to the production of
15 trehalose and ethanol and to the improvement of the stress resistance of organisms, in particular yeasts and crop plants.

BACKGROUND OF THE INVENTION:

20 It is well known that sugars and other polyhydric compounds stabilize isolated proteins and phospholipid membranes during dehydration, probably by replacing the water molecules that are hydrogen-bonded to these macromolecules [reviewed by Crowe, J.H. et al. (1987) Biochemical Journal 242, 1-10]. Trehalose
25 (α -glucopyranosyl- α -D-glucopyranose) is a dimer of two glucose molecules linked through their reducing groups. Because it has no reducing groups, it does not take part in the Maillard reactions that cause many sugars to damage proteins, and it is one of the most effective known protectants of proteins and
30 biological membranes in vitro.

In nature, trehalose is found at high concentrations in yeasts and other fungi, some bacteria, insects, and some littoral animals, such as the brine shrimp. It is notable that all these
35 organisms are frequently exposed to osmotic and dehydration stress. Accumulation of trehalose in higher plants is rare, but high levels occur in the so-called resurrection plants, such as

the pteridophyte, Selaginella lepidophylla, which can survive extended drought [Quillet, M. and Soulet, M. (1964) Comptes Rendus de l'Academie des Sciences, Paris 259, pp. 635-637; reviewed by Avigad, G. (1982) in Encyclopedia of Plant Research (New Series) 13A, pp. 217-347].

A decreased availability of intracellular water to proteins and membranes is a common feature not only of dehydration and osmotic stress, but also of freezing, in which ice formation withdraws water from inside the cells, and heat stress, which weakens the hydrogen bonds between water and biological macromolecules. In recent years several publications have shown a close connection between the trehalose content of yeast cells, especially of the species Saccharomyces cerevisiae, and their resistance to dehydration and osmotic, freezing and heat stresses. This work has lead to the concept [summarized by Wiemkem, A. (1990) Antonie van Leeuwenhoek 58, 209-217] that, whereas the main storage or reserve carbohydrate in yeast is glycogen, the prime physiological function of trehalose is as a protectant against these and other stresses, including starvation and even poisoning by copper, ethanol and hydrogen peroxide, which all stimulate trehalose accumulation [Attfield, P.V. (1987) Federation of European Biochemical Societies Letters 225, 259-263].

Thus, during growth of Saccharomyces cerevisiae on glucose, glycogen begins to accumulate about one generation before the glucose is exhausted, and begins to be steadily consumed as soon as all external carbon supplies are exhausted. In contrast, accumulation of trehalose (partly at the expense of glycogen) only begins after all the glucose has been consumed, and the trehalose level is then maintained until nearly all the glycogen has been consumed [Lillie, S.A. & Pringle, J.R. (1980) Journal of Bacteriology 143, 1384-1394]. The eventual consumption of trehalose is accompanied by a rapid decrease in the number of viable cells.

When trehalose levels in S. cerevisiae have been manipulated by

varying the growth conditions or administering heat shocks, high positive correlations have been found between the trehalose content of the cells and their resistance to dehydration [Gadd, G. et al. (1987) Federation of European Microbiological Societies Microbiological Letters 48, 249-254], heat stress [Hottiger, T. et al., (1987) Federation of European Biochemical Societies Letters 220, 113-115] and freezing [Gélinas, P. et al. Applied and Environmental Microbiology 55, 2453-2459]. Also, strains of S. cerevisiae and other yeasts selected for resistance to osmotic stress [D'Amore, T. et al. (1991) Journal of Industrial Microbiology 7, 191-196] or high performance in frozen dough fermentation [Oda, Y. (1986) Applied and Environmental Microbiology 52, 941-943] were found to have unusually high trehalose contents. Furthermore, a mutation in the cyclic AMP signaling system of S. cerevisiae that causes constitutive high trehalose levels also causes constitutive thermotolerance, whereas another mutation in this system that prevents the usual rise in trehalose during heat shock also prevents the acquisition of thermotolerance [Hottiger, T. et al., (1989) Federation of European Biochemical Societies Letters 255, 431-434]. Thus, there is much evidence pointing to a connection between trehalose content and stress resistance in yeasts, especially S. cerevisiae. Similar findings have been made for several other fungi [e.g., Neves, M.J., Jorge, J.A., Francois, J.M. & Terenzi, H.F. (1991) Federation of European Biochemical Societies Letters 283, 19-22]. However, a causative relationship has not yet been demonstrated. Further, nearly all conditions that cause increases in the trehalose content of yeast also cause increases in the levels of the so-called heat shock proteins. The 1989 publication of Hottiger and colleagues, cited above, claims that canavanine does not cause an increase in either trehalose levels or thermotolerance, whereas this compound is reported to induce heat shock proteins.

Whether or not there is a causal relation between trehalose content and stress resistance, it has become general practice

in the manufacture of baker's yeast to maximise the trehalose content of the yeast. Various maturation processes have been developed to achieve this aim, and they are of crucial importance in the manufacture of active dried yeast. The details of these processes are often secret, but they are generally empirical regimes in which carbon and nitrogen feeds, aeration and temperature are carefully controlled and selected strains of yeast are used. They demand time and energy inputs during which little increase in cell number occurs. A more rational and controlled process would be of economic benefit.

According to Cabib, E. & Leloir, L.F. [(1957) Journal of Biological Chemistry 231, 259-275], trehalose is synthesized in yeast from uridine diphosphoglucose (UDPG) and glucose-6-phosphate (G6P) by the sequential action of two enzyme activities, trehalose-6-phosphate synthase and trehalose-6-phosphate phosphatase. Londesborough, J. & Vuorio, O. [(1991) Journal of Microbiology 137, 323-330, expressly incorporated herein by reference] have purified from baker's yeast a proteolytically modified protein complex that exhibited both these activities and appeared to contain a short polypeptide chain (57 kDa) and two truncated versions (86 kDa and 93 kDa) of a long polypeptide chain. The intact long chain was estimated to have a mass of at least 115 kDa. It was not disclosed which enzyme activity or activities was associated with which polypeptide, nor indeed whether both polypeptide were essential for either or both enzymatic activities. Anti-sera against both polypeptides were reported, but no amino acid sequences were disclosed.

An earlier patent application [EP 451 896; see Claim 1] has claimed for a transformed yeast "comprising.... one gene encoding....trehalose-6-phosphate synthase". However, no information about the either the gene or the protein it encodes was provided.

Several authors have reported increases in TPS activity in

conditions that lead to accumulation of trehalose by S. cerevisiae, and Schizosaccharomyces pombe both during the approach to stationary phase [Winkler, K., et al. (1991) Federation of European Biochemical Societies Letters 291, 269-272; Francois, J., et al. (1991) Yeast 7, 575-587] and after temperature shift-ups to about 40 °C [De Virgilio, C., et al. (1990) Federation of European Biochemical, Societies Letters 273, 107-110]. Panek and her colleagues [Pānek, A.C., et al. (1987) Current Genetics 11, 459-465] have claimed that TPS activity is increased by dephosphorylation of pre-existing enzyme molecules, i.e., that it is the result of post-translational regulation. This claim has been challenged [Vandercammen, A., et al., (1989) European Journal of Biochemistry 182, 613-620] but continues to be made [Panek, A.D. & Panek, A.C. (1990) Journal of Biotechnology 14, 229-238]. Evidence for or against an increase in the amount of enzyme during trehalose accumulation is conflicting. Inhibitors of mRNA synthesis inhibited trehalose accumulation by S. cerevisiae shifted from 30 to 45 °C [Attfield (1987) loc.cit.], whereas under very similar conditions Winkler et al [(1991) loc.cit.] found that cycloheximide (an inhibitor of protein synthesis) did not prevent the accumulation of trehalose, which, however, occurred without an observable increase in TPS activity. In a lower temperature range (a shift from 23 to 36 °C), trehalose accumulation was accompanied by a three-fold increase in TPS activity, and cycloheximide prevented the increase in TPS [Panek, A.C., et al. (1990) Biochemie 72, 77-79]. In Schizosaccharomyces pombe, [De Virgilio, C., et al. (1991) loc. cit.] temperature shiftup caused a large accumulation of trehalose and increase of TPS which were not prevented by cycloheximide, leading the authors to suggest that in this yeast a post-translational activation occurs. We now disclose that in S. cerevisiae the co-ordinate increases in TPS and TPP activities during exhaustion of glucose are accompanied by an increase in antigenic material recognized by anti-sera to the short and long chains of a purified trehalose synthase. Hence, a method to increase the trehalose content of cells, and

so, their stress tolerance, would be to isolate, clone, and modify the structural genes (hereinafter referred to as TSS1, TSL1, and TSL2) of these polypeptides and cause their expression in yeast or other host cells under the control of suitable promoters. If the expression of these genes could be controlled, then so could the trehalose content of the host cells.

The well known metabolic theory of Kacser & Burns [(1973) Symposium of the Society of Experimental Biology 27, 65-107] teaches that in principle the concentration of any intermediate, such as trehalose, can be increased by increasing the amount of any enzyme synthesizing it or decreasing the amount of any enzyme degrading it, but that the size of the increase may not be significant. The novelty of the present invention lies in the identification and characterization of the particular yeast genes that must be modified to increase the amounts of trehalose synthase and the recognition of the advantages of modifying the synthetic pathway rather than the degradative pathway. These advantages include (i) leaving the highly regulated [see, e.g., Thevelein, J.M. (1988) Experimental Mycology 12, 1-12] degradative pathway intact to avoid the physiological problems likely in yeast that cannot activate this pathway, (ii) the possibility of causing yeast to synthesize trehalose under physiological conditions where wild type yeasts do not (so that blocking the degradative pathway cannot increase the amount of trehalose) and (iii) the important possibility of introducing by these genes a trehalose-synthetic capacity to organisms, such as most higher plants, that naturally lack this capacity.

Expression of the genes for trehalose synthesis in yeast under conditions where trehalase is active will increase the operation of a so-called "futile" cycle, in which glucose is continuously phosphorylated, converted to trehalose and regenerated by hydrolysis of the trehalose, resulting in increased consumption of ATP. This ATP must be regenerated, and

under fermentative conditions this will occur by conversion of sugars into ethanol. Therefore, introduction of TSS1, TSL1 and TSL2 into yeast under the control of promoters active under fermentative conditions is expected to decrease the yield of cell mass on carbon source and increase that of ethanol. The many attempts [e.g., Schaaf et al. (1989) Yeast 5, 285-290] to increase fermentation rates in yeast by increasing the levels of glycolytic enzymes have been unsuccessful. The probable reason is that availability of ADP limits the rate of glycolysis in yeast. Introduction of a futile cycle-ATPase is thus expected to increase this rate. The feasibility of this invention is demonstrated by the finding [Gancedo, J.-M. & Navas, M.A. (1992) Yeast 8 S574] that expression of the gluconeogenic enzymes, fructose biphosphatase and phosphoenolpyruvate carboxykinase under fermentative conditions (so causing two futile cycles) caused a 50 % increase in the fermentation rate of resting yeast. Use of the trehalose futile cycle has the added advantage that the cells must then contain a steady state level of trehalose, which increases their tolerance to osmotic and temperature stress.

The present invention includes transformed strains of distiller's yeast, in which the presence of modified forms of any or all of TSS1, TSL1 and TSL2 results in an increased yield of ethanol from carbohydrate sources.

As well as being used to improve the properties of yeast, especially active dried yeast and yeast for frozen doughs, this invention has other obvious applications. First, by increasing the proportion of trehalose in yeast, the industrial scale production of trehalose from yeast is made more economic. It is particularly advantageous to obtain trehalose from yeast because, since yeast is a traditional and safe food stuff, a minimal purification of the trehalose will often be adequate: preparations of trehalose containing yeast residues could be safely added to food stuffs for human or animal consumption. Trehalose also has medical applications, both as a stabilizer

of diagnostic kits, viruses and other protein material [WO 87/00196] and, potentially, as a source of anti-tumour agents [Ohtsuro et al. (1991) Immunology 74, 497-503]. Trehalose for internal applications in humans would be much more safely
5 obtained from yeast than from a genetically engineered bacterium.

Second, by transferring these genes to higher plants after making suitable modifications obvious to anyone skilled in the art (in general, replacements of adenine/thymine base pairs by
10 guanine/cytosine base pairs as suggested by Perlak et al. [(1991) Proceedings of the National Academy of Sciences of the U.S.A. 88, 3324-3328] and the introduction of suitable promoters, some of which may be tissue-specific, to direct the
15 synthesis of trehalose to frost and drought-sensitive tissues), the resistance of the plants to various stresses, especially frost and dehydration, should be improved. The economic importance of such improvements is potentially enormous, because even small increases in cold-tolerance will lead to
20 large increases in growing season, whereas dehydration resistance can save entire crops in time of drought. Frost and drought resistance in higher plants is usually accompanied by increases in compounds such as proline rather than trehalose [reviewed by Stewart (1989) in "Plants under Stress", pp
25 115-130], but, as mentioned above, resurrection plants accumulate large amounts of trehalose and there seems, a priori, to be no reason why this strategy should not be successful. Therefore, the present invention includes a process to transform crop plants by introducing recombinant forms of
30 the structural genes of yeast trehalose synthase (TSS1, TSL1 and TSL2) so as to increase the trehalose content of some of their tissues compared to those of the parent plant. Such transformed plants can also be economic and safe sources of trehalose. Third, the shelf-life of food products can be
35 increased by adding trehalose to them [WO 89/00012]. A further aspect of the present invention is a novel process for producing trehalose-enriched food products from plants by

causing them to express the structural genes for yeast trehalose synthase in their edible tissues.

SUMMARY OF INVENTION:

5

10

15

20

The present invention provides two isolated genes encoding, respectively a short and a long chain of yeast trehalose synthase and a third gene encoding a 99 kDa polypeptide that occurs in some trehalose synthase preparations and has trehalose-6-phosphatase activity. These genes can be used to transform an organism (such as a yeast, other fungus or higher eukaryote), whereby the transformed organism produces more trehalose synthase resulting in a trehalose content higher than that of the parent organism. The higher trehalose content confers improved stress resistance and storage properties on the transformed organism as compared to the parent organism, and the transformed organism can be used to provide large quantities of trehalose. Thus, a process for producing a crop plant which has increased resistance to water deprivation, heat and cold, comprises transforming the plant by introducing at least one of the novel genes into the plant's tissue.

25

The invention also provides a trehalose synthase which exhibits trehalose-6-phosphate synthase activity activatable by fructose-6-phosphate and also trehalose-6-phosphatase activity.

30

Finally, the invention provides processes for producing trehalose by cultivating a host or an organism which has been transformed with at least one of the novel genes, and processes for producing trehalose enriched food products from plants by introducing at least one of the novel genes and allowing said genes to express the trehalose synthase in the edible tissues of the plant.

BRIEF DESCRIPTION OF FIGURESFig. 1. SDS-PAGE of intact trehalose synthase

5 A 6-13 %T gradient gel was used. Lane 1 contains 8.3 μ g of intact trehalose synthase eluted from the UDPG-Glucuronate-Agarose column with 0.2 M NaCl (#11 of Table 1). Lanes 2, 3 and 4 contain, respectively, 7.7, 12 and 1.0 μ g of enzyme eluted from the column with 0.4 M NaCl containing 10 mM UDPG (#13, #14 and #15 from Table 1). Lane 5 contains about 1 μ g each of molecular mass markers (myosin, β -galactosidase, α -phosphorylase, BSA, ovalbumin, lactate dehydrogenase, triosephosphate-isomerase, myoglobin and cytochrome c). The major polypeptides of intact trehalose synthase are named on the left and the molecular mass calibration, in kDa, is shown on the right.

Fig. 2. SDS-PAGE of immunoprecipitates of wild-type yeast grown on YP/2 % glucose

20 A 9 %T gel was used. Lane 1 contains about 1 μ g each of the molecular mass markers used in Fig 1. Lanes 2, 3 and 4 contain immunoprecipitates from 3.8 mg fresh yeast harvested after 16.1 h (1.2 % residual glucose), 18.1 h (no residual glucose) and 39 h. The molecular mass calibration is shown on the left and the major polypeptides of trehalose synthase and the heavy chain of γ -globulin are shown on the right.

Fig. 3. The promoter and terminator of TSS1 and the amino acid sequence deduced from its ORF.

30 (a) In the promoter and terminator regions, the start ATG and tandem TGA stop codons are double underlined and a TATA box and putative catabolite repression element are underlined. (b) In the amino acid sequence (SEQ ID NO:2), the sequences found in peptides isolated from the short chain of trehalose synthase are underlined.

Fig. 4. The promoter and terminator regions of TSL1 and the amino acid sequence deduced from its ORF.

(a) In the promoter region, the start ATG codon is double underlined and two TATA boxes and six putative heat shock elements are underlined. A putative MIG1 binding site is overlined. In the terminator region, the TAA stop codon is double underlined and a putative transcription termination element is underlined. Lower case letters show the end of the terminator region of the ARGRII gene, which has opposite polarity. (b) In the amino acid sequence (SEQ ID NO:82), sequences found in peptides isolated from (fragments of) the 123 kDa long chain are underlined, and those from peptides liberated from intact trehalose synthase by limited digestion with trypsin are underlined and bold.

Fig. 5. Alignment of the amino acid sequences of the short and long chains of trehalose synthase

The complete short chain sequence (SEQ ID NO:2; the upper sequence) is aligned against residues 320 to 814 of the 123 kDa long chain (SEQ ID NO:4; the lower sequence). 32 gaps are introduced to optimize the alignment. Vertical dashes indicate identical residues. Colons indicate conservative substitutions.

Fig. 6. Important restriction sites in TSS1 and TSL1

The heavy lines indicate open reading frames. The scale bar shows one kb.

Fig. 7. Synthesis of [14 C]-trehalose from [U- 14 C]-glucose 6-phosphate by an extract of wild-type yeast

Reaction mixtures (100 μ l) contained 40 mM HEPES/KOH pH 6.8, 1 mg BSA/ml, 10 mM MgCl₂, 10 mM [U- 14 C]-G6P (736 c.p.m./nmol) and (a) no phosphate or (b) 5 mM K phosphate pH 6,8 and (0) 5 mM UDPG, (●) 2.5 mM ADPG or (□) neither UDPG nor ADPG. Reactions were started by adding 10 μ l (equivalent to 94 μ g fresh yeast)

of a 28,000 g supernatant of stationary phase X2180. Reactions were stopped by transfer to boiling water for 2 min and addition of 1.0 ml of a slurry of AG1-X8 (formate) anion exchange resin [Londesborough & Vuorio (1991) loc. cit.]. The
5 radioactivity in the resin supernatant was measured.

Fig. 8. Western analysis of Kl_g 102 and X2180 yeasts

Growth of the yeasts is described in Example 7. The loads of
10 fresh yeast per lane were: lane 1, 200 µg X2180/2; lanes 2 and 5, 330 µg 2669/1; lanes 3 and 6, 610 µg 2669/2; lanes 4 and 7, 810 µg 2670/1+2; lane 8, 560 µg X2180/1 and lane 9, 280 µg X2180/1. The blot was probed with anti-TPS/P serum at a dilution of 1/30,000. Major bands of trehalose synthase are
15 identified on the right.

Fig. 9. Treatment of truncated trehalose synthase with 1.9 mM NEM

20 Truncated enzyme (0.13 TPS units/ml \approx 43 µg/ml) in 2 mg BSA/ml 50 mM HEPES pH 7.0 containing 67 mM NaCl, 0.2 mM EDTA, 0.17 mM dithiothreitol, 0.17 mM benzamidine and 1.7 mM UDPG was incubated at 24 °C with (closed symbols) or without (open symbols) 1.9 mM NEM. TPS (●,○) and TPP (■,□) activities were
25 measured.

Fig. 10. Autoradiogram of truncated trehalose synthase labelled with [¹⁴C]-NEM and separated by SDS-PAGE

30 Labelling was performed as described in Example 8 for 1.5, 10.5, 63 and 190 min in lanes 1, 2, 3 and 4, respectively. The positions of the (57 kDa) short chain, 93 and 86 kDa long chain fragments and the carrier BSA are indicated.

Fig. 11. Treatment of truncated trehalose synthase with ethyl-labelled NEM.

Truncated enzyme (7.2 TPS units/ml \approx 0.24 mg/ml) in 1 mg BSA/ml
25 mM HEPES pH 7.0 containing 2 mM MgCl₂, 1 mM EDTA and 0.2 M
NaCl was incubated at 23 °C with (solid symbols) or without
(open symbols) 32 μ M ethyl-labelled NEM. TPS (●,○) and TPP
(■,□) activities and the amounts of [¹⁴C]-NEM incorporated into
the 93 (▲), 86 (+) and 57 (X) kDa polypeptides were measured.
0.1 mol NEM incorporated per mol (150 Kg) of enzyme corresponds
to an excess radioactivity of 75 c.p.m. in bands cut from the
gel.

Fig. 12. Stoichiometry of NEM labelling

Residual TPP activity is plotted against the amount of NEM
incorporated to the 93 and 86 kDa fragments of the long chain.
Ring-labelled (●) and ethyl-labelled (○) NEM were used.

Fig. 13. SDS-PAGE analysis of fractions eluted from the
cellulose-phosphate with buffer containing 0.3 % Triton

Lane L contains 47 μ l of the intact trehalose synthase applied
to the column. Lane M contains about 1 μ g each of the molecular
mass markers used in Fig 1. The numbered lanes contain 33 μ l of
selected 1.5 ml fractions eluted from the column. The NaCl
gradient began to appear in fraction 6 and reached 300 mM at
fraction 27. A step to 600 mM NaCl emerged between fractions 36
and 37. Fractions 40 to 42 were eluted with 200 mM K phosphate.
The major bands in the trehalose synthase preparation are
identified on the left. Details are given in Example 9.

Fig. 14. In vitro activation of trehalose synthase by limited
tryptic digestion

Intact trehalose synthase was incubated with (solid symbols)
and without (open symbols) trypsin and its TPS activity

measured in the presence of 5 mM F6P in reaction mixtures containing (○,) no phosphate or (■) 5 mM K phosphate pH 6,8. Details are given in Example 10.

5 Fig. 15. Limited tryptic digestion of intact trehalose synthase

Lane 1 contains the untreated trehalose synthase used in Fig. 15 and lane 2 the same amount of enzyme after 48 min treatment with trypsin. Lane 3 contains molecular mass standards. The
10 major polypeptides of trehalose synthase are identified on the left.

15 Fig. 16. The effect of fructose 6-phosphate on the TPS activity of intact trehalose synthase at different phosphate concentrations

The TPS activity of native trehalose synthase was measured between zero and 10 mM F6P. Other conditions were as in the standard TPS assay with (●) no changes, (○) 1.3 mM K phosphate pH 6.8 added or (■) 4 mM K phosphate pH 6.8 and 0.1 M KCl added
20 and the $MgCl_2$ concentration decreased to 2.5 mM. Activities are shown as percentages of that in the standard assay (i.e., at 5 mM F6P and no phosphate).

25 Fig. 17. Activation of the TPP activities of intact and truncated trehalose synthase by phosphate

TPP activities were measured at 0.5 mM [^{14}C]-trehalose-6-phosphate in assay mixtures containing 50 mM Hepes pH 6.8, 1 mg
30 bovine albumin/ml and the indicated concentrations of K phosphate pH 6.8 and are shown as percentages of the standard TPS activity. Initial rates are shown for the (■) intact and (●) truncated enzyme. Rates during the second five minutes of the accelerating reaction obtained with truncated enzyme are
35 also shown (○).

Fig. 18. Phosphate-dependence of the TPP activity of intact trehalose synthase

The reciprocal of the increase in rate (V_a) caused by the phosphate is plotted against (○) $[\text{phosphate}]^{-2}$ or (●) $[\text{phosphate}]^{-1}$. V_a is shown as a percentage of the standard TPS activity.

Fig. 19. Western analyses of E. coli transformed with TSS1 and TSL1

The gels were loaded with samples of whole homogenates (HOM) equivalent to $300 \pm 12 \mu\text{g}$ fresh cells or 28 000 g supernatants (SUP) equivalent to $340 \pm 25 \mu\text{g}$ fresh cells. The letters above the lanes indicate the cell types: K, control (HB101) cells; L, ALKO3568 (HB101 transformed with TSL1); S, ALKO3566 (HB101 transformed with TSS1). Gel 1 was probed with anti-57K serum (1/20 000) and gel 2 with anti-93K serum (1/20 000). The positions of the 57 kDa short chain and about 60, 36 and 35 kDa fragments of the 123 kDa long chain are shown. Molecular mass standards are labelled in kDas.

Fig. 20. Plasmids containing TSS1 and TSL1

pBluescript containing (a) TSS1 with its own promoter, (b) TSS1 without its promoter and (c) TSL1 with its own promoter are shown.

Fig. 21. Southern analysis of two tss1 disruptants of S.cerevisiae.

ClaI digests of DNA from control yeast (S150-2B; lanes 2, 5 and 9), and two tss1 disruptants, ALKO 3569 (lanes 3, 6 and 10) and ALKO 3570 (lanes 4, 7 and 11) were probed with TSS1 (lanes 2 to 4), LEU2 (lanes 5 to 7) and TSL1 (lanes 9 to 11). Lanes 1 and 8 contain DNA standards

DETAILED DESCRIPTION OF THE INVENTION:

In the following description, trehalose-6-phosphate synthase (TPS) and trehalose-6-phosphate phosphatase (TPP) refer to catalytic activities, not to proteins, unless specifically stated otherwise, whereas trehalose synthase refers to a protein that can convert uridine diphosphoglucose (UDPG) and glucose-6-phosphate (G6P) into trehalose, and also exhibits as partial reactions TPS and TPP activities. TSS1, TSL1, and TSL2 are structural genes that encode, respectively, the short (57 kDa) and the about 130 and 99 kDa long chains of trehalose synthase. It is well known that mutations occur in genes and can cause changes in the amino acid sequence of the encoded polypeptide. Changes can also be introduced by genetic engineering techniques. As used herein, the term TSS1 (or TSL1 or TSL2) gene includes all DNA sequences homologous with the sequences herein disclosed for TSS1 (or TSL1 or TSL2) and encoding polypeptides with the functional or structural properties of the 57 kDa (or about 130 kDa or 99 kDa, respectively) polypeptide. Sequences artificially derived from these genes but still encoding polypeptides with the desired functional or structural properties are also included.

The present inventors previously reported the isolation of a partially degraded protein preparation that contained a short (57 kDa) polypeptide chain and two fragments (86 and 93 kDa) of a long polypeptide chain and possessed both TPS and TPP catalytic activities [Londesborough, J & Vuorio, O. (1991) Journal of General Microbiology 137, 323-330]. The size of the full-length intact long chain, from which both the 86 and 93 kDa fragments were then believed to be derived, and whether one or other polypeptide possessed one or other of the catalytic activities were not known at that time.

The inventors have now isolated an undegraded trehalose synthase that contains the 57 kDa short chain, and two long

chains of about 130 kDa and 99 kDa as its major polypeptides. Traces of other polypeptides are also present that appear to be degradation products of the about 130 and 99 kDa chains. Two genes, TSS1 and TSL1, that encode, respectively, the short and about 130 kDa long chains have been cloned and sequenced.

Because the size of this long chain is now known from its gene to be 123 kDa, it is hereafter called the 123 kDa long chain. TSS1 encodes a polypeptide with a theoretical molecular weight of 56.2 kDa; however, this short chain and the 99 kDa long chain are still called after their apparent molecular weights by SDS-PAGE analysis, the error in such analyses being at least ± 10 kDa at 130 kDa.

The sequences of TSS1 and the polypeptide it encodes are disclosed as SEQ ID NOS:1 and 2, respectively. The sequences of TSL1 and the polypeptide it encodes are disclosed as SEQ ID NOS:83 and 82, respectively (earlier versions of these sequences, lacking the 5'- and N-terminal regions, are listed as SEQ ID NOS:3 and 4). Genetic evidence is disclosed that shows that a functional TSS1 gene is involved in the expression of both TPS and TPP catalytic activities in S. cerevisiae: (1) both activities are absent from a mutant strain (Klg 102) that lacks a properly functional TSS1 gene and does not express the short chain in a form recognizable in Western blots although it does express immunologically recognisable long chain; (2) disruption of TSS1 eliminates TPS and TPP activities, abolishes the short chain signal from Western blots and prevents the accumulation of trehalose, and these defects are simultaneously reversed by transformation with TSS1, which also increased the resistance of the cells to freezing stress; and (3) transformation of Escherichia coli with TSS1 causes a large increase in the TPS activity of the transformants (but no detected increase in their TPP activity).

We disclose biochemical evidence that the TPP catalytic activity of a truncated trehalose synthase requires a functional long chain: incorporation of about 1 mole of

¹⁴C-N-ethylmaleimide into the 93 kDa long chain fragment per mole of truncated trehalose synthase results in complete loss of TPP activity but only a slight loss of TPS activity. Furthermore, we have been able to isolate the 99 kDa polypeptide and show that it possesses residual TPP activity but no TPS activity. Also, intact trehalose synthase is partially resolved into a 99 kDa-enriched form with a relatively high TPP/TPS ratio and a 123 kDa-enriched form with a lower TPP/TPS ratio. However, truncation of the 123 kDa long chain has dramatic and important effects on the TPS activity of trehalose synthase: removal of the N-terminal 330 or so amino acids decreases the sensitivity of the TPS catalytic activity to inhibition by phosphate and almost eliminates its activation by fructose-6-phosphate. Further, transformation of E. coli with TSL1 causes an increase in the TPS activity of the transformants (but no detected increase in their TPP activity).

Thus, both the short and the long chains make essential contributions to both the TPS and the TPP catalytic activities of trehalose synthase. The situation is therefore that there are at least two different structural genes for a trehalose synthase, neither of which can be completely described as the structural gene of either a trehalose-6-phosphate synthase protein or a trehalose-6-phosphate phosphatase protein.

We disclose that the amino acid sequences of peptides isolated from both the 86 and 93 kDa long chain fragments found in the truncated enzyme described by Londesborough & Vuorio [(1991) loc. cit] are encoded by TSL1. Surprisingly, however, none of the peptides isolated from the 99 kDa polypeptide in the intact enzyme is encoded by TSL1. Therefore, the structural genes encoding polypeptides of yeast trehalose synthase include a third member, TSL2. The 99 kDa polypeptide encoded by TSL2 was not visible in SDS-PAGE analyses of truncated enzyme. However, one of the 6 peptides isolated from the 93 kDa fragment was not encoded by TSL1 and had an amino acid sequence also found in a peptide isolated from the 99 kDa polypeptide. Thus, traces of a

degradation product of the 99 kDa polypeptide are present in truncated enzyme, and migrate with the 93 kDa fragment during SDS-PAGE.

5 The inventors have not yet sequenced this third structural gene, TSL2, but disclose information that provides obvious methods for its isolation and cloning by a person ordinarily skilled in the art. Also a clone (pALK7756) comprising at least
10 part of this gene has been deposited (Accession number, DSM 7425; Deutsche Sammlung von Mikroorganismen und Zellkulturen, Mascheroder Weg 1 B, D-3300 Braunschweig)

We disclose that the genes TSS1 and TSL1 contain extensive similarities such that the amino acid sequence of the entire
15 short chain is 37 % identical to residues 495 to 814 of the long chain.

A novel feature of the present invention, therefore, is that in order to increase the capacity of a yeast or some other host
20 organism for trehalose synthesis it can be necessary to increase the expression of both the TSS1 and the TSL1 and TSL2 genes or modify these genes in some other way, not because either TPS or TPP activity is "rate-limiting", but because more than one gene affects each activity. Thus, the results
25 summarised above disclose that both TSS1 and TSL1 affect TPS activity and both TSS1 and TSL2 affect TPP activity. However, these results also disclose that the TSL2 gene product (the 99 kDa polypeptide) isolated by chromatography is itself a trehalose-6-phosphatase whereas the TSS1 gene product expressed
30 in E. coli is a trehalose-6-phosphate synthase, although the catalytic efficiency of these separate polypeptides can be less than when they are correctly assembled in a trehalose synthase complex.

35 A surprising finding was that the TSS1 gene is identical with a gene variously called FDP1 or CIF1. This gene has pleiotropic effects on the utilization of sugars by S. cerevisiae. In

particular, haploid yeast bearing certain alleles of this gene (the so-called *fdp1* and *cif1* mutants) are unable to grow on mannose, or on mannose or sucrose, or on mannose, sucrose or fructose, or on mannose, sucrose, fructose or glucose, depending upon the severity of the defect [Van de Poll & Schamhart, (1977) *Molecular and general Genetics* 154, 61-66; Bañuelos, M. & Fraenkel, D.G. (1982) *Molecular and Cellular Biology* 2, 921-929]. Such mutants grow normally on galactose. Therefore, during the selection of strains in which the TSS1 gene has been deleted or modified it is sometimes essential and always advisable to grow the transformants on galactose, because in many cases the desired transformant will be unable to grow on any other common sugar, including the routinely used glucose. This is an unexpected methodological consideration that would not be obvious even to a person skilled in the art: special knowledge about the sequence and chromosomal location of the TSS1 gene is required, which we now disclose.

Since our disclosure of the identity of TSS1 with FDP1 and CIF1 in USPA 841,997, a confirmation has been published by Bell, W., et al. [(1992) *European Journal of Biochemistry* 209, 951-959]

The inventors' previous work [Londesborough & Vuorio (1991) *loc. cit.*] showed that the TPS catalytic activity of what is now known to be trehalose synthase requires a so-called TPS-Activator protein, which is a dimer of 58 kDa subunits. We have identified this protein by the amino acid sequences of peptides it contains and by its catalytic activity and disclose that it is yeast phosphoglucosomerase. We disclose that fructose-6-phosphate (F6P), which could be made by phosphoglucosomerase from the glucose-6-phosphate (G6P) in the assay mixtures used to measure TPS activity, is a powerful activator of the TPS activity of intact trehalose synthase. Also, when the assay mixture contains an equilibrium mixture of G6P and F6P the TPS-Activator has no further effect, so that its phosphoglucosomerase activity is a complete explanation of the activation it causes. Furthermore, the TPS activity of

truncated trehalose synthase does not require F6P, and is not so strongly inhibited by phosphate as is that of the native enzyme. Thus, a trehalose synthetic pathway can in principle be transferred to any organism by transforming the organism with the structural genes for yeast trehalose synthase: it is not necessary to simultaneously introduce the TPS-activator, because F6P is a ubiquitous component of cells. Furthermore, if the amounts of F6P in an organism are inadequate, or phosphate concentrations are too high, the organism can be transformed with a truncated version of TSL1 encoding the truncated long chain that confers insensitivity to phosphate and F6P. This aspect of the present invention is particularly significant, because it both allows the introduction of a trehalose synthetic pathway to organisms in which the cytosolic phosphate and F6P concentrations would prevent the efficient function of yeast trehalose synthase, and also may permit trehalose synthase to function efficiently at stages of yeast growth when native trehalose synthase would be inhibited by cytosolic phosphate. We disclose that intact trehalose synthase can be liberated from phosphate inhibition by treatment with trypsin in vitro.

From the knowledge gained from the present invention, it is possible to produce trehalose recombinantly by transforming a host cell with the appropriately modified TSS1, TSL1 and TSL2 genes. Methods of transformation and appropriate expression vectors are well-known in the art.

Expression vectors are known in the art for both eukaryotic and prokaryotic systems, and the present invention contemplates use of both systems. For transformation of yeast at least two classes of promoters are contemplated. Yeast that accumulates more trehalose but at the usual time (i.e., after consumption of fermentable carbon sources) can be made by inserting extra copies of the genes under their own promoters, or stronger promoters with similar control. Such yeast can have improved storage properties and stress resistance and be more economic

sources of trehalose. Yeast that synthesizes trehalose during fermentation can be made by replacing the genes' own promoters with promoters (such as ADH1) that are active during fermentation. As explained above, such yeast can have increased fermentation rates, ethanol yields and resistance to osmotic and temperature stress during fermentation.

Also contemplated are modifications of the DNA sequence which would provide "preferred" codons for particular expression systems (e.g., bacteria and higher plants). In addition, the TSS1, TSL1 and TSL2 DNA sequences may be modified by certain deletions or insertions, provided the translated polypeptides are enzymatically functional. Expression of functional polypeptides from TSS1, TSL1 and TSL2 may be confirmed by assaying for TPS and/or TPP activity in the expression system by the methods described in Londesborough and Vuorio [(1991) loc. cit.]. Deletion of the first 330 amino acids or so from the 123 kDa long chain to give an enzyme active at higher phosphate and lower F6P concentrations has already been mentioned.

The genes of the present invention may be transferred and expressed in plants by using the Ti plasmid system which is well known in the art. The internal transforming genes of a cloned T-DNA can be removed by recombinant DNA techniques and replaced by the genes of the present invention and expressed in plant tissues. Commonly, the coding sequence of the foreign gene (for instance, TSL1) is substituted for the coding region of the opine synthetase gene. In this way, the natural promoter and polyadenylation signals of the opine synthetase gene confer high-level expression of the foreign protein. Any method known in the art, however, may be used to transform higher plants with the genes of the present invention.

The following examples are for illustration of the present invention and should not be construed as limiting the present invention in any manner.

EXAMPLESGeneral Methods and Materials.

Materials. Fructose 6-phosphate (F6P) and adenosine 5'-diphosphoglucose (ADPG) were from Sigma Chemicals. Glucose 6-phosphate (G6P), phenylmethylsulphonyl fluoride (PMSF), uridine 5'-diphosphoglucose (UDPG) and other commercial reagents were from the sources stated in Londesborough & Vuorio [(1991) loc. cit.]. Truncated trehalose synthase (proteolytically activated "TPS/P") and TPS activator were prepared as described in Londesborough & Vuorio [(1991) loc. cit.]. The antisera, anti-TPS/P, anti-57K and anti-93K were made in rabbits using as antigen, respectively, truncated trehalose synthase, the short (57 kDa) chain and the 93 kDa fragment of the long chain of trehalose synthase as described in Londesborough & Vuorio [(1991) loc. cit.].

Buffers for enzyme extraction and purification. Two standard cocktails, HBMED (25 mM Hepes/KOH pH 7.0/1 mM benzamidine/1 mM MgCl₂/0.1 mM EDTA/1 mM dithiothreitol) and HB2M1ED (HBMED but with final concentrations of 2 mM MgCl₂ and 1 mM EDTA) were used as basal buffers during preparation of cell extracts and purification of enzyme. Where indicated, the Hepes and benzamidine concentrations were increased to 50 mM and 5 mM, respectively.

Yeasts. Commercial baker's yeast was from Alko's Rajamäki factory. The standard laboratory strains of *S. cerevisiae* used were X2180 (ATCC 26109) and S288C (ATCC 26108). Mutant strains are described in the Examples and Table 1 lists important strains of microorganisms and plasmids. Laboratory yeast were routinely grown on 1 % yeast extract/2% peptone (YP) containing the indicated carbon source in aerobic shake flasks at 30 °C and 200 r.p.m. Cells were harvested by centrifugation for 5 minutes at 3000 g, resuspended in distilled water and again centrifuged 5 minutes at 3000 g. The pellets were suspended in about 20 volumes of HB2M1ED and centrifuged in tared tubes for 10 minutes at 15,000 g. Tubes and pellets were weighed to give

the mass of fresh yeast. For trehalose determinations, portions of the pellets were treated as described by Lillie, S.H. & Pringle, J.R. [(1980) Journal of Bacteriology 143, 1384-1394]. The washed cells were broken by suspending them at 0 °C in 1 to 4 volumes of HB2M1ED, adding fresh stock PMSF/pepstatin (1 mg pepstatin A/ml 0.1 M PMSF in methanol) to give final concentrations of 10 µg pepstatin/ml and 1 mM PMSF, and shaking with glass beads for three 1 minute periods in a Braun MK II homogenizer or (for amounts less than 0.3 g fresh yeast) by vortexing in an Eppendorf tube. The glass beads were removed and the volume of homogenate was measured. Samples for SDS-PAGE were made at once by dilution with Laemmli sample buffer [Laemmli, U.K. (1970) Nature, London 227, 680-685]. The homogenates were then centrifuged as indicated (usually 5 min at 5,000 g or 20 minutes at 28,000 g). Enzyme assays were made on the homogenates and supernatants and protein determined in the supernatants from A280 and A260 measurements.

20 Table 1. List of important strains and plasmids

	<u>Name</u>	<u>Description</u>	<u>Source</u>
	<u>Saccharomyces cerevisiae</u>		
25	X2180 (ATCC 26109)	Standard laboratory yeast (diploid)	-
	S288C (ATCC 26108)	Standard laboratory yeast (haploid)	-
30	Klg 102	cif1-102, leu1, ura1, trp5, MAT α	1
	MV6807	fdp1, leu2, ura3, his3, lys2, ade8, trp1, MAT α	2
35	S150-2B	leu2, his3, trp1, ura3, Mata	-
	ALK03569	tss1::LEU2 (from S150-2B)	This work

ALKO3570 tss1::LEU2 (from S150-2B) This work

WDC-3A cif1::HIS3, his3, ura3, ade2, MAT α 3

5

Escherichia coli

HB101 (ALKO 683)

10 ALKO3566 HB101 containing pALK752 This work

ALKO3568 HB101 containing pALK754 This work

Plasmids

15

pALK751 (DSM 6928) pBluescript containing an 8.2 kb This work
insert comprising TSL1

20

pALK752 pBluescript containing a 2.5kb This work
insert comprising TSS1

pALK753 pBluescript containing a 3.3 kb This work
insert comprising the ORF of TSS1

25

pALK754 pBluescript containing a 4.4 kb This work
insert comprising TSL1

30

pALK756 (DSM 7425) pBluescript containing a 3.5 kb This work
insert comprising at least part
of TSL2

pALK757 pBluescript containing an This work
insert comprising the ORF of TSL1

35

pMB14 YEpl352 containing CIF1 3

Sources: 1. Dr. D. Fraenkel, Harvard Medical School, U.S.A.

2. Dr. J. Thevelein, Lab voor Plantenbioch., Heverlee, Belgium.

5

3. Dr. C. Gancedo, CSIC, Madrid, Spain.

Enzyme Assays. TPP and TPS standard assays and other kinetic measurements were made as described by Londesborough & Vuorio [(1991) loc. cit.] except that the standard TPS assay mixture contained 5 mM F6P unless stated otherwise. Where appropriate, TPS assays were corrected by measuring UDP production from UDPG in the absence of G6P and F6P.

15 DNA manipulations. Stratagene's (La Jolla, California) Escherichia coli strain XL-1 Blue {recA1, endA1, gyrA96, thi, hsdR17, supE44, relA1, lac, [F' proAB, lacIq ADM15, Tn10 (tetR)]} were used as host bacteria. When needed, XL-1 Blue cells were made competent by the method of Mandel & Higa (1970) Journal of Molecular Biology 53, 159-162]. The cloning vector was Stratagene's Lambda Zap II, predigested with EcoRI, where the cloning site is near the N-terminus of the gene for β -galactosidase, thus enabling the color selection of recombinant clones. The sequencing vectors M13mpl8 and M13mpl9 from Pharmacia LKB Biotechnology were also used.

High molecular mass DNA from the haploid S288C strain was prepared as described Johnston, J.R. [(1988) in Yeast, A Practical Approach, IRL Press, Oxford] and partially digested with either HaeIII or EcoRI restriction enzyme. For the large scale HaeIII digestion, e.g., a reaction mixture of 330 μ l containing 30 μ g of DNA and 4.8 U of enzyme was incubated at 37 °C for 60 minutes. The reaction was stopped with 10 μ l of 0.5 M EDTA and transferred to ice. The methods for such digestions and their agarose gel electrophoretic analysis are well known in the art and are described, e.g., in Sambrook et al., Molecular Cloning, A Laboratory Manual [Cold Spring Harbor

Laboratory Press, 2nd ed., (1989)].

Plasmid DNA was isolated using standard methods for small scale purification Sambrook et al. [(1989) Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, hereby expressly incorporated by reference]. Large scale purifications of plasmid DNA were done with Qiagen tip-100 columns from Diagen following their instructions.

DNA sequences were determined either manually by the dideoxy-chain termination method [Sanger et al. (1977) Proceedings of the National Academy of Sciences U.S.A. 74, 5463-5467], sequencing directly from pBluescript plasmids, or automatically with the Applied Biosystems Model 373A automatic DNA sequencer, sequencing either directly from these plasmids or from M13 subclones.

Southern and Western hybridizations and other standard manipulations were carried out by well known procedures [see, e.g., Sambrook et al. (1989) loc. cit.].

Example 1. Purification of intact trehalose synthase

Intact trehalose synthase was purified from commercial baker's yeast. The method described by Londesborough & Vuorio [(1991) loc. cit.] for purification of "proteolytically activated TPS/P" was modified as follows:

1. All buffers contained 2 mM $MgCl_2$ and 1 mM EDTA. This increased yields in the early steps and probably helped to decrease proteolysis in the later steps.
2. In the first ammonium sulphate fractionation, the EDTA concentration was increased to 2.5 mM before addition of ammonium sulphate.
3. All buffers were adjusted to between 0.4 and 1 mM PMSF and

between 4 and 10 μ g pepstatin A/ml by addition, immediately before use, of the appropriate amount of a freshly prepared stock solution containing 1 mg pepstatin A/ml 0.1 M PMSF in methanol (called, stock PMSF/pepstatin). When, as in
5 chromatography, buffers were used for several hours, more stock PMSF/pepstatin was added at intervals, but so as not to exceed 1.5 % methanol in the buffer, or a fresh lot of buffer was taken into use, because of the short half-life of PMSF in
10 aqueous solution. All columns were equilibrated with at least one bed volume of buffer containing PMSF and pepstatin A immediately before application of enzyme.

4. Experience permitted the enzyme-containing fractions (a total of 17.8 ml in the preparation of Table 2) from
15 Heparin-Sepharose to be identified as soon as they were eluted. Stock PMSF/pepstatin (150 μ l) and 0.1 M EDTA (200 μ l) were immediately added to them. Then 7.2 g of powdered ammonium sulphate was slowly added (over 20 min). After 30 min equilibration, the mixture was centrifuged 15 min at 28,000 g.
20 The pellets were packed for 5 min at 28,000 g and expressed buffer was removed with a pasteur pipette. The pellets were dissolved to 2.0 ml in HB2M1ED containing 0.8 mM PMSF and 8 μ g pepstatin A/ml, centrifuged 5 min at 28,000 g and applied to a 2.6 x 34 cm column of Sepharose 6B freshly equilibrated with
25 HB2M1ED containing 50 mM NaCl, 0.4 mM PMSF and 4 μ g pepstatin A/ml. The interval between elution from Heparin-Sepharose and application to Sepharose 6B was 5 h. In the Londesborough & Vuorio [(1991) loc. cit.] procedure, the Heparin-Sepharose eluates were stored at about 3 °C, without addition of PMSF or
30 pepstatin A, for 5 days before the second ammonium sulphate fractionation and application to Sepharose 6B.

5. Fractions (3.7 ml) from the Sepharose 6B column were
immediately mixed with 20 μ l of stock PMSF/pepstatin and then
35 assayed. Again, experience permitted the correct fractions to be pooled, based on activity and A280 measurements without SDS-PAGE analysis, and immediately applied to a 0.7 x 7 cm

column of UDP-Glucuronate-Agarose equilibrated with HB2M1ED containing 50 mM NaCl, 0.4 mM PMSF and 4 μ g pepstatin A/ml. The enzyme was eluted as described by Londesborough & Vuorio [(1991) loc. cit.] and 10 μ l of stock PMSF/pepstatin added to each 1.7 ml fraction. Each fraction was divided into three. Two portions were stored at -70 °C and one at 0 °C.

Table 2 summarizes a purification and Fig. 1 shows the SDS-PAGE analysis of fractions eluted from UDP-Glucuronate-Agarose. No obvious differences were apparent between enzyme eluted by 0.2 M NaCl and that eluted by 10 mM UDPG/0.4 M NaCl. The major bands present had molecular masses of 57, 99 and 123 kDa. Several weaker bands were present between the 123 kDa band and about 90 kDa. In Western analyses the 123 kDa, 99 kDa and most, if not all, of the fainter bands in this region were recognized by the anti-TPS/P and anti-93K sera. This suggests that the fainter bands are partially degraded long chains. The weak bands at 68 kDa also reacted with the anti-93K serum, but could be removed by chromatography on DEAE-cellulose (see Example 9). When the antibodies from anti-93K serum that bound to the 99 kDa band were eluted from a nitrocellulose blot [as described by Pringle, J.R. (1991) *Methods in Enzymology* 194, 565-590] and used to probe another blot, they bound also to the 123 kDa band, showing that the two long chains of trehalose synthase have epitopes in common.

Intact enzyme binds less tightly to the UDP-Glucuronate-Agarose than the truncated enzyme purified by Londesborough & Vuorio [(1991) loc. cit.] and the proportion of enzyme remaining bound at 0.2 M NaCl varied from preparation to preparation. When #9 of Table 2 was re-run on the same column, 76 % of the TPS activity was again recovered at 0.2 M NaCl (and 25 % by 0.4 M NaCl/10 mM UDPG), so that overloading of the column is not the reason why this enzyme eluted at 0.2 M NaCl. However, when enzyme eluted at 0.2 M NaCl was truncated with trypsin as described in Example 10, it then bound to the column at 0.2 M NaCl and was only recovered at 0.4 M NaCl/10 mM UDPG. Thus, as

well as altering the kinetic properties of the enzyme (see Examples 10 & 12), this truncation also increases the affinity for UDP-Glucuronate-Agarose. Presumably there are subtle differences in factors such as the amount of adventitious proteolysis and state of aggregation between enzyme eluted at 0.2 M NaCl and that remaining bound. For the preparation summarised in Table 2, the ratio of standard TPP and standard TPS activities increased from 22 % in #9 to 39 % in #14, showing that there are differences, even though they could not be clearly detected by SDS-PAGE.

These findings disclose that a highly purified trehalose synthase containing a 57 kDa short chain, a 123 kDa long chain and a 99 kDa polypeptide that is recognised by the anti-93K serum possesses both TPS activity activatable by TPSActivator protein (or F6P) and TPP activity. The rate of hydrolysis of 1 mM G6P in either phosphate or Hepes buffer was less than 1 % of that of 0.5 mM trehalose-6-phosphate, so that the TPP activity is highly specific. An unexpected finding is that this highly purified preparation contains the 99 kDa polypeptide, which is not present in the purified truncated trehalose synthase. It is disclosed later that this polypeptide is not a degradation product of the long (123 kDa) chain, whereas both the 86 and 93 kDa polypeptides of truncated enzyme contain amino acid sequences that identify them as fragments of the long (123 kDa) chain. This novel preparation possesses some unexpected catalytic properties, which are described in more detail in Example 11.

Table 2. Purification of intact trehalose synthase

The preparation is from 60 g of pressed baker's yeast. TPS activities "Without Activator" were measured as described by Londesborough & Vuorio [(1991) loc. cit.], i.e., in the absence of F6P. Assays "With Activator" were determined similarly but in the presence of a saturating amount of pure TPS activator (similar values were obtained when some fractions were later

assayed in the presence of 5 mM F6P instead of TPS activator, and are shown in parentheses). ND, not determined.

Fraction	Volume (ml)	Without Activator			With Activator		
		U/ml	U/mg	Total U	U/ml	U/mg	Total U
1st. (NH ₄) ₂ SO ₄ Precipitate	13.4	58	1.0	810	ND	ND	ND ^b
G25 eluate	22.2	30	1.1	668	ND	ND	ND
Heparin-Sepharose eluate	18.2	ND	ND	ND	≈21	≈11	≈380
Sepharose 6B eluate	26	1.4	5.1	36	4.7	17	121
UDP-glucuronate agarose eluates:							
at 0.2 M NaCl							
# 9	1.7	4.6	3.1	-	11.5 (12)	12	
# 10	1.7	ND	ND	ND	12.2	21	
# 11	1.7	ND	ND	ND	6.3	23	58
# 12	1.7	ND	ND	ND	3.9 (3.3)	22	
at 0.4 M NaCl/10 mM UDPG							
# 13	1.7	2.1	-	-	5.9 (6.2)	25-30 ^a	
# 14	1.7	3.7	-	-	9.3	25-30 ^a	
# 15	1.7	ND	-	-	0.8	-	

^a Based on protein contents estimated from Coomassie blue-stained SDS-PAGE gels

^b Results from other preparations show that the activity with excess TPS-activator (or 5 mM F6P) is not, at this step, more than 10 % greater than that without activator.

Example 2 Increased expression by *S. cerevisiae* of the long and short chains of trehalose synthase after consumption of glucose

Three 500 ml lots of YP/2 % glucose in 1 l shake flasks were each inoculated with 1 ml of a suspension of X2180 cells of A600 1.0 and shaken at 200 r.p.m. at 30 °C. At the times shown in Table 3, the cells were harvested, broken and analyzed as described in General Materials and Methods. The 28,000 g supernatants were stored for a week at -18 °C, thawed and re-centrifuged for 20 min at 28,000 g. Portions of 150 µl (each equivalent to 53 mg of fresh yeast) were mixed with 30 µl of anti-TPS/P serum, equilibrated for 30 min at 0 °C and centrifuged for 10 min at 10,000 g. The pellets were washed with 250 µl of HBMED and then dissolved in Laemmli sample buffer and subjected to SDS-PAGE (Fig 2). Bands at 57, 99 and

123 kDa were strong in the sample (C) from stationary phase yeast and in the sample (B) harvested immediately after disappearance of glucose from the medium, but were absent or very weak in the sample (A) from yeast growing in the presence of 1.2 % glucose.

Table 3. Appearance of TPS and TPP activities in X2180 yeast grown on YP/2 % glucose.

Enzymes were assayed in the 28,000 g supernatants.

	A	B	C
Age (h)	16.1	18.1	39.0
Residual glucose (g/100 ml medium)	1.2	≤0.001	≤0.001
Fresh yeast mass (mg/ml medium)	7.6	14.8	29.5
Trehalose (mg/g dry yeast)	0.73	3.1	94
TPS (U/g fresh yeast)	1.2	7.4	10.5
TPP (U/g fresh yeast)	0.29	2.2	3.0
TPP/TPS (%)	24	30	29

Control experiments (not shown) indicated that pre-immune serum did not precipitate the 57, 99 and 123 kDa bands, and that using 50 µl of serum instead of 30 µl did not precipitate more of these three bands from the C sample.

These results disclose that the co-ordinate, 7-fold increase in TPS and TPP activities that occurs during less than 2 h when glucose disappears from the medium is accompanied by increases in the amounts in yeast of three polypeptides, of mass 57, 99 and 123 kDa, that are immunoprecipitated by anti-TPS/P serum. These polypeptides are those found in the intact trehalose synthase purified in Example 1. Thus, increase in the amount of enzyme protein is a major mechanism by which the capacity of yeast to synthesize trehalose is increased.

Example 3 Determination of the N-terminal amino acid sequences of peptides isolated from the various polypeptides of trehalose synthase

5 The 57, 86 and 93 kDa polypeptides of the truncated trehalose
synthase were separated by SDS-PAGE, digested on nitro-
cellulose blots and fractionated by HPLC as described by
Londesborough & Vuorio [(1991) loc. cit.]. Also, these
10 polypeptides and polypeptides of molecular mass 57, 99 and 123
kDa immunoprecipitated from yeast extracts as described in
Example 2 were separated by SDS-PAGE and digested in the gel
with lysylendopeptidase C as described by Kawasaki, H., Emori,
Y. and Suzuki, K. (in press). The derived peptides were
15 separated by HPLC using a DEAE pre-column before the reverse-
phase column essentially as described by Kawasaki et al [(1990)
Analytical Biochemistry 186, 264-268]. The 99 kDa polypeptide
isolated by chromatography on phosphocellulose in the absence
of triton (see Example 9) was digested with lysylendopeptidase
C and the peptides separated by HPLC. In all cases, isolated
20 peptides were sequenced in a gas-pulsed liquid phase sequencer
as described by Kalkinen, N. & Tilgman, C [(1988) Journal of
Protein Chemistry 7, 242-243], the released PTH-amino acids
being analysed by on-line, narrow-bore, reverse-phase HPLC. The
sequences are shown in Table 4.

25

Table 4. N-terminal amino acid sequences of peptides isolated from (fragments of) the polypeptides of trehalose synthase.

30 When two sequences were obtained from the same HPLC peak, they
are shown as a and b sequences, where possible according to the
sequences predicted from the genes. Tentative identifications
from the amino acid sequencer are shown by the one letter codes
followed by double queries. Unidentified residues are shown by
Xaa. (In the Sequence Listings, also tentatively identified
35 residues are indicated as Xaa). The location of each amino acid
sequence in the short (S) and long (123 kDa) (L) chains of Figs
3b and 4b is shown below the sequence.

Short (57) chain peptidesTryptic peptides from blots of the 57 kDa polypeptide from truncated trehalose synthase.

- 5
- 848 Tyr-Ile-Ser-Lys
(SEQ ID NO:5) (S 463-66)
- 10
- 850 Asp-Val-Glu-Glu-Tyr-Gln-Tyr-Leu-Arg
(SEQ ID NO:6) (S 333-41)
- 859 His-Phe-Leu-Ser-Ser-Val-Gln-Arg
(SEQ ID NO:7) (S 223-30)
- 15
- 862a Val-Leu-Asn-Val-Asn-Thr-Leu-Pro-Asn-Gly-Val-Glu-
Tyr-Gln
(SEQ ID NO:8) (S 231-44)
- 20
- 862b Ser-Val-Val-Asn-Glu-Leu-Val-Gly-Arg
(SEQ ID NO:9) (S 342-50)
- 863 Leu-Tyr-Lys
(S 460-2)
- 25
- 864 Glu-Thr-Phe-Lys
(SEQ ID NO:10) (S 280-3)
- 866 Leu-Asp-Tyr-Ile-Lys
(SEQ ID NO:11) (S 294-8)
- 30
- 870 Ile-Leu-Pro-Val-Arg
(SEQ ID NO:12) (S 196-200)

From lysylendopeptidase C digests of immunoprecipitated 57 kDa band

5	966a	Glu-Val-Asn-Xaa-Glu-Lys (SEQ ID NO:13) (S 454-9)
	966b	Phe-Tyr-Asp-Xaa-L?? (SEQ ID NO:14) (not found)
10	980	Leu-Xaa-Ala-Met-Glu-Val-Phe-Leu-Asn-Glu-Xaa-Pro-Glu (SEQ ID NO:15) (S 304-16)
15	981	Tyr-Thr-Ser-Ala-Phe-Trp-Gly-Glu-Asn-Phe-Val-Xaa-Glu-Leu (SEQ ID NO:16) (S 467-80)
	987	Phe-Gly-Xaa-Pro-Gly-Leu-Glu-Ile-Pro. (SEQ ID NO:17) (S 63-71)

20

Long (123 kDa) chain peptides

Tryptic peptides from blots of the 86 and 93 kDa fragments.

25	889	D??-Gly-Ser-Val-Met-Gln (SEQ ID NO:18) (L 587-592)
	890/891	Leu-Pro-Gly-Ser-Tyr-Tyr-Lys (SEQ ID NO:19) (L 917-23)
30	892a	Ala-Ile-Val-Val-Asn-Pro-Met-Asp-Ser-Val-Ala (SEQ ID NO:20) (see peptide 1299)
35	892b	Met-Ile-Ser-Ile-Leu (SEQ ID NO:21) (L 842-7)

From lysylendopeptidase digest of combined 86 and 93 kDa fragments.

5 1171 Arg-Arg-Pro-Gln-Trp-Lys
 (SEQ ID NO:22) (L 770-5)

From lysylendopeptidase digest of the 86 kDa fragment.

10 1479 Thr-Leu-Met-Glu-Asp-Tyr-Gln-Ser-Ser-Lys
 (SEQ ID NO:52) (L 816-26)

1483a Ala-Phe-Glu-Asp-His-Ser-Trp-Lys
 (SEQ ID NO:78) (L 445-52)

15 1483b Ala-Gly-His-Ala-Ile-Val-Tyr-Gly-Asp-Ala-Thr-Ser-Thr-
 Tyr-Ala-Lys
 (SEQ ID NO:79) (L 1064-79)

20 1481 Glu-Arg-Leu-Pro-Gly-Ser-Tyr-Tyr-Lys
 (SEQ ID NO 80) (L 914-23)

From lysylendopeptidase digest of the 93 kDa fragment.

25 1480 Thr-Leu-Met-Glu-Asp-Tyr-Gln
 (SEQ ID NO:81) (L 816-23)

1484a Ala-Phe-Glu-Asp-His-Ser-Trp-Lys
 (SEQ ID NO:78) (L 445-52)

30 1484b Ala-Gly-His-Ala-Ile-Val-Tyr-Gly-Asp-Ala-Thr-Ser-
 Thr-Tyr-Ala-Lys
 (SEQ ID NO:79) (L 1064-79)

35 1485 Glu-Arg-Leu-Pro-Gly-Ser-Tyr-Tyr-Lys
 (SEQ ID NO:80) (L 914-23)

From lysylendopeptidase digests of immunoprecipitated 124 kDa band

5	1047	Ser-D??-Pro-Gln-Lys (SEQ ID NO:23) (not found)
	1048	Phe-Tyr-Arg-Asn-Leu-Asn-Gln-Arg-Phe-Ala-Asp-Ala-Ile-Val-Lys (SEQ ID NO:24) (L 453-67)
10	1054a	Asp-Gly-Ser-Val-Met-Gln-W??-Xaa-Gln-Leu-I?? (SEQ ID NO:25) (L 587-97)
15	1054b	Asn-Ala-Ile-Asn-Thr-Ala-Val-Leu-Glu-Asn-Ile-Ile-Pro-H??-Xaa-H??-Val-Lys (SEQ ID NO:26) (L 360-77)
	1061	Leu-Val-Asn-Asp-Glu-Ala-Ser-Glu-Gly-Gln-Val-Lys (SEQ ID NO:27) (L 1052-63)
20	1063	V??-Gln-Asp-Ile-Leu-Leu-Asn-Asn-Thr-Phe-N?? (SEQ ID NO:28) (not found)
25	1375	Phe-Leu-Val-Glu-Asn-Pro-Glu-Tyr-Val-Glu-Lys (SEQ ID NO:50) (L 629-39)
	1376	R??-Ile-Thr-Pro-His-Leu-Thr-Ala-Xaa-Ala-Ala (SEQ ID NO:51) (L 245-55)
30	1377	Thr-Leu-Met-Glu-Asp-Tyr-Gln-Ser-Ser-Lys (SEQ ID NO:52) (L 816-26)
35	1378-I	Ile-Leu-Glu-Gly-Leu-Thr-Gly-Ala-Asp-Phe-Val-Gly-Phe-Gln-Thr (SEQ ID NO:53) (L 521-35)

- 1378-II Gln-Ile-Leu-Xaa-Pro-Thr-Leu-Xaa-Tyr-Gln-Ile-Pro-
Asp-Asn
(SEQ ID NO:54) (L 427-40)
- 5 1380 Phe-Gly-Gly-Tyr-Ser-Asn-Lys
(SEQ ID NO:55) (L 319-25)
- 10 1381 Phe-Xaa-Thr-Glu-Asn-Ala-Glu-Asp-Gln-Asp-Xaa-Val-
Ala-Xaa-Val-Ile-Gly-G??-Ala-Ile-Xaa-Xaa-Ile
(SEQ ID NO:56) (L 931-53)
- 15 1382 Xaa-Val-Gly-Thr-Val-Gly-Ile-Pro-Thr-Asp-Glu-Ile-
Pro-Glu-Asn-Ile-Leu-Ala
(SEQ ID NO:57) (L 378-95)
- The 99 kDa polypeptide
- From lysylendopeptidase digests of immunoprecipitated 99 kDa
band
- 20 959 Asp-Thr-Thr-Gln-Thr-Ala-Pro-Val-T??-Asn-Asn-Val-
Xaa-Pro
(SEQ ID NO:29)
- 25 961 Asn-Gln-Leu-Asp-Ala-A??-Asn-Tyr-Ala-Glu-Val
(SEQ ID NO:30)
- 30 1002a Asn-Leu-Ser-Arg-Trp-Arg-Asn-Tyr-Ala-Glu
(SEQ ID NO:31)
- 1002b Trp-Gln-Gly-Lys
(SEQ ID NO:32)
- 35 1043 Ile-Gln-Leu-Gly-Glu-Ser-Asn-Asp-Asp-D??-L??
(SEQ ID NO:33)

- 1055 Glu-Val-Pro-Thr-Ile-Gln-Asp-Xaa-Thr-Asn-Lys
(SEQ ID NO:34)
- 5 1287 Xaa-Tyr-Xaa-Tyr-Val-Lys
(SEQ ID NO:35)
- 1297a Asn-Gln-Leu-Gly-Asn-Tyr
(SEQ ID NO:36)
-
- 10 1297b Val-Ala-Leu-Thr
(SEQ ID NO:37)
- 1299 Asp-Ala-Ile-Val-Val-Asn-Pro-Xaa-Asp-Ser-Val-Ala
(SEQ ID NO:38)
- 15 1306 Ser-Leu-Leu-Asp-Ala-Gly-Ala-Lys
(SEQ ID NO:44)
- 20 1307a Glu-Lys-Pro-Gln-Asp-Leu-Asp-Asp-Asp-Pro-Leu-Tyr-
Leu-Thr
(SEQ ID NO:45)
- 25 1307b D??-Gln-Xaa-His-Gln-Asp-Xaa-Xaa-Asn-Leu-Thr
(SEQ ID NO:46)
- 1308 Phe-Asn-Asp-Glu-Ser-Ile-Ile-Ile-Gly-Tyr-Phe-P??-
Xaa-Ala-Pro
(SEQ ID NO:47)
- 30 1309 Ser-Arg-Leu-Phe-Leu-Phe-Asp-Tyr-Asp-Gly-Thr-Leu-
Thr-Pro
(SEQ ID NO:48)

From lysylendopeptidase digest of 99 kDa protein purified on phosphocellulose

1451 Gln-Leu-Gly-Asn-Tyr-Gly-Phe-Tyr-Pro-Val-Tyr
5 (SEQ ID NO:49)

10 Apart from peptide 966b, all the amino acid sequences
determined from the short chain samples have been located in
the protein sequence deduced from the TSS1 gene (see Figure
3b). Apart from peptides 892a, 1047 and 1063, all the amino
acid sequences determined from the 86 and 93 kDa fragments of
15 the long chain and from the intact 123 kDa long chain itself
have been located in the protein sequence deduced from TSL1.
The HPLC profiles obtained from digests of the 86 kDa fragment
were essentially identical with those from digests of the 93
kDa fragment when either trypsin or lysylendopeptidase C was
20 used (not shown). Also, corresponding HPLC peaks from 86 and 93
kDa digests yielded the same sequences or double sequences
(peptide pairs 890 & 891; 1479 & 1480; 1483a,b & 1484a,b; 1481
& 1485). These results disclose that both the 86 and 93 kDa
polypeptides in truncated enzyme are derived from the 123 kDa
long chain encoded by TSL1. In particular, it is not the case
25 that one or other of these fragments is derived from the 99 kDa
polypeptide, although contamination with minor amounts of
(degradation products of) that polypeptide is probable (see
below).

30 None of the 16 amino acid sequences obtained from the 99 kDa
polypeptide is encoded by TSL1. The first 5 residues of peptide
1451 from the 99 kDa polypeptide purified on phosphocellulose
are identical with the last 5 residues of peptide 1297a from
immunoprecipitated 99 kDa polypeptide. This confirms that the
35 99 kDa polypeptide immunoprecipitated by anti-TPS/P serum from
yeast extracts is the same as the 99 kDa polypeptide in
purified intact enzyme. These results disclose that the 99 kDa

polypeptide is not encoded by TSL1 (or TSS1) but by another gene, which the inventors call TSL2.

The origin of peptides 1047 and 1067 found in the digest of the intact (123 kDa) long chain is not known. The only peptide from the long chain fragments of truncated enzyme not encoded by TSL1 is 892a from the 93 kDa fragment. This is identical with the last 11 residues of peptide 1299 from the 99 kDa

polypeptide. This suggests that the 93 kDa band was contaminated with some material derived from the 99 kDa polypeptide, although this polypeptide itself was not visible in SDS-PAGE analyses of the truncated enzyme. The identical HPLC profiles of digests of the 86 and 93 kDa fragments and the fact that only one peptide derived from the 99 kDa polypeptide was identified in these digests shows that the contamination was at a low level. This discloses that a functional truncated trehalose synthase with both TPS and TPP activities probably requires only polypeptides encoded by TSS1 and TSL1.

20 Example 4 Cloning and sequencing of TSS1

(a) Preparation and screening of a yeast genomic DNA library

A genomic library was constructed in the bacteriophage lambda vector, Lambda Zap II, using a partial HaeIII digest of S. cerevisiae strain S288C chromosomal DNA, according to Stratagene's Instruction Manual for the Zap-cDNA synthesis kit. The DNA from the ligation reaction was packaged into Giga II Gold packaging extract (Stratagene) according to the manufacturer's instructions (1990). The titer of the recombinants was determined on Luria broth plates containing X-β-galactoside (5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside) as a chromogenic substrate for β-galactosidase and IPTG (isopropyl β-D-thiogalactopyranoside) as an inducer. About 50,000 recombinants were amplified on large (150 mm) NZY-plates according to Stratagene's instructions. The titre of the resulting library was 5×10^9 pfu/ml with a total of 150 ml.

Several positive clones were found by screening with anti-TPS/P serum. After three rounds of purification, all clones were positive. They were screened again, now with anti-57K serum.

- 5 For further manipulations of DNA, the plasmid part, pBluescript, of the Lambda Zap vector was excised as described in the manual for Predigested Lambda ZapII/EcoRI Cloning Kit (1989).

10 (b) Sequencing of TSS1

- A strongly positive clone from the Lambda ZapII library was selected and sequenced manually. The sequence obtained included an open reading frame that encoded a 58 kDa protein, but none
15 of the short chain peptide sequences disclosed in Example 3 was found in the amino acid sequence encoded by this ORF.

- Therefore, a second clone was selected, from a group of clones that gave distinct restriction maps compared with the group
20 including the first clone. It also responded less strongly to anti-57K serum, which is why it was not chosen in the first place. It was sequenced using the Exonuclease III/Mung Bean nuclease system for producing series of unidirectional deletions. The deletions were prepared according to
25 Stratagene's manual for the pBluescript Exo/Mung DNA sequencing system. The plasmid was first digested with the restriction enzymes SacI, which leaves a 3' overhang, and BamHI, which leaves a 5' overhang. For filling in possible recessed
3' termini created by Mung Bean nuclease, 2.5 μ l of 10X
30 nick-translation buffer, 1 μ l of dNTP (a mixture of all four dNTPs, each at 2 mM) and 1 μ l (2U) of Klenow fragment were added. The reaction proceeded for 30 min at room temperature and was then stopped with 1 μ l of 0.5 M EDTA [Sambrook *et al.* (1989) loc. cit.]. The deletion time points were run on a 0.8 %
35 low melting agarose gel. The bands were cut out, melted and ligated according to Stratagene's instructions. Portions (5 μ l) of each ligation mixture were used to transform XL-1 Blue

cells.

The clone proved to encode all the short chain peptide sequences disclosed in Example 3, except the poorly defined pentapeptide, 966b. It is notable that the anti-57K serum alone was an inadequate tool for cloning this gene: the amino acid sequence data disclosed in Example 3 were also essential.

Comparison of sequences with the Microgenie Data Bank showed that the gene sequence of the clone was available as an unknown reading frame in the post-translational region of the gene for yeast (*S. cerevisiae*) vacuolar H⁺-ATPase. The data in the bank contain sequence errors, and have thus been erroneously interpreted as two short unidentified ORFs instead of one long ORF. The complete sequence of the TSS1 gene with 800 bp of promoter and 200 bp of terminator regions is disclosed as SEQ ID NO:1 and the amino acid sequence deduced from its ORF (starting at nucleotide 796) as SEQ ID NO:2. SEQ ID NO:1 now incorporates the following minor corrections to the promoter region, made since February 14th 1992: the original nucleotides 60 and 61 (CA) become AC, original nucleotides 646 to 653 (CGCGTGGT) become GCCGGG and the original nucleotide 711 (C) is deleted. Fig 3A shows the promoter and terminator regions, and Fig 3b shows the deduced amino acid sequence.

Example 5 Cloning and sequencing of TSL1 and TSL2

(a) Preparation and screening of genomic DNA libraries

The gene TSL1 was first found in the same library as described in Example 4. Screening was done using first anti-TPS/P serum and then anti-93K serum. Later, another library was constructed from a partial EcoR1 digest of chromosomal DNA from *S. cerevisiae*, strain S288C, using the methods described in Example 4. The anti-93K positive clones were classified by restriction mapping into groups, not all of which can represent TSL1.

(b) Sequencing of TSL1

Clones from one group of anti-93K positive clones from the HaeIII library were partially sequenced manually and then
5 automatically from pBluescript exonuclease deletion series as described in Example 4.

~~The HaeIII clones did not contain the whole of this long gene,~~
and the N-terminus was not found in any clone. Therefore, the
10 new EcoRI library was constructed and screened, first with anti-93 serum and then with nucleotide probes derived from the sequenced parts of TSL1.

Several anti-93K positive clones, which also hybridized with
15 the nucleotide probes, were obtained. These contained a plasmid with an 8.2 kb insert. From this plasmid a 2 kb fragment was cut with restriction enzymes StuI and ScaI, religated into the pBluescript SmaI site and sequenced using exonuclease deletions. The deletions were started using the enzymes SacI
20 and SpeI. Sequencing was done with the automatic sequencer. The sequence of TSL1 was thus completed.

The complete sequence is contained in the 8.2 kb insert of the EcoRI clones, and has been deposited as plasmid pALK751 on
25 February 18, 1992 with the Deutsche Sammlung von Microorganismen (DSM), Gesellschaft für Biotechnologische Forschung GmbH, Grisebachstr. 8, 3400 Göttingen, Germany and given the accession number DSM 6928.

30 The sequence is shown as SEQ ID NO:83. Nucleotides 2282 to 5575 comprise an ORF that encodes the amino acid sequence SEQ ID NO: 82. The promoter and terminator regions and amino acid sequence are also shown in Fig 4. The amino acid sequence includes the amino acid sequences obtained from (fragments of) the long (123
35 kDa) chain of trehalose synthase disclosed and discussed in Example 3.

(c) Isolation and sequencing of TSL2

The information disclosed about the 99 kDa polypeptide (especially in Examples 1 & 3) provides obvious procedures for the isolation and characterization of the TSL2 gene by one ordinarily skilled in the art. Because the anti-93K serum recognizes the 99 kDa polypeptide, anti-93K positive clones isolated as described above can include clones representing TSL2. Several positive clones not representing TSL1 were identified by restriction mapping. One of these was deposited on January 28th 1993 as the plasmid pALK756 (see Table 1) with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1 B, D-3300 Braunschweig, Germany (Accession number DSM 7425). This plasmid comprises a 3.5 kb insert in pBluescript. The insert was not cut by the restriction enzymes, NotI, SacI, SpeI or XhoI. The sequences of these and similar clones can be examined to identify an ORF that encodes the amino acid sequences of peptides isolated from the 99 kDa polypeptide (viz., SEQ ID NO:S 29 to 38 and 44 to 49). Another well established procedure is to use these amino acid sequences to design nucleotide primers that can be used to amplify parts of the TSL2 gene by the polymerase chain reaction. When a part of the TSL2 gene has been isolated and sequenced by either procedure, the rest of the gene can be easily isolated as described for TSL1.

Example 6. Characterization of TSS1 and TSL1

The nucleotide sequence of TSS1 encodes a polypeptide of 495 amino acid residues with a calculated molecular mass of 56 kDa. This open reading frame starts with an ATG codon and ends with two TGA codons. The promoter region contains a TATA box at -186 (see Fig 3) and the sequence CCCCGC at -270, which has been implicated in catabolite repression [Nehlin & Ronne, (1990) European Molecular Biology organization Journal 9, 2891-2898]. This may account for the low expression of trehalose synthase

in the presence of glucose disclosed in Example 2.

The open reading frame of TSL1 encodes a polypeptide of 1098 amino acids, corresponding to a calculated molecular mass of 123 kDa. This ORF starts with an ATG codon and ends with a TAA codon. Sixty base pairs downstream from the TAA codon is a possible TATATA transcription termination element [Russo *et al.* (1991) European Molecular Biology Organization Journal 10, 563-571].

10

The promoter sequence of TSL1 contains two putative TATA boxes at -100 and -117. The promoter was searched for possible heat shock elements and four AAGGGG elements were found (-166, -180, -232 and -378). Of these, the one furthest upstream, at -378, was part of the sequence GGTAAAAGGGGCGAA, which corresponds well to the UAS₋₃₆₀ heat shock stress control element GGTAAGGGGCCAA [Marchler, G. *et al.* (1992) Yeast 8, S154]. Two copies of the canonical heat shock element GAANNTTC were found, one at -353 and the other at -425; thus, one on either side of the UAS₋₃₆₀ element.

20

The sequence GCCCCTGCATTTT at -327 could be a MIG1 protein binding site (the consensus sequence is TCCCCRGATTNT). MIG1 appears to act as a repressor of transcription in the presence of glucose [Nehlin, J.O. & Ronne, H. (1990) European Molecular Biology Organization Journal 9, 2891-2898; Nehlin, J.O. *et al.* (1991) *ibid* 10, 3373-3378]. These features of the TSL1 sequence are shown in Fig 4.

25

The amino acid sequence encoded by TSL1 contains two polyglutamine tracts, four Qs starting at amino acid 42 and five Qs starting at 164. Such glutamine-rich sequences have been associated with heteromeric protein-protein interaction [Gancedo, J.-M. (1992) European Journal of Biochemistry 206, 297-313].

35

Fig. 5 discloses that the entire TSS1 gene exhibits 37 %

identity at the amino acid level to a 502 amino acid stretch from the middle of the TSL1 product. The genes are obviously closely related.

5 Most surprisingly, the TSS1 gene is identical to the CIF1 gene that has been recently cloned and sequenced by Gancedo's group [Gonzales et al (1992) Yeast 8 183-192]. This disclosure reveals that special methodology is required to handle mutants containing modified forms of the TSS1 gene, because cif1
10 mutants have severe defects in sugar metabolism, as discussed in the Detailed Description. It also explains, of course, why no recognisable short chain is present in the Klg 102 mutants, which carry the cif1 mutation (see Example 7). Previously, it has been (tacitly) assumed that failure of cif1 and fdp1
15 mutants to express TPS activity is the consequence of a lengthy cascade of regulatory effects. The findings disclosed here and in Example 7 show that absence of the short chain of trehalose synthase is the primary defect, from which, in an as yet completely obscure way, the other regulatory defects of these
20 mutants result.

S.cerevisiae chromosomes were separated by pulsed field electrophoresis, with pulse times of 60 sec for 15 h and 90 sec for 9 h at 200 volts, as recommended by the instruction manual
25 for the CHEF-DR II BioRad Laboratories, Richmond, California]. Genes were located using digoxigenin-labelled non-radioactive probes, following the instructions in the manual by Boehringer Mannheim. The following probes were used: a 2.1 kb DraI restriction fragment from TSL1 and a 1.9 kb NarI-SmaI
30 restriction fragment of TSS1 (the SmaI site is in the linker between the insert and the vector; important restriction sites in TSS1 and TSL1 are shown in Fig 6). TSS1 was located exclusively on Chromosome 2, which is where both FDP1 [Van de Poll and Schambert (1977) loc. cit.] and CIF1 [Gonzales et al.
35 (1992) loc. cit.] have been located. This disclosure further strengthens the evidence for the identity of TSS1 with CIF1 and FDP1. By using the GalH gene as a marker for chromosome 16 TSL1

was located exclusively on the adjacent Chromosome 13. Immediately downstream of TSL1 lies, in opposite orientation, the ARGRII gene, sequenced by Messenguy et. al. [(1986) European Journal of Biochemistry 157, 77-81]. The start of the overlapping sequence is shown in Fig 4.

Example 7 A functional TSS1 gene is required for expression of both TPS and TPP activities

The S. cerevisiae mutant Klg 102, was obtained from Dan Fraenkel (Harvard Medical School) and has the genotype MAT α , ural, leu1, trp5, cif1-102. It was routinely grown on YP/2% galactose or YP/2% glucose, and long term storage was under liquid nitrogen. As reported by others [Navon, G., et al. (1979) Biochemistry 18, 4487-4499; Bañuelos, M. & Fraenkel, D.G. (1982) Molecular and Cellular Biology 2, 921-929], this mutant would not grow on YP/2% fructose, though revertants were frequent.

Six individual colonies from each of two substrains of Klg 102, ALKO 2669 and ALKO 2670, that differed in reversion frequency and colony size, were streaked onto YP/2% fructose and YP/2% glucose at 30 °C. After 45 h, all 12 streaks were growing on glucose, although slower than the control yeast, X2180, but none showed any growth on fructose. After 4 days, five of the ALKO 2669 streaks showed several large, but isolated colonies on fructose and one ALKO 2670 streak showed several small colonies on fructose. From the glucose plates, three streaks from each substrain were chosen for the smallest number of revertants on the corresponding fructose plate, and used to inoculate 100 ml portions of YPD in 250 ml shake flasks, and grown at 200 r.p.m. and 30 °C. Three parallel flasks were inoculated with X2180. A600 and residual glucose in the media were monitored and samples were plated out quantitatively onto YP/2% glucose and YP/2% fructose. The ALKO 2669 cultures grew faster than the ALKO 2670 cultures, and both grew much slower

then X2180 (not shown).

At appropriate times the cells were harvested, broken and analyzed as described in the General Materials and Methods.

5 Results are shown in Table 5.

Table 5. Growth of Klq 102 and X2180 strains on YPD

The cultures were performed as described in the text. Residual glucose and cell mass are given as, respectively, g/100 ml and mg/ml of growth medium. Phosphoglucosomerase (PGI) was determined as described in Example 11. PGI, TPS and TPP are given as U/g of wet cells (TPS was determined in the presence of 5 mM F6P). Trehalose is given as mg/g of wet cells.

Viability Fru/Glu shows the number of cells able to grow on fructose as a percentage of the number of cells able to grow on glucose at the time of harvesting. Cells from the cultures 2670/1 and 2670/2 were combined for breakage and subsequent analysis. ND, not determined.

Strain	Age (h)	Residual Glucose (g %)	Cell Mass (mg/ml)	PGI (U/G)	TPS (U/G)	TPP (U/G)	Trehalose (mg/g)	Viability Fru/Glu (%)
<u>Klq 102 cultures</u>								
2569/1	24	ND	4.3	88	≤0.02	ND	ND	2.4
2569/2	48	≤0.02	11.6	81	≤0.03	0.034	ND	≤1.7
2569/3	114	none	10.3	ND	ND	≤0.02	≤0.22	≤1.8
2670/1	110	none	9.7	89	≤0.03	0.081	ND	1.4
2670/2	110	none	9.7	89	≤0.03	0.081	ND	4.0
2670/4	114	none	11.2	ND	ND	≤0.02	≤0.19	≤0.3
<u>X2180 cultures</u>								
1	24	ND	19.1	93	6.3	1.7	ND	ND
2	110	none	31.7	126	6.3	2.3	ND	ND
3	114	none	34.4	ND	ND	2.9	29.3	ND

These results show that TPS activity was below the detection level in the Klq 102 samples and less than 0.5 % of the value in X2180, which is typical of wild type *S. cerevisiae*. This agrees with previously reported results [Paschoalin, V.M.F., et al. (1989) Current Genetics 16, 81-87]. Surprisingly, however, TPP activities were also very low, between ≤ 1 % and 5 % of the X2180 values. Even this residual ability to hydrolyse

trehalose-6-phosphate is likely to be due to non-specific phosphatases. Paschoalin *et al.* [(1989) loc. cit.] claim that Klg 102 specifically lacks UDPG-linked TPS activity, but that, like the wild-type yeast S288C (which is the haploid form of X2180), it contains an ADPG-linked activity. If this were true, and accepting the conventional view that trehalose synthesis in yeast proceeds via free trehalose-6-phosphate, Klg 102 should contain significant TPP activity. Our results disclose that this is not the case. Furthermore, when we tested whether wild type yeast (X2180) was able to synthesise [^{14}C]-trehalose from [^{14}C]-G6P in the presence of UDPG or ADPG, we found significant activity only in the presence of UDPG. The assay systems used by Paschoalin *et al.* [(1989) loc. cit.] have been criticised by Vandercammen *et al.* [(1989) loc. cit.], so we tested the overall reaction directly. Yeast extracts were incubated in 40 mM HEPES pH 6.8 containing 1 mg BSA/ml, 10 mM MgCl_2 and 10 mM [^{14}C]-G6P (736 c.p.m./nmol) in the presence or absence of 5 mM UDPG or 2.5 mM ADPG and presence or absence of 5 mM K phosphate. Reactions were stopped by boiling for 2 min and addition of AG1-X8 (formate) anion exchange resin, as in the TPP assay system described by Londesborough & Vuorio [(1991) loc. cit.]. Results are shown in Fig 7. Without UDPG or ADPG, radioactivity appeared in the resin supernatants, presumably due to phosphatases active on G6P. UDPG caused a clear increase in this rate in the absence of phosphate and a marked increase in the presence of 5 mM phosphate, which stimulates the TPP activity and inhibits the TPS activity of trehalose synthase. With UDPG and 5 mM phosphate, the increase in rate corresponded, after a lag phase, to $0.94 \mu\text{mol/min/g}$ of fresh yeast, which is about 50 % of the TPP activity of this yeast at 20 mM phosphate. ADPG, however, did not cause any significant increase in the rate of appearance of radioactivity in the resin supernatant, indicating that no ADPG-linked TPS activity was present.

Western blots of the homogenates of Klg 102 and X2180 yeast are shown in Fig. 8. The origin of the bands marked D is not clear:

they may be degraded short chain. X2180 shows a strong 57 kDa band, due to the short chain of trehalose synthase and several weak bands at 100 to 130 kDa due to intact and truncated versions of the long chain. In contrast, although the Klg 102 samples showed stronger long chain bands, because more yeast sample was applied to the gel, they showed no trace of a short chain band. Thus, Klg 102 does not contain a recognisable form of the product of the TSS1 gene (it might contain a truncated version lacking the epitopes recognised by our polyclonal antibodies), but contains normal amounts of the TSL1 product. Furthermore, the TSL1 product appears to increase as Klg 102 traverses the diauxic lag (compare e.g. lanes 3 and 2 of Fig. 8), suggesting that expression of the long chain of trehalose synthase in this yeast increases when all glucose is consumed. In wild type yeast, increases in both short and long chains occur concomitant with the increases in TPS and TPP activities when glucose is consumed (Example 2).

These results disclose that the failure of Klg 102 to express immunologically recognisable short chain of trehalose synthase is correlated with the absence of both TPS and TPP activities. This unexpected behaviour, in contradiction of the views of Paschoalin et al. [(1989) loc. cit.], indicates that a functional short chain is required to assemble a trehalose synthase with either partial activity.

Similar experiments were done with S. cerevisiae, strain MV6807 (obtained from Johan Thevelein, Laboratorium voor Moleculaire Celbiologie, Instituut voor Plantkunde, Heverlee, Belgium), which carries the fdp1 mutation, which is allelic to CIF1 and TSS1. This strain grew poorly on glucose (fructose was not tested) and so was grown on galactose. Stationary phase cells contained 6 ± 6 % of normal TPS but about 20 % of normal TPP. Western analyses showed the presence of a band at 57 kDa recognised by anti-57K serum as well as normal long chain bands, so the mutation in MV6807 must be an aminoacid substitution. Apparently, this substitution causes a greater

decrease in TPS activity than TPP activity.

Example 8. Biochemical evidence that a long chain of trehalose synthase is required for TPP activity

5

Truncated trehalose synthase containing the short (57 kDa) chain and the 86 and 93 kDa long chain fragments was prepared according to the method of Londesborough & Vuorio (1991) loc. cit.] for proteolytically activated TPS/P complex. TPS and TPP activities were assayed as described by Londesborough & Vuorio [(1991) loc. cit.]. [N-ethyl-1-¹⁴C]-maleimide (ethyl-labelled NEM; 40 mCi/mmol) was NEC-454 from New England Nuclear. N-ethyl-[2,3-¹⁴C]-maleimide (ring-labelled NEM; 6 mCi/mmol) was CFA 293 from Amersham International. Both were obtained as solutions in n-pentane and the manufacturer's stated specific activities were assumed to be correct. Unlabelled N-ethyl-maleimide (NEM) was E-3876 from Sigma. It was dissolved in 25 mM HEPES pH 7.0 immediately before use and standardized by absorption measurements at 305 nm, assuming an $E^{1\%}_{1\text{cm}}$ of 0.62.

20

Treatment of truncated trehalose synthase with 1.9 mM NEM at 24 °C in the presence of about 0.17 mM dithiothreitol (which presumably rapidly consumes about 0.34 mM NEM) caused a rapid and essentially complete ($\geq 98\%$) loss of TPP activity, but little ($\leq 24\%$) loss of TPS activity (Fig. 9). This suggested that NEM modified one or more amino acid (presumably cysteine) side chains that are required intact for TPP but not for TPS.

30

To permit quantitative experiments with low concentrations of labelled NEM, the dithiothreitol in the enzyme preparation was removed by gel-filtration through Pharmacia NAP5 columns equilibrated with 1 mg BSA/ml of 25 mM HEPES pH 7.0 containing 2 mM MgCl_2 , 1 mM EDTA and 0.2 M NaCl. Recoveries of TPS and TPP activities through this gel-filtration were above 85%.

35

In one experiment, 2.0 μl of 2.4 mM ethyl-labelled NEM was mixed with 150 μl of gel-filtered enzyme and incubated at 23

°C. Samples (10 μ l) taken at various times up to 190 min were mixed with 60 μ l of Laemmli sample buffer (the mercapto-ethanol in this buffer should destroy residual NEM), boiled for 5 min and subjected to SDS-PAGE. At closely similar times (and also
5 at 23 h) other samples (10 μ l) were mixed with 100 μ l (for TPS) or 700 μ l (for TPP) of 5 mg BSA/ml 25 mM HEPES pH 7.0 containing 2 mM $MgCl_2$, 1 mM EDTA, 0.2 M NaCl and 1 mM dithiothreitol (the dithiothreitol should destroy residual NEM) and assayed for TPS and TPP. The enzyme dilution used for the
10 TPP assay was sufficient that radioactivity from the NEM (about 1/3 of which remains in the resin supernatant) did not interfere with the TPP determinations.

After electrophoresis, the upper (cathode) buffer, containing
15 most of the added radioactivity, was completely removed before disassembling the apparatus. The gel was then fixed, stained and destained as described by Laemmli [(1970) Nature, London 227, 680-685] and dried. An autoradiogram of this gel (Fig. 10) showed that the 93 kDa band (and also BSA) became labelled
20 during the experiment, while the 86 and 57 kDa bands were much more weakly labelled. The Coomassie blue stained bands and adjacent, empty areas (as blanks) were cut out of the dried gel (in later experiments, they were cut from undried gels), broken up and extracted overnight with 1 ml of 5 % SDS in pre-blanked
25 scintillation vials. Then 10 ml of a toluene/Triton X100-based scintillant was added, and the tubes were repeatedly counted using a wide energy window to minimise quench effects. After 10 h constant counting levels were reached. Excess radioactivity was calculated by subtracting a blank value obtained from empty
30 regions of the gel. Results are shown in Fig. 11. In control experiments, in which enzyme was omitted, it was shown that the excess radioactivity found in the 93 and 86 kDa bands did not originate from potential labelling of impurities in the BSA.

35 Fig. 11 shows that label from NEM enters mainly the 93 kDa fragment of the long chain, with relatively small amounts entering the 86 kDa fragment and the 57 kDa short chain. Also,

the amount of label entering the long chain fragments (93 + 86 kDa) is roughly proportional to the loss of TPP activity, but lags increasingly behind this loss: at 10.5 min 30 % of the initial TPP was lost and 0.20 moles of NEM had entered the long chain fragments per mole (150 Kg) of enzyme, whereas at 190 min, 56 % of TPP was lost and 0.32 moles of NEM had entered the long chain fragments. Possibly, since trehalose synthase may be an octamer (its native molecular mass is about 800 kDa), reaction of one long chain with NEM can eventually lead to loss of activity associated with the other long chains in the octamer. Fig. 12 collates data from several experiments, using both ring- and ethyl-labelled NEM. Parallel experiments with identical concentrations of ring- and ethyl-labelled NEM suggested that about 25 % of the radioactivity from ethyl-labelled NEM originally fixed in the protein was lost during SDS-PAGE processing (some loss is expected in acidic condition), and the results with ethyl-labelled NEM have been corrected accordingly. Within the limits of accuracy (a specific activity of 30 TPS units/mg was used to calculate the mass of protein and a dimer molecular mass of 150 kDa was assumed for the truncated enzyme) complete loss of TPP reflected incorporation of rather less than 1 mole of NEM into, specifically, the long chain fragments.

Another reagent with high specificity for cysteine, dithiodinitro-benzoate (DTNB), also caused a specific loss of TPP activity: after 10 min treatment with 0,9 mM DTNB over 95 % of the TPP was lost and less than 28 % of the TPS.

These findings disclose that TPP activity requires a long chain with a proper structure, because modification of a single amino acid (presumable cysteine) residue in the 93 kDa fragment eliminates TPP but not TPS activity. Sequencing data given in Example 3 disclosed that the 93 kDa band contained material from both the 99 kDa and 123 kDa long chains. Thus, the present results disclose that either the 99 kDa or the 123 kDa or both long chains are involved in TPP activity.

Example 9. An isolated 99 kDa polypeptide from trehalose synthase contains TPP activity

Because the long and short chains of trehalose synthase were difficult to separate by usual chromatographic procedures, fractionations were attempted in the presence of a non-ionic detergent. During fractionation with a NaCl gradient on DEAE-cellulose (Whatman DE52) in 1 % Triton X100 at pH 8.0, the enzyme was recovered in about 90 % yield at 140 mM NaCl. Some minor polypeptides (e.g. the weak 68 kDa polypeptides visible in Fig 1) were removed, but the main 57, 99 and 123 kDa polypeptides were not resolved. However, the ratio of the 99 and 123 kDa bands changed from about 1.5 to 0.3 across the enzyme peak, while concomitantly the TPP/TPS ratio decreased steadily from 0.54 to 0.42 (data not shown). This suggested that the procedure was partially resolving trehalose synthase molecules enriched in the 99 kDa polypeptide from those enriched in the 123 kDa polypeptide and that the former had a relatively higher TPP activity. By extrapolation it can be calculated that the TPP/TPS ratio of (hypothetical) enzyme containing only 57 and 99 kDa chains would be 0.65 ± 0.10 , whereas that of enzyme with only 57 and 123 kDa chains would be 0.32 ± 0.10 .

Because the long chain appears to contain an avid phosphate binding site (see Examples 10 and 12), chromatography on phosphocellulose was attempted. Native trehalose synthase (4.2 TPS units) was transferred above a PM10 membrane in an Amicon cell to 25 mM HEPES pH 7.0 containing 2 mM $MgCl_2$, 1 mM EDTA, 1 mM dithiothreitol and 0.3 % Triton X100 (HMED/0.3 %T) and applied to a 0.7 x 4.2 cm column of phosphocellulose (Whatman P11-cellulose) equilibrated with the same buffer. The column was washed with 4 ml of HMED/0.3 %T and developed with a linear gradient from zero to 0.6 M NaCl in 60 ml of HMED/0.3 %T at 5 ml/h. By 0.35 M NaCl only traces of TPS had been eluted (≤ 3 % in the first 9 ml and ≤ 9 % spread between 0.15 and 0.35 M NaCl). The gradient was interrupted and the column was washed

sequentially with (a) 8 ml of 10 mM fructose-6-phosphate in HMED/0.3 %T/0.35 M NaCl, (b) 6 ml of HMED/0.3 %T/0.6 M NaCl and (c) 0.2 M K phosphate pH 7.0/2 mM MgCl₂/1 mM EDTA/1 mM dithiothreitol. No TPS or TPP activity was recovered except in a single 1.5 ml fraction in which the 0.6 M NaCl began to elute. This contained 12 % of the applied TPP, but ≤ 0.1 % of the applied TPS.

Fractions were examined by SDS-PAGE (Fig. 13), which showed:

- (1) almost pure short chain eluted at and just before the start of the NaCl gradient in fractions devoid of enzyme activity;
- (2) traces of short and long chain eluted diffusely at about 0.2 to 0.35 M NaCl in fractions containing altogether ≤ 7 % of the applied TPS activity;
- (3) at least 50 % and possibly all of the applied 99 kDa polypeptide eluted at 0.6 M NaCl in the fraction containing 12 % of the applied TPP activity; and
- (4) most of the 123 kDa polypeptide remained bound to the column.

Intact trehalose synthase has also been fractionated on phosphocellulose in the absence of Triton, and with elution by a simple linear gradient from 0 to 0.6 M NaCl. Pure or nearly pure 99 kDa polypeptide eluted at about 0.45 M NaCl and contained specific TPP activity (¹⁴C-G6P was not hydrolyzed). This activity differed from the TPP activity of intact trehalose synthase in that the ratio of activities at 25 mM phosphate and 50 mM Hepes was between 1.5 and 3 in different experiments (cf, this ratio is 5 to 6 for intact trehalose synthase). Furthermore, during storage of the isolated 99 kDa polypeptide at 0 °C, the TPP activity at 25 mM phosphate decreased and that at 50 mM Hepes increased, until the ratio was about 0.7 after 7 weeks.

These findings disclose that the 99 kDa polypeptide isolated from intact trehalose synthase is a specific trehalose-6-phosphatase, but that its catalytic properties are unstable and differ from the TPP activity of intact trehalose synthase. Together with the disclosure in Example 7 that yeast requires a

properly functional TSS1 gene to exhibit TPP activity, the results suggest that proper folding of the 99 kDa polypeptide requires the presence of the 57 kDa chain.

5 These findings also disclose that when the short chain is separated from the long chain by chromatography in a buffer containing 0.3 % Triton, in which intact trehalose synthase is stable, it rapidly loses any TPP or TPS activity it possessed when correctly folded in the trehalose synthase.

10

The findings also indicate that the full-length long chain has extraordinarily high affinity for phosphocellulose, which is consistent with the location of a high affinity phosphate binding site in a terminal portion of this chain as suggested by Examples 10 and 12.

15

Example 10 Truncation of the 123 kDa long chain of trehalose synthase by trypsin in vitro dramatically increases TPS activity

20

Removal of the N-terminal 325 or so amino acids from the 123 kDa long chain of intact trehalose synthase by treatment with trypsin in vitro produces an enzyme with catalytic properties like those of the truncated enzyme purified by Londesborough & Vuorio [(1991) loc. cit.]. In one experiment intact trehalose synthase (0.28 TPS units, $\approx 9.4 \mu\text{g}$) was incubated with or without 0.5 μg of trypsin at 30 °C in 250 μl of 13 mM HEPES pH 7.0 containing 1 mM MgCl_2 , 0.5 mM EDTA, 0.5 mM dithiothreitol, 0.2 M NaCl and 0.5 mM benzamidine. Its TPS activity was determined at intervals using standard assay mixtures (containing 5 mM F6P) containing no or 4 mM K phosphate pH 6.8, and samples were prepared for SDS-PAGE analysis immediately before and 48 min after addition of the trypsin.

25

30

35 During the first 48 min the TPS activity measured in the absence of phosphate decreased faster in the presence of trypsin than in its absence. However, in the first 10 min,

trypsin caused a 4-fold increase in the activity measured at 4 mM phosphate, and by 48 min the activities with and without phosphate were essentially equal (Fig. 14). By 48 min, the 123 kDa full length long chain had disappeared and been replaced by a doublet of polypeptides at 85 kDa (Fig. 15). In contrast, the short chain (57 kDa) was unchanged and the 99 kDa band was only slightly decreased in strength. The changes in TPS activity were accompanied by loss of about 50 % of the TPP activity.

Which part of the 123 kDa chain was removed by trypsin was determined as follows. Intact trehalose synthase (180 µg) was transferred to 0.5 ml of 25 mM HEPES pH 7.0 containing 2 mM MgCl₂, 1 mM EDTA, 1 mM dithiothreitol and 0.2 M NaCl using a Centricon 30 tube, and then treated with 11 µg trypsin at 25°C. The standard TPS activity did not decrease during the trypsin treatment, whereas TPS activity measured in the absence of F6P and presence of 10 mM phosphate increased from 26 % to 73 % of the standard activity during the first 30 min of treatment. After 68 min treatment, when SDS-PAGE analysis showed the complete disappearance of the 123 and 99 kDa bands and appearance of a doublet with apparent molecular mass about 85 kDa (the components differing by about 1.5 kDa), the mixture was centrifuged through a Centricon 30 tube to separate the tryptic peptides from the core enzyme. The retentate was then boiled in 0.5 % SDS and again centrifuged through the Centricon 30 tube. The combined filtrates were diluted to 0.1 % SDS and incubated for 18 h at 25 °C with 4 % by weight of endoproteinase Glu-C (Boehringer). The peptides were then separated by HPLC using a DEAE pre-column and sequenced as described in Example 3.

Twenty sequences were obtained (Seq ID NOs 58 to 77 in Table 6). Fifteen of these were found in the N-terminal 325 amino acids coded by TSL1. One (peptide 1407, recovered at less than half the yield of the others) was amino acids 1089 - 1093, i.e., 5 amino acids from the C-terminus of the protein coded by TSL1. This peptid is presumably derived by endoproteinase Glu-

C cleavage of the tryptic peptide starting after Lys 1079. Both the 86 and 93 kDa long chain fragments in the truncated trehalose synthase purified by Londesborough & Vuorio [(1991) loc. cit.] are disclosed in Example 3 to contain a peptide (1483b & 1484b) derived from Ala1064 to Lys1079, confirming that the truncated polypeptides extend at least this close to the C-terminus of the full length 123 kDa chain. The N-terminal peptide furthest from the N-terminus was peptide 1443, obtained by cleavage after Arg 335. Thus, the truncated long chain extends from Ser 336 to Lys 1079 or Asp 1098, and is predicted to have a molecular mass of 87.3 or 86.2 kDa. The SDS-PAGE analysis of trypsin-treated enzyme suggests both of these truncated chains are formed, and because the TPS activity in the presence of F6P changes little during the trypsin treatment, the two truncated chains probably have similar activities.

Of the remaining four peptides in Table 5, two (1419b and 1437b) are still unidentified, but may originate from the 99 kDa polypeptide, whereas two (1442 and 1451) clearly originate from that polypeptide. Thus, peptide 1442 is identical to peptide 1307a of Table 4, and the first 5 amino acids of peptide 1451 are identical to peptide 1297a (Table 4).

These results disclose that removal of the N-terminal 325 amino acids of the long chain, with or without removal of the C-terminal 19 amino acids, results in a trehalose synthase that is relatively insensitive to inhibition by phosphate, and does not require F6P for full activity. Analysis of the secondary structure of the long chain according to Garnier et al [(1978) Journal of Molecular Biology, 120, 97-120] suggests that whereas the C-terminal 700 amino acids are likely to be in alpha-helices or beta-sheets, the N-terminal 360 amino acid portion of the protein is relatively devoid of such structures. Taken together, these data suggest that the N-terminal 330 or so amino acids comprise a distinct domain, that confers regulatory properties upon the TPS activity of trehalose

synthase, including sensitivity to inhibition by phosphate and a requirement for F6P to express full catalytic activity. Thus, the TSL1 gene product must also be involved in TPS activity.

5 Table 6 Peptides released from intact trehalose synthase during
 activation by limited treatment with trypsin.

When two sequences were obtained from the same HPLC peak, they are shown as a and b sequences, assigned according to the sequences predicted from the TSL1 gene. Tentative identifications from the amino acid sequencer are shown by one letter codes and double queries; unidentified residues Xaa. (In the Sequence Listings also tentative identifications are indicated as Xaa). The location of each amino acid sequence in the long (123 kDa) chain of trehalose synthase in Fig 4b is shown below the sequence.

- 1400 Leu-Leu-Val-His-Ser-Leu-Leu-Asn-Asn-Thr-Ser-Gln-Thr-Ser-
20 Leu-Glu-Gly-Pro-Asn
 (SEQ ID NO:58) (181-200)
- 1401 Ser-Ser-Thr-Thr-Asn-Thr-Ala-Thr-Leu-Xaa-Xaa-Leu-Val-Ser-
 Ser-Xaa-Ile-Phe-Met-Glu
25 (SEQ ID NO:59) (84-104)
- 1406 Ala-G??-Asn-Arg-Pro-Thr-Ser-Ala-Ala-Thr-Ser-Leu-Val-Asn-
 Arg
 (SEQ ID NO:60) (210-24)
- 30 1407 Xaa-Phe-Thr-Ile-Ile-S??
 (SEQ ID NO:61) (1088-93)
- 35 1408 Asn-Leu-Thr-Ala-Asn-Ala-Thr-Thr-Ser-His-Thr-Pro-Thr-Ser-
 Lys
 (SEQ ID NO:62) (105-19)

62

- 1409 Phe-G??-G??-Tyr-Ser-Asn-Lys
(SEQ ID NO:63) (319-25)
- 1416 S??-Pro-S??-Ala-Phe-Asn-R??
5 (SEQ ID NO:64) (77-83)
- 1417a Ile-Ala-Ser-Pro-Ile-Gln-T??-Glu
(SEQ ID NO:65) (145-52)
- 10 1417b Gln-Arg-Pro-Leu-Leu-Ala-Lys
(SEQ ID NO:66) (257-63)
- 1418 Phe-Phe-Ser-Pro-Ser-Ser-Asn-Ile-Pro-Thr-Asp-Arg
(SEQ ID NO:67) (133-44)
- 15 1419a Ala-Leu-Ser-Asn-Asn-Ile-Ser-Gln-Glu
(SEQ ID NO:68) (47-55)
- 1419b A??-L??-S??-Tyr-Thr-Pro
20 (SEQ ID NO:69) (not found)
- 1420 Ile-Ala-Ser-Pro-Ile-Gln-Gln-Gln-Gln-Asp-Pro-Thr-Ala-
Asn-Leu
(SEQ ID NO:70) (159-74)
- 25 1437a Thr-Met-Leu-Lys-Pro-Arg
(SEQ ID NO:71) (120-25)
- 1437b Ile-Ile-Glu-Asp-Glu-Ala
30 (SEQ ID NO:72) ((not found)
- 1438 Ile-Thr-Pro-His-Leu-Thr-Ala-Ser-Ala-Ala-Lys
(SEQ ID NO:73) (246-56)
- 35 1439 Ser-Leu-Val-Ala-Pro-Ala-Pro-Glu
(SEQ ID NO:74) (56-63)

1442 Lys-Pro-Gln-Asp-Leu-Asp-Asp-Asp-Pro-Leu-Tyr-Leu
(SEQ ID NO:75) (from 99 kDa)

1443 Lys-Tyr-Ala-Leu-Leu-Arg
(SEQ ID NO:76) (330-35)

1451 Gln-Leu-Gly-Asn-Tyr-G??-Phe-Tyr-Pro-Val-Tyr
(SEQ ID NO:77) ((from 99 kDa)

10

Example 11 Identification of the TPS activator as
phosphoglucosomerase

TPS activator was transferred to 0.1 M Tris/HCl pH 9.0 above a
15 PM10 membrane in an Amicon cell. A 300 μ l sample (34 μ g) was
digested for 20 h at 37 °C by 0.8 μ g of lysylendo-peptidase C
(Wako). Peptides were separated by HPLC and sequenced as
described in Example 3. All five sequences obtained and
disclosed in Table 7 are identical to sequences found in yeast
20 phosphoglucosomerase (PGI).

Table 7. Peptide sequences from TPS activator

The PGI sequences are from Tekamp-Olson, P., et al. (1988) Gene 73, 153-161.

5	<u>TPS-Activator Peptide</u>	<u>PGI Residues</u>
	TA1156 TFTNYDGSK (SEQ ID NO:39)	51 - 59
10	TA1158 TGNDPSHIK (SEQ ID NO:40)	241 - 251
15	TA1159 IYESQ GK (SEQ ID NO:41)	24 - 30
	TA1160 AEGATGGLVPHK (SEQ ID NO:42)	456 - 467
20	TA1161 LATELPAXSK (SEQ ID NO:43)	11 - 19

25 The PGI activity of a sample of TPS activator that had been stored for several months at 0 °C was measured in 50 mM HEPES/KOH pH 7.0, 5 mM MgCl₂, 5 mM F6P and 0.4 mg/ml NADP. A specific activity of 190 U/mg was found.

30 These findings disclose that TPS activator from S. cerevisiae is identical to PGI. Example 12 discloses that F6P is a powerful activator of the TPS activity of intact, but not of truncated, trehalose synthase. Because the assay mixtures for TPS contain G6P, it is clear that TPS activator can activate

35 TPS by producing F6P from the substrate G6P. This is a complete explanation for the activation. Thus, at initial concentrations of 6.7 mM G6P and 1.9 mM F6P (i.e. G6P/F6P = 3.5, the experimental equilibrium ratio) the rate was independent of TPS activator and equal to that at 9 mM G6P with TPS activator.

40 Previous investigations [Londesborough & Vuorio (1991) loc. cit.] had to use crude preparations of intact trehalose synthase because pure intact trehalose synthase was not available. Although the effectiveness of TPS activator preparations was reported to vary between different enzyme

preparations, under certain circumstances data were obtained that suggested TPS activator might interact stoichiometrically with native trehalose synthase [Londesborough & Vuorio (1991) loc. cit.]. The present findings show that this suggestion was completely incorrect. The findings also imply that kinetic data in the literature are confused, because some preparations of so-called "trehalose-6-phosphate synthase" will have contained PGI whereas some may not. With the former preparations, the activator F6P will have been generated from the substrate G6P, but the amount so generated will have depended upon the details of the experimental procedure used.

Example 12. The different kinetic behaviours of intact and truncated trehalose synthase

Truncated trehalose synthase was prepared as described by Londresborough & Vuorio [(1991) loc. cit.] and contained the 57 kDa short chain and 86 and 93 kDa fragments of the long chain. Intact trehalose synthase was prepared as in Example 1. Kinetic assays were done at 30 °C as described in General Methods and Materials.

(a) The TPS Partial ActivityTable 8. Inhibition of the TPS activities of intact and truncated enzyme by phosphate at 5 mM F6P

5

The effect of adding K phosphate pH 6.8 to standard assay mixtures (10 mM G6P, 5 mM UDPG and 5 mM F6P) is shown. For each enzyme, the activity without phosphate is set at 100 %.

10	<u>Added Phosphate</u>	<u>Intact Enzyme</u>	<u>Truncated Enzyme</u>
	None	100 %	100 %
	1.3 mM	69 %	94 %
15	4.0 mM	14 %	83 %

The TPS activity of intact enzyme was much more sensitive to inhibition by phosphate than was that of the truncated enzyme (Table 8). The results in Table 8 underestimate the difference between the phosphate responses of intact and truncated enzyme, because F6P partially reverses the phosphate inhibition of intact enzyme (see below) but has virtually no effect on truncated enzyme. Table 9 shows the effect of shifting from the salt conditions of the standard assay (40 mM HEPES/KOH pH 6.8, 10 mM MgCl₂) to conditions closer to those of yeast cytosol. In the absence of F6P, the shift caused 67 % inhibition of intact enzyme (from 43 % to 14 % of the standard activity) but only 10 % inhibition of truncated enzyme (from 96 % to 86 %).

30

Table 9. Effect on the TPS activity of intact and truncated enzyme of shifting to more physiological salt conditions

For measurements at "physiological conditions", 1.3 mM K phosphate and 0.1 M KCl were added to the standard assay mixtures and the MgCl₂ was decreased from 10 to 2.5 mM.

35

	<u>Standard Cond.</u>		<u>Physiological Cond.</u>	
	<u>(5 mM F6P)</u>	<u>No F6P</u>	<u>5 mM F6P</u>	<u>No F6P</u>
Intact	100 %	43 %	72 %	14 %
Truncated	100 %	96 %	90 %	86 %

These results disclose the insensitivity of the TPS activity of truncated trehalose synthase to physiological phosphate concentrations and the presence or absence of F6P at a concentration well above the normal value in yeast cytosol (between 0.1 and 1 mM; Lagunas, R. & Gancedo, C. (1983) European Journal of Biochemistry 137, 479-483).

Fig. 16 illustrates the F6P-dependence of the TPS activity of intact enzyme at different phosphate concentrations. Double-reciprocal plots of these data (not shown) indicate that at 1.3 mM phosphate, and perhaps at 4 mM phosphate, sufficiently high concentrations of F6P completely overcome the inhibition by phosphate. With no added phosphate, F6P caused a maximum activation of 2.5-fold, with a K_m of 60 μ M. At 1.3 mM phosphate, the maximum activation was at least 20-fold, and the K_m was 1.4 mM F6P. The slopes of these double-reciprocal plots varied linearly with the square of the phosphate concentration, suggesting that two phosphate binding sites are involved. At 4 mM phosphate, which is still within the probable range of phosphate concentrations in yeast cytosol [Lagunas & Gancedo (1983) loc. cit], inhibition was so severe that even 10 mM F6P permitted only 40 % of the activity observed under standard conditions. Thus, expression of a truncated trehalose synthase in yeast would be expected to cause a large increase in the intracellular specific activity of the enzyme.

Fructose-1-phosphate, fructose-1,6-bisphosphate, fructose-2,6-bisphosphate and glucose-1-phosphate were tested at sub-optimal F6P concentrations (1 mM F6P at 1.3 mM phosphate). None caused activation at 5 or 2.5 mM concentrations; instead inhibitions of about 25 % occurred, probably due to competition with G6P and F6P.

(b) The TPP Partial Activity.

At phosphate concentrations equal to or less than 1 mM, the progress curves of TPP reactions catalysed by truncated
5 trehalose synthase accelerated markedly over at least the first 10 min of reaction. This did not happen with intact enzyme. For the initial rates of reaction, intact enzyme was activated by smaller phosphate concentrations than was truncated enzyme (Fig. 17). For truncated enzyme, double-reciprocal plots of the
10 activation (v_A = the rate with phosphate, v_{pi} , minus the rate without phosphate, v_o) were linear when $1/v_A$ was plotted against $1/[\text{phosphate}]$, with a K_m of 3 mM phosphate. For intact enzyme these plots were non-linear, and linear plots resulted when $1/[\text{phosphate}]^2$ was used (Fig. 18). This, again, suggests
15 that intact enzyme has two strong phosphate binding sites, one of which is lost in the truncated enzyme. For intact enzyme, half maximal activation was obtained at 0.6 mM phosphate.

In the absence of phosphate, F6P did not affect the TPP
20 activity of intact enzyme. At sub-optimal phosphate concentrations, 5 mM F6P caused modest (20 to 30 %) inhibitions of the TPP activity of both intact and truncated enzymes, and at saturating phosphate concentrations, smaller inhibitions (10 to 15 %) were observed (data not shown).

25 These findings disclose a profound sensitivity of the TPS activity of intact trehalose synthase to physiological phosphate and F6P concentrations that is lost by truncation of the 123 kDa long chain to about 85 kDa. The effects of
30 truncation are less marked on the TPP activities, both enzymes being activated by physiological phosphate concentrations, and neither showing a strong response to F6P. The data suggest that intact enzyme has two strong phosphate binding sites, one of which is located in the region of the 123 kDa long chain
35 removed by truncation. The finding that the 123 kDa long chain could not be recovered from phosphocellulose, disclosed in Example 9 supports this conclusion.

Example 13 Expression of TPS activity in Escherichia coli cells transformed with TSS1 and TSL1

E. coli, strain HB101 (ALKO 683) was transformed with the plasmids pALK752 and pALK754 consisting of pBluescript containing TSS1 and TSL1, respectively (see Example 14 and Figs 20a and 20c). Transformants ALKO3566 and ALKO3568 containing, respectively, pALK752 and pALK754 were selected and maintained by growth in the presence of 50 µg/ml of ampicillin. Shake flasks containing Luria Broth with no ampicillin (ALKO 683) or 15 µg/ml ampicillin (ALKO3566 and ALKO3568) were inoculated with 1 ml of a suspension ($A_{600} = 1.5$) of the appropriate cells and shaken at 250 rpm and 30 °C for 15 h. Cells were harvested (5 min and 3000g), washed twice with water, suspended (1.5 g cells/3.7 ml) in HBMED containing 1 mM PMSF and 10 µg/ml pepstatin A, and broken by two passes through a French press (Aminco) at 15 000 psi. Samples of the homogenates were centrifuged 20 min at 28 000g. Homogenates and supernatants were assayed for TPS and TPP at once and the protein contents of the supernatants were determined (Table 10).

Table 10. Expression of TPS activity in *E. coli* transformed with TSS1 and TSL1.

Host (ALKO 683) and transformants (ALKO3566 containing TSS1 and ALKO3568 containing TSL1) were grown, harvested and broken as described in the text. Cell homogenates and supernatants were assayed at once for TPS, using the standard assay and a blank assay from which G6P and F6P were omitted, and for TPP. Activities are shown as mU/g fresh cells unless stated otherwise.

70

		<u>ALKO 683</u>	<u>ALKO3566</u>	<u>ALKO3568</u>
	Cell yield (g/200 ml)	1.57	1.51	1.56
5	<u>Homogenates</u>			
	Standard TPS	361 ± 75	1065 ± 118	260 ± 23
	TPS Blank	363 ± 57	227 ± 45	117 ± 77
	Net TPS	0 ± 20	840 ± 70	140 ± 50
10	Standard TPP	1130 ± 70	1110 ± 100	1190 ± 80
	<u>Supernatants</u>			
	Standard TPS	273 ± 73	699 ± 47	233 ± 68
	TPS Blank	263 ± 21	155 ± 42	135 ± 9
15	Net TPS	10 ± 50	540 ± 10	100 ± 60
	Net TPS (mU/mg protein)	0.08	4.50	0.87
20	Standard TPP	1130 ± 100	910 ± 90	1020 ± 80

Standard and blank TPS assays both showed accelerating progress curves and results in Table 10 are mean ± range of 5 min and 10 min assays, which were handled separately to calculate the net TPS activity. Essentially all of the standard TPS activity measured in the host cells and about half of that in ALKO3568 cells was due to a blank reaction (presumably a phosphodiesterase) generating UDP from UDPG in the absence of G6P and F6P. The net TPS activity of host cells grown under these conditions was close to zero, whereas cells transformed with TSS1 or TSL1 contained 840 or 140 mU/g fresh cells, most of which (64 % and 71 %, respectively) was soluble. Compared to the host preparation, the specific activities of the net TPS in the 28 000 g supernatants were increased about 50-fold (ALKO3566) and 10-fold (ALKO3568). There are probably two reasons for the very low TPS activity of the host cells: trehalose-6-phosphate synthase of *E. coli* is induced by high osmotic strength, and although some strains also acquire activity in stationary phase, the enzyme activity itself is strongly activated by higher (0.25 M) cation concentrations than in our assay conditions [Giaever *et al* (1988) *Journal of Bacteriology* 170, 2841-2849].

No significant change in the TPP activities was observed. Host cells already contained 1100 mU/g of TPP measured in 25 mM phosphate (and more than 5 U/g measured in 25 mM Hepes buffer). If transformation with the plasmids would have generated TPP activity with a TPP/TPS ratio the same as in pure trehalose synthase from yeast, then the increments in TPP (about 250 and 40 mU/g for ALK03566 and ALK03568, respectively) would have been undetectable for ALK03568 and close to the experimental error for ALK03566.

Western analyses (Fig. 19) showed that ALK03566 specifically expressed a 57 kDa band recognized by anti-57K serum and more weakly reacting bands with smaller molecular masses. ALK03568 specifically expressed bands recognized by anti-93K serum at about 60, 36 and 35 kDa (strong), suggesting that extensive degradation of the long chain occurs in ALK03568 or that TSL1 is not correctly transcribed and translated.

These results disclose (1) TPS activity can be transferred to heterologous cells by either TSS1 or TSL1, (2) a TSS1 gene product has TPS activity and (3) also one or more (degraded) products of TSL1 has TPS activity. This latter finding is unexpected, because yeast containing a defective (Example 7) or disrupted (Example 14) TSS1 gene lack TPS activity. Possibly ALK03568 accumulates fortuitously degraded proteolytic products of the 123 kDa long chain of trehalose synthase that exhibit TPS activity even in the absence of the TSS1 product.

Obviously, transformation with TSS1 (or TSL1) alone can be used to introduce a trehalose synthetic pathway to an organism, such as E. coli HB101, that already has the capacity to generate trehalose from trehalose-6-phosphate, possibly via a non-specific phosphatase.

Example 14. Transformation of Yeast(1) Assembly of complete genes and truncated versions of TSL1.

5 Plasmids comprising the complete ORFs of TSS1 and TSL1 and a truncated ORF of TSL1 were assembled from appropriate immunopositive clones of the HaeIII and EcoRI libraries used in Examples 4 and 5 to sequence these genes:

10 (a) The TSS1 gene with its promoter (pALK 752)

A 516 bp fragment was cut from HaeIII clone 7 with restriction enzymes DraI and BstEII (see Fig 6 for restriction sites). The DraI site marks the beginning of the disclosed TSS1 sequence.
15 This fragment was joined to HaeIII clone 20 after this had been digested with BstEII and ClaI (the ClaI site was in the polylinker) and the ClaI end filled with Klenow fragment. The sequence at the junction at the BstEII site in the religated plasmid (shown in Fig 20a) was confirmed by sequencing.

20 (b) The TSS1 gene without its promoter (pALK753)

HaeIII clone 21 was cut with the restriction enzyme Tth111I. To this site the following linker (SEQ ID NO:84, synthesized with the ABI DNA Synthesizer) was added:

5'-CGGGAAGACA TAGAACTATG ACTACGGATA ACGCTAAGGC GCAACTGACC -3'
3'-GCCCTTCTGT ATCTTGATAC TGATGCCTAT TGCGATTCCG CGTTGACTGG -5'

This includes nucleotides -13 to +33 of TSS1 (see Fig. 4) but, when correctly orientated, introduces a SmaI site at nucleotide -16 from the ATG start site. The plasmid (shown in Fig 20b) can be used to release with SmaI the ORF of the TSS1 gene and about 200 bp of its terminator for further constructions (e.g. expression vectors containing a new promoter).

(c) The TSL1 gene with its promoter (pALK754)

EcoRI clone 10 was cut with the restriction enzymes MluI and NdeI, and the resulting 4.4 kb fragment was religated into the pBluescript SmaI site. This procedure destroyed all these sites, so that these restriction enzymes cannot be used in further manipulations. The plasmid is shown in Fig 20c.

(d) The TSL1 gene without its promoter (pALK757)

Primers for the polymerase chain reaction (PCR) were made against the beginning of the TSL1 gene and the sequence at +318. PCR (Techne PHC-2 Heat/Cool Dri-Block^R) was used to synthesize (at 55 °C) a 325 bp fragment, which had at one end a SpeI site and close to the other end a BsmI site. This fragment was digested with BsmI and can be ligated to pALK754 after cutting the latter with SpeI (at the site in the pBluescript polylinker) and BsmI and filling the SpeI site with Klenow fragment. For further manipulations, the gene can be isolated by cutting the resulting plasmid with SpeI and, for example, ClaI.

(e) A truncated TSL1 gene

A truncated version of TSL1 can be made by cutting pALK754 with StuI and joining the following linker (SEQ ID NO:85) to this site:

5'-GGGCCCAACA ACACAATGGT TACCCCGAAA TCGAGGGCGG GCAACAGG -3'
3'-CCCGGGTTGT TGTGTTACCA ATGGGGCTTT AGCTCCCGCC CGTTGTCC -5'

The linker recreates the StuI site and creates a new ATG start codon at +627 in frame with the coding sequence. Thus, this version of the gene encodes a truncated 123 kDa long chain lacking the first 209 amino acids. It was disclosed in Example 10 that removal of the first 325 or so amino acids proceeds without loss of catalytic activity, but releases trehalose synthase from strong inhibition by phosphate and the

requirement for F6P. Hence, this construction can encode a truncated 123 kDa polypeptide leading to a trehalose synthase with increased activity at physiological phosphate and F6P concentrations. A new SmaI site is included in the linker. The sequence flanking the new ATG on the 5'-side resembles the original ATG flanking sequence and the surrounding nucleotides are in accordance with the sequences known to occur most frequently at positions -7 to +4.

10 (2) Disruption mutants.

The TSS1 gene was disrupted to confirm that it is an essential gene in trehalose synthesis. The one-step gene disruption method [Rothstein, R.J. (1983) *Methods in Enzymology* 101, 202-211] was used as follows:

Plasmid pALK752 was cut with XcmI. A blunted SalI-XhoI fragment containing the LEU2 gene from plasmid yEp13 [Broach, J et al (1979) *Gene* 8, 121-133] was ligated to the blunted XcmI site. The resulting plasmid was cut with NsiI and PvuI and the reaction mixture was run through a 0.8% low-melting point agarose gel. A band of 4 kb was excised from the gel and purified. *S. cerevisiae* strain S150-2B was transformed (using the one-step alkali-cation method of Chen et al [(1992) *Current Genetics* 21, 83-84]) with the 4 kb DNA fragment containing the TSS1 gene interrupted by the LEU2 gene. *Leu*⁺ transformants were selected on minimal plates lacking leucine and containing glucose or galactose, and the clones obtained were then grown on YPD or YP/2% galactose, respectively.

As expected the phenotype of the disruptants resembled the *fdp1* and *cif1* phenotypes (see Example 2). Only one transformant (ALK03569) was isolated on glucose and the several transformants isolated on galactose were unable to grow on glucose. The glucose transformant and the tested galactose transformant (ALK03570) did not accumulate trehalose in stationary phase (≤ 0.2 % of dry wt.), lacked TPS and had low

TPP activity (≤ 10 % of wild type). The 57 kDa band could not be seen on Western blots. Southern analysis (Fig 21) showed that the TSS1 gene had been disrupted by a LEU2 gene, but the TSL1 gene was intact.

5

Another mutant, WDC-3A (see Table 1) with a disrupted TSS1 gene was obtained from the laboratory of Dr. C. Gancedo (Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain) as a *cif1::HIS3* disruptant. This mutant was easier to transform than were the *tss1::LEU2* disruptants, and so it was used to confirm that the TSS1 gene on a plasmid can confer TPS and TPP activities, trehalose accumulation and improved stress resistance. WDC-3A was transformed with the plasmid pMB4 (see Table 1; the plasmid contains an intact *CIF1* \equiv TSS1 gene and a selectable URA3 marker) and transformants selected in the absence of uracil. Western analyses (not shown) indicated that the transformants has acquired the 57 kDa band absent from WDC-3A. The parent and a transformant were grown in parallel in minimal medium containing 2 % galactose and (transformant) no uracil or (parent) uracil. Duplicate cultures of each strain were harvested in early stationary phase after 28 h growth samples taken for studies of stress resistance, and the rest used for trehalose and enzyme assays (Table 11).

25 Table 11. Analysis of WDC-3A and its pMB14 transformant.

Duplicate cultures were analyzed separately for trehalose and combined for enzyme assays. TPS activities were corrected for UDPGase activity in the absence of G6P and F6P.

30

76

	<u>WDC-3A</u> <u>(tss1::HIS3)</u>	<u>pMB14 (TSS1)</u> <u>Transformant</u>
Cell mass (g/100 ml medium)	2.6	2.8
Trehalose (% of dry wt.)	0.84, 0.81	2.9, 3.0
5 <u>Whole homogenates</u>		
TPP (U/g fresh yeast)	0.02	0.84
TPS (U/g fresh yeast)	0.84 \pm 0.37	17.9 \pm 3.5
<u>28,000 g supernatants</u>		
TPP (U/g fresh yeast)	0.01	0.67
10 TPS (U/G fresh yeast)	0.22 \pm 0.20	14.6 \pm 3.3
TPS (mU/mg protein)	4.0	223

These results disclose that introduction of TSS1 on a plasmid can restore both TPS and TPP activities and increase the trehalose content of an organism. The TPP/TPS ratio (5 %) is much lower than that (about 35 %) of purified trehalose synthase whereas the baker' yeast used in Example 1 and the X2180 used in Example 2 both have TPP/TPS ratios in their homogenates close to that of pure enzyme. This suggests that transformation with TSS1 in pMB14 increases TPP only up to a limit set by the genetic background of the host (probably the amounts of 99 and 123 kDa polypeptides present) but causes a larger increase in TPS due to activity associated also with 57 kDa chains not incorporated into the trehalose synthase complex.

Samples of the transformant and host were frozen in water at 1 μ g yeast/ml and kept for 5 days at -20 °C. The viability was then tested on plates containing YP/2 % galactose. After freezing stress, 1.0 \pm 0.1 % of the transformants and \leq 0.05 % of the host cells were viable. These results disclose that transformation of an organism with TSS1 can increase its resistance to freezing-stress.

(3) Strategies for transformation.

Laboratory strains of S. cerevisiae bearing auxotrophic markers such as his3, leu2, lys 2, trp1 and ura3 can be easily transformed with the trehalose synthase genes by essentially the same methods described for transformation of tss1 disruptants with TSS1. Versions of the genes in which the natural promoters and terminators are intact or have been replaced by (stronger and regulatable) promoters and terminators from other yeast genes can be used. For example, PGKI [pMA91; Mellor et al (1983) Gene 24, 1-14], ADC1 [pAAH5; Ammerer (1983) Methods in Enzymology 101, 192-201] and MEL1 [pALK3537, pALK41, etc., Suominen, P.L. (1988) Doctoral dissertation, University of Helsinki] systems have been used to increase the expression levels of genes in S. cerevisiae and other yeast. The MEL1 system has the advantage that the expression can be regulated, being repressed by glucose and induced by galactose. Standard vectors are available [episomal and integrating and centromere yeast plasmids are reviewed by Rose & Broach (1990) Methods in Enzymology 185, 234-279 and Stearns, T., Ma, H & Botstein, D. (1990) Methods in Enzymology 185, 280-291] that incorporate auxotrophic markers such as HIS3, LEU2, TRP1 and URA3, which can be used to select the transformants. Vectors based on these principles, but suited to a particular task can be constructed by a person familiar with the art.

The basic strategy is to leave the yeast with an intact version of its natural genes for trehalose synthase and introduce, either on episomes or integrated into a yeast chromosome, extra copies of the genes. These may be under control of their own promoters, or of stronger promoters and promoters that can be regulated, for example by adding substances such as galactose to the growth medium or by changing the temperature. The use of such promoters has been described [see, e.g., Mylin et al. (1990) Methods in Enzymology 185, 297-308; Sledziewski et al. (1990) Methods in Enzymology 185, 351-366]. This strategy

avoids problems that can be foreseen if all copies of the genes
genes are put under tight control (such as the defects in sugar
catabolism expected if TSS1 is not properly expressed; see
Example 7.) Transformed yeast bearing additional copies of the
5 genes with their natural promoters may accumulate enough
trehalose to exhibit the desired improvement in stability. They
may also cycle enough glucose units through trehalose during
fermentative conditions to generate an ATPase that accelerates
fermentation and increases the yield of ethanol on glucose.
10 Alternatively, the promoters of one or more genes can be
changed to promoters that are more active under fermentative
conditions. In another aspect of the invention, copies of the
ORFs of the genes can be inserted into expression vectors
equipped with powerful promoters (that may be regulatable) to
15 cause still larger increases in trehalose. This can be
particularly useful for the production of trehalose.

Transforming yeast with two or all three genes can be achieved
in several ways. The most obvious procedure is to use different
20 auxotrophic markers and introduce the genes sequentially.
Another method is to construct a YIp containing URA3 and a
modified version of, say, TSL1 with a stronger promoter but
still containing a region of homology upstream of this
promoter. After directed integration of this plasmid to the
25 chromosomal ura3 site and selection of URA⁺ transformants,
mutants in which the URA3 has again been excised (with a
frequency of about 1×10^{-4}) can be selected by growth on media
containing 5-fluoroorotic acid [see Stearns et al. (1990) loc.
cit.]. Some of the selected cells would contain a new version
30 of the gene, with the stronger promoter and can again be
transformed, this time with, say, a modified TSS1 gene. The
resultant transformants will contain one copy of TSL1 driven by
the new promoter, and two copies of TSS1, one of which is still
under the control of its natural promoter. Thirdly, a YIp
35 containing two or all three genes can be used to introduce the
genes in a single step.

Various methods to transform industrial, polyploid yeast, which lack auxotrophic markers have been described in the literature. Earlier methods have been reviewed by Knowles, J.K.C. & Tubb, R.S. [(1987) E.B.C. symposium on brewer's yeast, Helsinki, 1986. Monograph XII 169-185] and include the use of marker genes that confer resistance to antibiotics, methylglyoxal, copper, cinnamic acid and other compounds. These markers facilitate selection of transformants. Some of the marker genes are themselves of yeast origin, and so are preferred for acceptability reasons. When suitable modifications and combinations of the genes have been identified by using laboratory yeast, they may be transferred to industrial yeast using these procedures or others described in the literature, such as co-transformation with pALK2 and pALK7 [Suominen, P. I. (1988) loc. cit.]. These plasmids contain a readily selectable MEL1 marker gene on a 2 μ -based plasmid that can readily be cured, thus facilitating sequential transformation with more than one gene if it is not practicable to introduce the modified genes in one step using this co-transformation procedure.

Example 15. Transformation of crop plants.

Methods for the transformation of higher plants, including crop plants of economic importance, have been described [Goodman et al (1987) Science 236, 48-54; Weising et al, (1988) Annual Review of Genetics 22, 421-477; Glasser & Fraley (1989) Science 244, 1293-1299; Lindsey, K. (1992) Journal of Biotechnology 26, 1 - 28] and laboratory manuals setting out standard procedures are available such as the Plant Molecular Biology Manual [ed. Gelvin & Schnilperoort (1988) Kluwer Academic Press]. Of particular utility is the use of tissue specific promoters from the genes of proteins that are expressed in a highly tissue-specific manner [see, e.g., Higgins (1984) Annual Review of Plant Physiology 35, 191 et seq.; Shotwell and Larkins (1989) in The Biochemistry of Plants 15, 297 et seq.]. The use of such promoters will allow the expression of trehalose

synthase in (a) specifically the frost- and drought-sensitive tissues of plants so that they may be protected from these and equivalent stresses without diverting carbohydrate metabolism in the major storage tissues, or alternatively (b) precisely in the edible tissues. The purpose of this second alternative is to cause the accumulation of trehalose in products such as the fruit of tomatoes, in order to increase the shelf-life of these products. The expression of non-plant genes, with higher A+T contents than are commonly found in plant genes can generally be improved by changing the codons to increase the G+C content, and in particular to avoid regions of overall high A+T content Perlak et al. (1991) loc. cit.]. It is foreseen that such modifications will be beneficial in the case of the genes TSS1 and TSL1, which have A+T-rich regions. Selection systems are available for use in the transformation of higher plants, including plasmids comprising the gene (hpt) for hygromycin phosphotransferase [Dale & Ow (1991) Proceedings of the National Academy of Sciences, USA 88, 1055810562]. These and similar methods familiar to persons skilled in the art can be used, first to introduce various modifications of the yeast trehalose synthase genes into Arabidopsis thaliana, and then to transfer the most successful modifications to plants of economic importance.

One example of how one would transform a crop plant (dicots and some monocots) is via a Ti plasmid. A large fragment of the Ti plasmid encompassing both the T-DNA and vir regions is first cloned into the common bacterial plasmid pBR322. One or more of the trehalose synthase genes are then cloned into a non-essential region of the T-DNA and introduced into Agrobacterium tumefaciens carrying an intact Ti plasmid. The plants are then infected with these bacteria and the gene products of the vir region on the intact Ti plasmid mobilize the recombinant T-DNA, and the recombinant T-DNA integrates into the plant genome. One or more of the trehalose synthase genes can be introduced into the plant in this manner, by inserting the genes into either the same plasmid or separate plasmids.

SEQUENCE LISTING

(1) GENERAL INFORMATION

5

(i) APPLICANT:

(A) NAME: ALKO LTD. (et al.)
(B) STREET: Salmisaarenranta 7
(C) CITY: Helsinki
10 (D) COUNTRY: FINLAND
(E) POSTAL CODE: SF-00100

15 (ii) TITLE OF INVENTION: Increasing the trehalose content of
organisms by transforming them with
combinations of the structural genes
for trehalose synthase.

20 (iii) NUMBER OF SEQUENCES: 85

(iv) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US / 07/836,021
25 (B) FILING DATE: 14 February 1992

(A) APPLICATION NUMBER: US / 07/841,997
30 (B) FILING DATE: 28 February 1992

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 2481 base pairs
(B) TYPE: Nucleotide
(C) STRANDEDNESS: Doublestranded
(D) TOPOLOGY: Linear

40 (ii) MOLECULAR TYPE: Genomic DNA

(iii) HYPOTHETICAL: no

45 (iv) ANTI-SENSE: no

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Saccharomyces cerevisiae
(B) STRAIN: S288C
50 (E) HAPLOTYPE: Haploid

(vii) IMMEDIATE SOURCE

(A) LIBRARY: Genomic
(B) CLONE: 20

55 (viii) POSITION IN GENOME:

(A) CHROMOSOME: 2R

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1

	TTTTTAAACG	TATATAGATG	TCTACATGTG	TGTTTTTGTT	TTTTTACGTA	50
5	CGTATACCCA	CCTATATATG	CATAATCCGT	AATTGAAAAA	AAAAAAAGTA	100
	AAGATCAAGG	AACACATCAC	CCTGGGCACA	TCAAGCGTGA	GGAATGCCGT	150
	CCAACTGGTG	GAGACGCTTG	ATTTGCTCTT	TTTGTTCCTG	GGTCCAACCC	200
	GGTCTCGAAG	AACATCAGCA	CCACGCCCGC	AACGACAAAG	AACATTGCAA	250
	TACACTTGCA	TATGTGAGCA	TAGTCGAGCG	GTCCGTTCTG	TGTTTGATGC	300
10	TGTTGTTCTT	TCTTCTGTTT	GTCAGGGGTG	ATAGCCATAT	CTTCGTGCTC	350
	TTGTTGCGAT	TGTTCTGTTC	CATCTGCACC	AGAACAAAGA	ACAAAAGAAC	400
	AAGGAACAAA	GTCCAAGCAC	GTCAGCGCTG	TTTATAAGGG	GATTGACGAG	450
	GGATCGGGCC	TAGAGTGCCA	GCGCGCCAGG	GAGAGGGAGC	CCCCTGGGCC	500
	CTCATCCGCA	GGCTGATAGG	GGTCACCCCG	CTGGGCAGGT	CAGGGCAGGG	550
15	GCTCTCAGGG	GGGCGCCATG	GACAACTGCG	ACTGAGGTTT	TAAGACACAT	600
	GTATTATTGT	GAGTATGTAT	ATATAGAGAG	AGATTAAAGG	GTACAGCCGG	650
	GTGGTAGAGA	TTGATTAACT	TGGTAGTCTT	ATCTTGTCAG	TTGAGTTTCT	700
	GTCAGTTTCT	TCTTGAACAA	GCACGCAGCT	AAGTAAGCAA	CAAAGCAGGC	750
	TAACAAACTA	GGTACTCACA	TACAGACTTA	TTAAGACATA	GAACATATGAC	800
20	TACGGATAAC	GCTAAGGCGC	AACTGACCTC	GTCTTCAGGG	GGTAACATTA	850
	TTGTGGTGTC	CAACAGGCTT	CCCGTGACAA	TCACTAAAAA	CAGCAGTACG	900
	GGACAGTACG	AGTACGCAAT	GTCGTCCGGA	GGGCTGGTCA	CGGCGTTGGA	950
	AGGGTTGAAG	AAGACGTACA	CTTTCAAGTG	GTTCCGATGG	CCTGGGCTAG	1000
	AGATTCCCTGA	CGATGAGAAG	GATCAGGTGA	GGAAGGACTT	GCTGGAAGAG	1050
25	TTTAATGCCG	TACCCATCTT	CCTGAGCGAT	GAAATCGCAG	ACTTACACTA	1100
	CAACGGGTTT	AGTAATTCTA	TTCTATGGCC	GTTATTCCAT	TACCATCCTG	1150
	GTGAGATCAA	TTTCGACGAG	AATGCGTGGT	TCGGATACAA	CGAGGCAAAC	1200
	CAGACGTTCA	CCAACGAGAT	TGCTAAGACT	ATGAACCATA	ACGATTTAAT	1250
	CTGGGTGCAT	GATTACCATT	TGATGTTGGT	TCCGGAAATG	TTGAGAGTCA	1300
30	AGATTCACGA	GAAGCAACTG	CAAAACGTTA	AGGTCGGGTG	GTTCCCTGCAC	1350
	ACACCATTCC	CTTCGAGTGA	AATTTACAGA	ATCTTACCTG	TCAGACAAGA	1400
	GATTTTGAAG	GGTGTTTTGA	GTTGTGATTT	AGTCGGGTTC	CACACATACG	1450
	ATTATTGCAAG	ACATTTCTTG	TCTTCCGTGC	AAAGAGTGCT	TAACGTGAAC	1500
	ACATTGCCTA	ATGGGGTGGA	ATACCAAGGC	AGATTGCTTA	ACGTAGGGGC	1550
35	CTTCCCTATC	GGTATCGACG	TGGACAAGTT	CACCGATGGG	TTGAAAAAGG	1600
	AATCCGTACA	AAAGAGAATC	CAACAATTGA	AGGAACTTTT	CAAGGGCTGC	1650
	AAGATCATAG	TTGGTGTGCG	CAGGCTGGAT	TACATCAAAG	GTGTGCCTCA	1700
	GAAGTTGCAC	GCCATGGAAG	TGTTTCTGAA	CGAGCATCCA	GAATGGAGGG	1750
	GCAAGGTTGT	TCTGGTACAG	GTTGCAGTGC	CAAGTCGTGG	AGATGTGGAA	1800
40	GAGTACCAAT	ATTTAAGATC	TGTGGTCAAT	GAGTTGGTCG	GTAGAATCAA	1850
	CGGTACAGTT	GGTACTGTGG	AATTCGTCCC	CATCCATTTC	ATGCACAAGT	1900
	CTATACCATT	TGAAGAGCTG	ATTTTCGTTT	ATGCTGTGAG	CGATGTTTGT	1950
	TTGGTCTCGT	CCACCCGTGA	TGGTATGAAC	TTGGTTTCCT	ACGAATATAT	2000
	TGCTTGCCAA	GAAGAAAAGA	AAGGTTCCCT	AATCCTGAGT	GAGTTCACAG	2050
45	GTGCCGCACA	ATCCTTGAAT	GGTGCTATTA	TTGTAAATCC	TTGGAACACC	2100
	GATGATCTTT	CTGATGCCAT	CAACGAGGCC	TTGACTTTGC	CCGATGTAAA	2150
	GAAAGAAGTT	AACTGGGAAA	AACTTTACAA	ATACATCTCT	AAATACACTT	2200
	CTGCCTTCTG	GGGTGAAAAT	TTCGTCCATG	AATTATACAG	TACATCATCA	2250
	AGCTCAACAA	GCTCCTCTGC	CACCAAAAAC	TGATGAACCC	GATGCAAAATG	2300
50	AGACGATCGT	CTATTCTCTG	TCCGGTTTTT	TCTGCCCTCT	CTTCTATTCA	2350
	CTTTTTTTAT	ACTTTATATA	AAATTATATA	AATGACATAA	CTGAAACGCC	2400
	ACACGTCCTC	TCCTATTCTG	TAACGCCTGT	CTGTAGCGCT	GTTACTGAAG	2450
	CTGCCCAAGT	AGTTTTTTTCA	CCGTATAGGC	C		2481

(3) INFORMATION FOR SEQ ID NO:2

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 495 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: Polypeptide

10 (iii) HYPOTHETICAL: Yes

---(xi) SEQUENCE DESCRIPTION:SEQ ID-NO:2

15	Met Thr Thr Asp Asn Ala Lys Ala Gln Leu Thr Ser Ser Ser Gly	5	10	15
	Gly Asn Ile Ile Val Val Ser Asn Arg Leu Pro Val Thr Ile Thr	20	25	30
	Lys Asn Ser Ser Thr Gly Gln Tyr Glu Tyr Ala Met Ser Ser Gly	35	40	45
20	Gly Leu Val Thr Ala Leu Glu Gly Leu Lys Lys Thr Tyr Thr Phe	50	55	60
	Lys Trp Phe Gly Trp Pro Gly Leu Glu Ile Pro Asp Asp Glu Lys	65	70	75
25	Asp Gln Val Arg Lys Asp Leu Leu Glu Lys Phe Asn Ala Val Pro	80	85	90
	Ile Phe Leu Ser Asp Glu Ile Ala Asp Leu His Tyr Asn Gly Phe	95	100	105
	Ser Asn Ser Ile Leu Trp Pro Leu Phe His Tyr His Pro Gly Glu	110	115	120
30	Ile Asn Phe Asp Glu Asn Ala Trp Phe Gly Tyr Asn Glu Ala Asn	125	130	135
	Gln Thr Phe Thr Asn Glu Ile Ala Lys Thr Met Asn His Asn Asp	140	145	150
35	Leu Ile Trp Val His Asp Tyr His Leu Met Leu Val Pro Glu Met	155	160	165
	Leu Arg Val Lys Ile His Glu Lys Gln Leu Gln Asn Val Lys Val	170	175	180
	Gly Trp Phe Leu His Thr Pro Phe Pro Ser Ser Glu Ile Tyr Arg	185	190	195
40	Ile Leu Pro Val Arg Gln Glu Ile Leu Lys Gly Val Leu Ser Cys	200	205	210
	Asp Leu Val Gly Phe His Thr Tyr Asp Tyr Ala Arg His Phe Leu	215	220	225
45	Ser Ser Val Gln Arg Val Leu Asn Val Asn Thr Leu Pro Asn Gly	230	235	240
	Val Glu Tyr Gln Gly Arg Phe Val Asn Val Gly Ala Phe Pro Ile	245	250	255
	Gly Ile Asp Val Asp Lys Phe Thr Asp Gly Leu Lys Lys Glu Ser	260	265	270
50	Val Gln Lys Arg Ile Gln Gln Leu Lys Glu Thr Phe Lys Gly Cys	275	280	285
	Lys Ile Ile Val Gly Val Asp Arg Leu Asp Tyr Ile Lys Gly Val	290	295	300
55	Pro Gln Lys Leu His Ala Met Glu Val Phe Leu Asn Glu His Pro	305	310	315

84

	Glu	Trp	Arg	Gly	Lys	Val	Val	Leu	Val	Gln	Val	Ala	Val	Pro	Ser	
					320					325					330	
	Arg	Gly	Asp	Val	Glu	Glu	Tyr	Gln	Tyr	Leu	Arg	Ser	Val	Val	Asn	
					335					340					345	
5	Glu	Leu	Val	Gly	Arg	Ile	Asn	Gly	Gln	Phe	Gly	Thr	Val	Glu	Phe	
					350					355					360	
	Val	Pro	Ile	His	Phe	Met	His	Lys	Ser	Ile	Pro	Phe	Glu	Glu	Leu	
					365					370					375	
10	Ile	Ser	Leu	Tyr	Ala	Val	Ser	Asp	Val	Cys	Leu	Val	Ser	Ser	Thr	
					380					385					390	
	Arg	Asp	Gly	Met	Asn	Leu	Val	Ser	Tyr	Glu	Tyr	Ile	Ala	Cys	Gln	
					395					400					405	
	Glu	Glu	Lys	Lys	Gly	Ser	Leu	Ile	Leu	Ser	Glu	Phe	Thr	Gly	Ala	
					410					415					420	
15	Ala	Gln	Ser	Leu	Asn	Gly	Ala	Ile	Ile	Val	Asn	Pro	Trp	Asn	Thr	
					425					430					435	
	Asp	Asp	Leu	Ser	Asp	Ala	Ile	Asn	Glu	Ala	Leu	Thr	Leu	Pro	Asp	
					440					445					450	
20	Val	Lys	Lys	Glu	Val	Asn	Trp	Glu	Lys	Leu	Tyr	Lys	Tyr	Ile	Ser	
					455					460					465	
	Lys	Tyr	Thr	Ser	Ala	Phe	Trp	Gly	Glu	Asn	Phe	Val	His	Glu	Leu	
					470					475					480	
	Tyr	Ser	Thr	Ser	Ser	Ser	Ser	Thr	Ser	Ser	Ser	Ala	Thr	Lys	Asn	
					485					490					495	
25																

(4) INFORMATION FOR SEQ ID NO:3

- (i) SEQUENCE CHARACTERISTICS
- 30 (A) LENGTH: 3000 base pairs
- (B) TYPE: Nucleotide
- (C) STRANDEDNESS: Doublestranded
- (D) TOPOLOGY: Linear
- 35 (ii) MOLECULAR TYPE: Genomic DNA
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- 40 (vi) ORIGINAL SOURCE:
- (A) ORGANISM: *Saccharomyces cerevisiae*
- (B) STRAIN: S288C
- (E) HAPLOTYPE: Haploid
- 45 (vii) IMMEDIATE SOURCE:
- (A) LIBRARY: Genomic
- (B) CLONE: 6
- 50 (vii) POSITION IN GENOME
- (A) CHROMOSOME: 13
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3

	CCTCCTCTGG	ATCTTCTGGG	TCTTCTGCGC	CACCTTCCAT	TAAAAGGATT	50
	ACGCCCCACT	TGACTGCGTC	TGCTGCAAAA	CAGCGTCCCT	TATTGGCTAA	100
	ACAGCCTTCT	AATCTGAAAT	ATTTCGGAGTT	AGCAGATATT	TCGTGAGTG	150
	AGACGTCTTC	GCAGCATAAT	GAGTCGGACC	CGGATGATCT	AACTACTGCC	200
5	CTGACGAGGA	TATGTTTCTG	ATTAGGAATT	GATGACGCGA	GAGGACTACA	250
	AGGTTCAAAG	TTCGGCGCTA	TTCATAAATC	AACTAAGAAA	TATGCGCTGT	300
	TAAGGTCATC	TCAGGAGCTG	TTTAGCCGTC	TTCCATGGTC	GATCGTTCCC	350
	TCTATCAAAG	GTAATGGCGC	CATGAAGAAC	GCCATAAACA	CTGCAGTCTT	400
	GGAGAATATC	ATTCCGCACC	GTCATGTTAA	GTGGGTCGGT	ACCGTCGGAA	450
10	TCCCAACGGA	TGAGATTCCG	GAAAATATCC	TTGCGAACAT	CTCTGACTCT	500
	TTAAAAGACA	AGTACGACTC	CTATCCTGTC	CTTACGGACG	ACGACACCTT	550
	CAAAGCCGCA	TACAAAAACT	ACTGTAAACA	AATCTTGTGG	CCTACGCTGC	600
	ATTACCAGAT	TCCAGACAAT	CCGAACCTGA	AGGCTTTTGA	AGATCACTCT	650
	TGGAAGTTCT	ATAGAAACTT	AAACCAAAGG	TTTGCGGACG	CGATCGTTAA	700
15	AATCTATAAG	AAAGGTGACA	CCATCTGGAT	TCATGATTAC	CATTTAATGC	750
	TGGTTCCGCA	GATGCTGAGA	GACGTCTTGC	CTTTTGCCAA	AATAGGATTT	800
	ACCTTACATG	TCTCGTTCCC	CAGTAGTGAA	GTGTTTAGGT	GTCTGGCTCA	850
	GCGTGAGAAG	ATCTTAGAAG	GCTTGACCGG	TGCAGACTTT	GTCGGCTTCC	900
	AGACGAGGGA	GTATGCAAGA	CATTTCTTAC	AGACGTCTAA	CCGTCTGCTA	950
20	ATGGCGGACG	TGGTACATGA	TGAAGAGCTA	AAGTATAACG	GCAGAGTCGT	1000
	TTCTGTGAGG	TTCACCCCAG	TTGGTATCGA	CGCCTTTGAT	TTGCAATCGC	1050
	AATTGAAGGA	TGGAAGTGTC	ATGCAATGGC	GTCAATTGAT	TCGTGAAAGA	1100
	TGGCAAGGGA	AAAAACTAAT	TGTGTGTCTG	GATCAATTCG	ATAGAATTAG	1150
	AGGTATTAC	AAGAAATTGT	TGGCTTATGA	AAAATTCTTG	GTCGAAAATC	1200
25	CGGAATACGT	GGAAAAATCG	ACTTTAATTC	AAATCTGTAT	TGGAAGCAGT	1250
	AAGGATGTAG	AACTGGAGCG	CCAGATCATG	ATTGTCGTGG	ATAGAATCAA	1300
	CTCGCTATCC	ACCAATATTA	GTATTTCTCA	ACCTGTGGTG	TTTTTGTCATC	1350
	AAGATCTAGA	TTTTTCTCAG	TATTTAGCTT	TGAGTTCAGA	GGCAGATTTG	1400
	TTCTAGTCA	GCTCTCTAAG	GGAGGGTATG	AACTTGACAT	GTCACGAATT	1450
30	TATCGTTTGT	TCTGAGGACA	AAAATGCTCC	CCTACTGTTG	TCAGAATTTA	1500
	CTGGTAGTGC	ATCTTTATTG	AATGATGGCG	CTATAATAAT	TAACCCATGG	1550
	GATACCAAGA	ACTTCTCACA	AGCCATTCTC	AAGGGGTTGG	AGATGCCATT	1600
	CGATAAGAGA	AGGCCACAGT	GGAAGAAATT	GATGAAAGAC	ATTATCAACA	1650
	AGGACTCTAC	AAACTGGATC	AAGACTTCTT	TACAAGATAT	TCATATTTTCG	1700
35	TGGCAATTCA	ATCAAGAAGG	TTCCAAGATC	TTCAAATTGA	ATACAAAAAC	1750
	ACTGATGGAA	GATTACCAGT	CATCAATAAA	GCGTATGTTT	GTTTTCAACA	1800
	TTGCTGAACC	ACCTTCATCG	AGAATGATTT	CCATACTGAA	TGACATGACT	1850
	TCTAAGGGCA	ATATCGTTTA	CATCATGAAC	TCATTTCCAA	AGCCCATTCT	1900
	GGAAAATCTT	TACAGTCGTG	TGCAAAACAT	TGGGTTGATT	GCCGAGAATG	1950
40	GTGCATACGT	TAGTCTGAAC	GGTGTATGGT	ACAACATTGT	TGATCAAGTC	2000
	GATTGGCGTA	ACGATGTAGC	CAAAATTCTC	GAGGACAAAG	TGGAGAGATT	2050
	ACCTGGCTCG	TACTACAAGA	TAAATGAGTC	CATGATCAAG	TTCCACACTG	2100
	AAAATGCGGA	AGATCAAGAT	CGTGTAGCTA	GTGTTATCGG	TGATGCCATC	2150
	ACACATATCA	ATACTGTTTT	TGACCACAGA	GGTATTCATG	CCTACGTTTA	2200
45	CAAAAACGTT	GTTTCCGTAC	AACAAGTGGG	ACTTTCCTTA	TCGGCAGCTC	2250
	AATTTCTTTT	CAGATTCTAT	AATTCTGCTT	CGGATCCACT	GGATACGAGT	2300
	TCCGGCCAAA	TCACAAATAT	TCAGACACCA	TCTCAACAAA	ATCCTTCAGA	2350
	TCAAGAACAA	CAACCTCCAG	CCTCTCCAC	TGTGTCGATG	AACCATATTG	2400
	ATTTTCGCATG	TGTCTCTGGT	TCATCGTCTC	CTGTGCTTGA	ACCATTGTTT	2450
50	AAATTGGTCA	ATGATGAAGC	AAGTGAAGGG	CAAGTAAAG	CCGGACACGC	2500
	CATTGTTTAT	GGTGATGCTA	CTTCTACTTA	TGCCAAAGAA	CATGTAAATG	2550
	GGTTAAACGA	ACTTTTCACG	ATCATTTCAA	GAATCATTGA	AGATTAAATT	2600
	TTACCATTTT	AAAATTTTAA	TGTTCTTGGG	TATGAACTTT	TATTTTCAAC	2650
	TGCTTATTAT	ATATCAATT	TATAAATTTT	TTTCTTCTCT	CTAACGACCA	2700
55	ATTATAAAAT	TCATCCTCTT	ATTTATTACA	GCATCTTATA	CATTATGTAT	2750
	ATGGGTAGCT	ATTATTCAAT	TTTGCTTCGT	AAGGACTTTT	TTTGTCAACT	2800

TTTTCATCCT AAGCGGCTAA AAGTGATTGG AGAGGAATGT CCAGGCGACC 2850
 AATGATAAAA ACGCTTTCTC TTGGAACAAG AAATAGGAGC AATTGACAGT 2900
 TGTCGATGAA CAGCGAAAAT AGTAAGATAA CCTTCAAGCC CAATATTCTA 2950
 ATTAAAGGCG TTTATATATT TGTACTTTAT GGTATGTGCA TATGTATTGT 3000

5

(5) INFORMATION FOR SEQ ID NO:4

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 785 amino acids

(B) TYPE: Amino acid

(D) TOPOLOGY: Linear

15 (ii) MOLECULAR TYPE: Polypeptide

(iii) HYPOTHETICAL: Yes

(v) FRAGMENT TYPE: C-terminal

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4

25	Arg Gly Leu Gln Gly Ser Lys Phe Gly Ala Ile His Lys Ser Thr	5	10	15
	Lys Lys Tyr Ala Leu Leu Arg Ser Ser Gln Glu Leu Phe Ser Arg	20	25	30
	Leu Pro Trp Ser Ile Val Pro Ser Ile Lys Gly Asn Gly Ala Met	35	40	45
30	Lys Asn Ala Ile Asn Thr Ala Val Leu Glu Asn Ile Ile Pro His	50	55	60
	Arg His Val Lys Trp Val Gly Thr Val Gly Ile Pro Thr Asp Glu	65	70	75
	Ile Pro Glu Asn Ile Leu Ala Asn Ile Ser Asp Ser Leu Lys Asp	80	85	90
35	Lys Tyr Asp Ser Tyr Pro Val Leu Thr Asp Asp Asp Thr Phe Lys	95	100	105
	Ala Ala Tyr Lys Asn Tyr Cys Lys Gln Ile Leu Trp Pro Thr Leu	110	115	120
40	His Tyr Gln Ile Pro Asp Asn Pro Asn Ser Lys Ala Phe Glu Asp	125	130	135
	His Ser Trp Lys Phe Tyr Arg Asn Leu Asn Gln Arg Phe Ala Asp	140	145	150
	Ala Ile Val Lys Ile Tyr Lys Lys Gly Asp Thr Ile Trp Ile His	155	160	165
45	Asp Tyr His Leu Met Leu Val Pro Gln Met Val Arg Asp Val Leu	170	175	180
	Pro Phe Ala Lys Ile Gly Phe Thr Leu His Val Ser Phe Pro Ser	185	190	195
50	Ser Glu Val Phe Arg Cys Leu Ala Gln Arg Glu Lys Ile Leu Glu	200	205	210
	Gly Leu Thr Gly Ala Asp Phe Val Gly Phe Gln Thr Arg Glu Tyr	215	220	225
	Ala Arg His Phe Leu Gln Thr Ser Asn Arg Leu Leu Met Ala Asp	230	235	240
55	Val Val His Asp Glu Glu Leu Lys Tyr Asn Gly Arg Val Val Ser			

		245		250		255
	Val Arg Phe Thr	Pro Val Gly Ile Asp	Ala Phe Asp Leu Gln Ser			
		260		265		270
5	Gln Leu Lys Asp	Gly Ser Val Met Gln Trp Arg Gln Leu Ile Arg				
		275		280		285
	Glu Arg Trp Gln	Gly Lys Lys Leu Ile Val Cys Arg Asp Gln Phe				
		290		295		300
	Asp Arg Ile Arg	Gly Ile His Lys Lys Leu Leu Ala Tyr Glu Lys				
		305		310		315
10	Phe Leu Val Glu	Asn Pro Glu Tyr Val Glu Lys Ser Thr Leu Ile				
		320		325		330
	Gln Ile Cys Ile	Gly Ser Ser Lys Asp Val Glu Leu Glu Arg Gln				
		335		340		345
	Ile Met Ile Val	Val Asp Arg Ile Asn Ser Leu Ser Thr Asn Ile				
15		350		355		360
	Ser Ile Ser Gln	Pro Val Val Phe Leu His Gln Asp Leu Asp Phe				
		365		370		375
	Ser Gln Tyr Leu	Ala Leu Ser Ser Glu Ala Asp Leu Phe Val Val				
		380		385		390
20	Ser Ser Leu Arg	Glu Gly Met Asn Leu Thr Cys His Glu Phe Ile				
		395		400		405
	Val Cys Ser Glu	Asp Lys Asn Ala Pro Leu Leu Leu Ser Glu Phe				
		410		415		420
	Thr Gly Ser Ala	Ser Leu Leu Asn Asp Gly Ala Ile Ile Ile Asn				
25		425		430		435
	Pro Trp Asp Thr	Lys Asn Phe Ser Gln Ala Ile Leu Lys Gly Leu				
		440		445		450
	Glu Met Pro Phe	Asp Lys Arg Arg Pro Gln Trp Lys Lys Leu Met				
		455		460		465
30	Lys Asp Ile Ile	Asn Asn Asp Ser Thr Asn Trp Ile Lys Thr Ser				
		470		475		480
	Leu Gln Asp Ile	His Ile Ser Trp Gln Phe Asn Gln Glu Gly Ser				
		485		490		495
	Lys Ile Phe Lys	Leu Asn Thr Lys Thr Leu Met Glu Asp Tyr Gln				
35		500		505		510
	Ser Ser Lys Lys	Arg Met Phe Val Phe Asn Ile Ala Glu Pro Pro				
		515		520		525
	Ser Ser Arg Met	Ile Ser Ile Leu Asn Asp Met Thr Ser Lys Gly				
		530		535		540
40	Asn Ile Val Tyr	Ile Met Asn Ser Phe Pro Lys Pro Ile Leu Glu				
		545		550		555
	Asn Leu Tyr Ser	Arg Val Gln Asn Ile Gly Leu Ile Ala Glu Asn				
		560		565		570
	Gly Ala Tyr Val	Ser Leu Asn Gly Val Trp Tyr Asn Ile Val Asp				
45		575		580		585
	Gln Val Asp Trp	Arg Asn Asp Val Ala Lys Ile Leu Glu Asp Lys				
		590		595		600
	Val Glu Arg Leu	Pro Gly Ser Tyr Tyr Lys Ile Asn Glu Ser Met				
		605		610		615
50	Ile Lys Phe His	Thr Glu Asn Ala Glu Asp Gln Asp Arg Val Ala				
		620		625		630
	Ser Val Ile Gly	Asp Ala Ile Thr His Ile Asn Thr Val Phe Asp				
		635		640		645
	His Arg Gly Ile	His Ala Tyr Val Tyr Lys Asn Val Val Ser Val				
55		650		655		660
	Gln Gln Val Gly	Leu Ser Leu Ser Ala Ala Gln Phe Leu Phe Arg				

88

					665					670					675
	Phe	Tyr	Asn	Ser	Ala	Ser	Asp	Pro	Leu	Asp	Thr	Ser	Ser	Gly	Gln
					680					685					690
	Ile	Thr	Asn	Ile	Gln	Thr	Pro	Ser	Gln	Gln	Asn	Pro	Ser	Asp	Gln
5					695					700					705
	Glu	Gln	Gln	Pro	Pro	Ala	Ser	Pro	Thr	Val	Ser	Met	Asn	His	Ile
					710					715					720
	Asp	Phe	Ala	Cys	Val	Ser	Gly	Ser	Ser	Ser	Pro	Val	Leu	Glu	Pro
					725					730					735
10	Leu	Phe	Lys	Leu	Val	Asn	Asp	Glu	Ala	Ser	Glu	Gly	Gln	Val	Lys
					740					745					750
	Ala	Gly	His	Ala	Ile	Val	Tyr	Gly	Asp	Ala	Thr	Ser	Thr	Tyr	Ala
					755					760					765
	Lys	Glu	His	Val	Asn	Gly	Leu	Asn	Glu	Leu	Phe	Thr	Ile	Ile	Ser
15					770					775					780
	Arg	Ile	Ile	Glu	Asp										
					785										

20 (6) INFORMATION FOR SEQ ID NO:5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: Amino acid

25 (D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:5

35 Tyr Ile Ser Lys

(7) INFORMATION FOR SEQ ID NO:6

40 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: Amino acid

(D) TOPOLOGY: Linear

45 (ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

50

(v) SEQUENCE DESCRIPTION: SEQ ID NO:6

Asp Val Glu Glu Tyr Gln Tyr Leu Arg

5

55

(8) INFORMATION FOR SEQ ID NO:7

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: Amino acid

(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

~~(iv) FRAGMENT TYPE: N-terminal~~

(v) SEQUENCE DESCRIPTION: SEQ ID NO:7

15

His Phe Leu Ser Ser Val Gln Arg

5

20 (9) INFORMATION FOR SEQ ID NO:8

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids

(B) TYPE: Amino acid

25

(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:8

35 Val Leu Asn Val Asn Thr Leu Pro Asn Gly Val Glu Tyr Gln

5

10

(10) INFORMATION FOR SEQ ID NO:9

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: Amino acid

(D) TOPOLOGY: Linear

45

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:9

Ser Val Val Asn Glu Leu Val Gly Arg

55

5

90

(11) INFORMATION FOR SEQ ID NO:10

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 4
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

~~(iv) FRAGMENT TYPE: N-terminal~~

(v) SEQUENCE DESCRIPTION: SEQ ID NO:10

15 Glu Thr Phe Lys

(12) INFORMATION FOR SEQ ID NO:11

20

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

25

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:11

35 Leu Asp Tyr Ile Lys
5

(13) INFORMATION FOR SEQ ID NO:12

40

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

45

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:12

Ile Leu Pro Val Arg
5

55

(14) INFORMATION FOR SEQ ID NO:13

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: Amino acid

(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:13

15

Glu Val Asn Xaa Glu Lys

5

20 (15) INFORMATION FOR SEQ ID NO:14

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: Amino acid

25

(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:14

35

Phe Tyr Asp Xaa Xaa

5

(16) INFORMATION FOR SEQ ID NO:15

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: Amino acid

45

(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:15

55

Leu Xaa Ala Met Glu Val Phe Leu Asn Glu Xaa Pro Glu

5

10

(17) INFORMATION FOR SEQ ID NO:16

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 14 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

~~(iv) FRAGMENT TYPE: N-terminal~~

(v) SEQUENCE DESCRIPTION: SEQ ID NO:16

15

Tyr Thr Ser Ala Phe Trp Gly Glu Asn Phe Val Xaa Glu Leu
5 10

20 (18) INFORMATION FOR SEQ ID NO:17

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 9 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

30 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:17

35 Phe Gly Xaa Pro Gly Leu Glu Ile Pro
5

40 (19) INFORMATION FOR SEQ ID NO:18

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 6 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:18

55 Xaa Gly Ser Val Met Gln
5

93

(20) INFORMATION FOR SEQ ID NO:19

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 7 amino acids

(B) TYPE: Amino acid

(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:19

15

Leu Pro Gly Ser Tyr Tyr Lys

5

20 (21) INFORMATION FOR SEQ ID NO:20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 12 amino acids

(B) TYPE: Amino acid

25

(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:20

35

Asp Ala Ile Val Val Asn Pro Met Asp Ser Val Ala

5

10

(22) INFORMATION FOR SEQ ID NO:21

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 5 amino acids

(B) TYPE: Amino acid

(D) TOPOLOGY: Linear

45

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:21

Met Ile Ser Ile Leu

55

5

(23) INFORMATION FOR SEQ ID NO:22

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 6 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:22

15 Arg Arg Pro Gln Trp Lys
5

20 (24) INFORMATION FOR SEQ ID NO:23

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 5 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:23

35 Ser Xaa Pro Gln Lys
5

(25) INFORMATION FOR SEQ ID NO:24

- 40 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH 15 amino acids
(B) TYPE: Amino acid
45 (D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:24

55 Phe Tyr Arg Asn Leu Asn Gln Arg Phe Ala Asp Ala Ile Val Lys
5 10 15

95

(26) INFORMATION FOR SEQ ID NO:25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 11 amino acids

(B) TYPE: Amino acid

(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:25

15

Asp Gly Ser Val Met Gln Xaa Xaa Gln Leu Xaa
5 10

20 (27) INFORMATION FOR SEQ ID NO:26

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 18 amino acids

(B) TYPE: Amino acid

25 (D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:26

35 Asn Ala Ile Asn Thr Ala Val Leu Glu Asn Ile Ile Pro Xaa Xaa
5 10 15
Xaa Val Lys

40 (28) INFORMATION FOR SEQ ID NO:27

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 12 amino acids

(B) TYPE: Amino acid

45 (D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:27

55 Leu Val Asn Asp Glu Ala Ser Glu Gly Gln Val Lys
5 10

(29) INFORMATION FOR SEQ ID NO:28

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 11 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

- 10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

15 (v) SEQUENCE DESCRIPTION: SEQ ID NO:28

Xaa Gln Asp Ile Leu Leu Asn Asn Thr Phe Xaa
5 10

20

(30) INFORMATION FOR SEQ ID NO:29

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 14 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

30 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:29

35 Asp Thr Thr Gln Thr Ala Pro Val Xaa Asn Asn Val Xaa Pro
5 10

40 (31) INFORMATION FOR SEQ ID NO:30

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 11 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:30

55 Asn Gln Leu Asp Ala Xaa Asn Tyr Ala Glu Val
5 10

(32) INFORMATION FOR SEQ ID NO:31

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH 10 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: Yes

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:31

Asn Leu Ser Arg Trp Arg Asn Tyr Ala Glu
 5 10

(33) INFORMATION FOR SEQ ID NO:32

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH 4 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: Yes

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:32

Trp Gln Gly Lys

(34) INFORMATION FOR SEQ ID NO:33

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH 11 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:33

Ile Gln Leu Gly Glu Ser Asn Asp Asp Xaa Xaa
 5 10

(35) INFORMATION FOR SEQ ID NO:34

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 11 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:34

15 Gln Val Pro Thr Ile Gln Asp Xaa Thr Asn Lys
5 10

20 (36) INFORMATION FOR SEQ ID NO:35

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 6 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:35

35 Ile Tyr Xaa Tyr Val Lys
5

40 (37) INFORMATION FOR SEQ ID NO:36

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 6 amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION: SEQ ID NO:36

55 Asn Gln Leu Gly Asn Tyr
5

99

(38) INFORMATION FOR SEQ ID NO:37

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 4 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

15 (v) SEQUENCE DESCRIPTION FOR SEQ ID NO:37

Val Ala Leu Thr

20 (39) INFORMATION FOR SEQ ID NO:38

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 12 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

25 (ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:38

35 Asp Ala Ile Val Val Asn Pro Xaa Asp Ser Val Ala
5 10

40 (40) INFORMATION FOR SEQ ID NO:39

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 9 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

45 (ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:39

55 Thr Phe Thr Asn Tyr Asp Gly Ser Lys
5

100

(41) INFORMATION FOR SEQ ID NO:40

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 10 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:40

15 Thr Gly Asn Asp Pro Ser His Ile Ala Lys
5 10

20 (42) INFORMATION FOR SEQ ID NO:41

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 7 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:41

35 Ile Tyr Glu Ser Gln Gly Lys
5

(43) INFORMATION FOR SEQ ID NO:42

40

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 12 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:42

55 Ala Glu Gly Ala Thr Gly Gly Leu Val Pro His Lys
5 10

101

(44) INFORMATION FOR SEQ ID NO:43

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 10 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

~~(iv) FRAGMENT TYPE: N-terminal~~

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:43

15

Leu Ala Thr Glu Leu Pro Ala Xaa Ser Lys
5 10

20 (45) INFORMATION FOR SEQ ID NO:44

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 8 amino acids

(B) TYPE: Amino acid

25 (C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:44

35 Ser Leu Leu Asp Ala Gly Ala Lys
5

40 (46) INFORMATION FOR SEQ ID NO:45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 14 amino acids

(B) TYPE: Amino acid

45 (C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:45

55 Glu Lys Pro Gln Asp Leu Asp Asp Asp Pro Leu Tyr Leu Thr
5 10

102

(47) INFORMATION FOR SEQ ID NO:46

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 11 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:46

15

Xaa Gln Xaa His Gln Asp Xaa Xaa Asn Leu Thr
5 10

20 (48) INFORMATION FOR SEQ ID NO:47

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 15 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

30 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:47

35 Phe Asn Asp Glu Ser Ile Ile Ile Gly Tyr Phe Xaa Xaa Ala Pro
5 10 15

40 (49) INFORMATION FOR SEQ ID NO:48

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 14 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:48

55 Ser Arg Leu Phe Leu Phe Asp Tyr Asp Gly Thr Leu Thr Pro
5 10

103

(50) INFORMATION FOR SEQ ID NO:49

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 11 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

~~(iv) FRAGMENT TYPE: N-terminal~~

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:49

15

Gln Leu Gly Asn Tyr Gly Phe Tyr Pro Val Tyr
5 10

20 (51) INFORMATION FOR SEQ ID NO:50

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 11 amino acids

(B) TYPE: Amino acid

25

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:50

35

Phe Leu Val Glu Asn Pro Glu Tyr Val Glu Lys
5 10

(52) INFORMATION FOR SEQ ID NO:51

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 11 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

45

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:51

55

Xaa Ile Thr Pro His Leu Thr Ala Xaa Ala Ala
5 10

104

(53) INFORMATION FOR SEQ ID NO:52

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 10 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) ~~FRAGMENT TYPE: N-terminal~~

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:52

15

Thr Leu Met Glu Asp Tyr Gln Ser Ser Lys
5 10

20 (54) INFORMATION FOR SEQ ID NO:53

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 15 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

30 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:53

35 Ile Leu Glu Gly Leu Thr Gly Ala Asp Phe Val Gly Phe Gln Thr
5 10 15

(55) INFORMATION FOR SEQ ID NO:54

40

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 14 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:54

55 Gln Ile Leu Xaa Pro Thr Leu Xaa Tyr Gln Ile Pro Asp Asn
5 10

105

(56) INFORMATION FOR SEQ ID NO:55

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 7 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

15 (v) SEQUENCE DESCRIPTION FOR SEQ ID NO:55

Phe Gly Gly Tyr Ser Asn Lys
5

20 (57) INFORMATION FOR SEQ ID NO:56

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 23 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

30 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:56

35 Phe Xaa Thr Glu Asn Ala Glu Asp Gln Asp Xaa Val Ala Xaa Val
5 10 15
Ile Gly Xaa Ala Ile Xaa Xaa Ile
20

40

(58) INFORMATION FOR SEQ ID NO:57

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 18 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

50 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

106

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:57

[illegible]

(59) INFORMATION FOR SEQ ID NO:58

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 19 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

15

(ii) MOLECULAR TYPE: Peptides

(iii) HYPOTHETICAL: No

20 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:58

25 Leu Leu Val His Ser Leu Leu Asn Asn Thr Ser Gln Thr Ser Leu
 5 10 15
Glu Gly Pro Asn

30 (60) INFORMATION FOR SEQ ID NO:59

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 20 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

35

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

40

(iv) **FRAGMENT TYPE: N-terminal**

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:59

45 Ser Ser Thr Thr Asn Thr Ala Thr Leu Xaa Xaa Leu Val Ser Ser
 5 10 15
Xaa Ile Phe Met Glu
 20

50

107

(61) INFORMATION FOR SEQ ID NO:60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 15 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:60

Ala Xaa Asn Arg Pro Thr Ser Ala Ala Thr Ser Leu Val Asn Arg
5 10 15

(62) INFORMATION FOR SEQ ID NO:61

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 6 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:61

Xaa Phe Thr Ile Ile Xaa
5

(63) INFORMATION FOR SEQ ID NO:62

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH 15 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:62

Asn Leu Thr Ala Asn Ala Thr Thr Ser His Thr Pro Thr Ser Lys
5 10 15

108

(64) INFORMATION FOR SEQ ID NO:63

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 7 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:63

15 Phe Xaa Xaa Tyr Ser Asn Lys
5

20 (65) INFORMATION FOR SEQ ID NO:64

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 7 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

30 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:64

35 Xaa Pro Xaa Ala Phe Asn Xaa
5

(66) INFORMATION FOR SEQ ID NO:65

40

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 8 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:65

55 Ile Ala Ser Pro Ile Gln Xaa Glu
5

(67) INFORMATION FOR SEQ ID NO:66

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 7 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:66

15 Gln Arg Pro Leu Leu Ala Lys
5

20 (68) INFORMATION FOR SEQ ID NO:67

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 12 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

30 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:67

35 Phe Phe Ser Pro Ser Ser Asn Ile Pro Thr Asp Arg
5 10

40 (69) INFORMATION FOR SEQ ID NO:68

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 9 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

50 (iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:68

55 Ala Leu Ser Asn Asn Ile Ser Gln Glu
5

110

(70) INFORMATION FOR SEQ ID NO:69

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH 6 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

10 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:69

15

Xaa Xaa Xaa Tyr Thr Pro
5

20 (71) INFORMATION FOR SEQ ID NO:70

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH 16 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

30

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:70

35 Ile Ala Ser Pro Ile Gln Gln Gln Gln Gln Asp Pro Thr Ala Asn
5 10 15
Leu

40

(72) INFORMATION FOR SEQ ID NO:71

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH 6 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

50 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

111

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:71

Thr Met Leu Lys Pro Arg
5

5

(73) INFORMATION FOR SEQ ID NO:72

(i) SEQUENCE CHARACTERISTICS:
10 (A) LENGTH 6 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

15 (ii) MOLECULAR TYPE: Peptide

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

20 (v) SEQUENCE DESCRIPTION FOR SEQ ID NO:72

Ile Ile Glu Asp Glu Ala
5

25

(74) INFORMATION FOR SEQ ID NO:73

(i) SEQUENCE CHARACTERISTICS:
30 (A) LENGTH 11 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

35 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

40 (v) SEQUENCE DESCRIPTION FOR SEQ ID NO:73

Ile Thr Pro His Leu Thr Ala Ser Ala Ala Lys
5 10

45 (75) INFORMATION FOR SEQ ID NO:74

(i) SEQUENCE CHARACTERISTICS:
50 (A) LENGTH 8 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

55 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

112

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:74

Ser Leu Val Ala Pro Ala Pro Glu

5

5

(76) INFORMATION FOR SEQ ID NO:75

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH 12 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

15

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

20 (v) SEQUENCE DESCRIPTION FOR SEQ ID NO:75

Lys Pro Gln Asp Leu Asp Asp Asp Pro Leu Tyr Leu

5

10

25

(77) INFORMATION FOR SEQ ID NO:76

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH 6

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

35 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

40 (v) SEQUENCE DESCRIPTION FOR SEQ ID NO:76

Lys Tyr Ala Leu Leu Arg

5

45 (78) INFORMATION FOR SEQ ID NO:77

(i) SEQUENCE CHARACTERISTICS:

50 (A) LENGTH 11 amino acids

(B) TYPE: Amino acid

(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

55 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

113

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:77

Gln Leu Gly Asn Tyr Xaa Phe Tyr Pro Val Tyr
5 10

5

(79) INFORMATION FOR SEQ ID NO:78

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH 8 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

15

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

20

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:78

Ala Phe Glu Asp His Ser Trp Lys
5

25

(80) INFORMATION FOR SEQ ID NO:79

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH 16 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

35

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

40

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:79

Ala Gly His Ala Ile Val Tyr Gly Asp Ala Thr Ser Thr Tyr Ala
5 10 15
Lys

45

(81) INFORMATION FOR SEQ ID NO:80

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH 9 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

55

114

(iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

5 (v) SEQUENCE DESCRIPTION FOR SEQ ID NO:80

Glu Arg Leu Pro Gly Ser Tyr Tyr Lys
5

10

(82) INFORMATION FOR SEQ ID NO:81

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH 7 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Peptide

20 (iii) HYPOTHETICAL: No

(iv) FRAGMENT TYPE: N-terminal

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:81

25

Thr Leu Met Glu Asp Tyr Gln
5

30

(83) INFORMATION FOR SEQ ID NO:82

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH 1098 amino acids
(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULAR TYPE: Polypeptide

40 (iii) HYPOTHETICAL: Yes

(v) SEQUENCE DESCRIPTION FOR SEQ ID NO:82

45	Met	Ala	Leu	Ile	Val	Ala	Ser	Leu	Phe	Leu	Pro	Tyr	Gln	Pro	Gln
				5						10					15
	Phe	Glu	Leu	Asp	Thr	Ser	Leu	Pro	Glu	Asn	Ser	Gln	Val	Asp	Ser
				20						25					30
	Ser	Leu	Val	Asn	Ile	Gln	Ala	Met	Ala	Asn	Asp	Gln	Gln	Gln	Gln
50				35						40					45
	Arg	Ala	Leu	Ser	Asn	Asn	Ile	Ser	Gln	Glu	Ser	Leu	Val	Ala	Pro
				50						55					60
	Ala	Pro	Glu	Gln	Gly	Val	Pro	Pro	Ala	Ile	Ser	Arg	Ser	Ala	Thr
				65						70					75
55	Arg	Ser	Pro	Ser	Ala	Phe	Asn	Arg	Ala	Ser	Ser	Thr	Thr	Asn	Thr
				80						85					90

115

	Ala	Thr	Leu	Asp	Asp	Leu	Val	Ser	Ser	Asp	Ile	Phe	Met	Glu	Asn	
				95						100						105
	Leu	Thr	Ala	Asn	Ala	Thr	Thr	Ser	His	Thr	Pro	Thr	Ser	Lys	Thr	
				110						115						120
5	Met	Leu	Lys	Pro	Arg	Lys	Asn	Gly	Ser	Val	Glu	Arg	Phe	Phe	Ser	
				125						130						135
	Pro	Ser	Ser	Asn	Ile	Pro	Thr	Asp	Arg	Ile	Ala	Ser	Pro	Ile	Gln	
				140						145						150
	His	Glu	His	Asp	Ser	Gly	Ser	Arg	Ile	Ala	Ser	Pro	Ile	Gln	Gln	
10				155						160						165
	Gln	Gln	Gln	Asp	Pro	Thr	Thr	Asn	Leu	Leu	Lys	Asn	Val	Asn	Lys	
				170						175						180
	Ser	Leu	Leu	Val	His	Ser	Leu	Leu	Asn	Asn	Thr	Ser	Gln	Thr	Ser	
				185						190						195
15	Leu	Glu	Gly	Pro	Asn	Asn	His	Ile	Val	Thr	Pro	Lys	Ser	Arg	Ala	
				200						205						210
	Gly	Asn	Arg	Pro	Thr	Ser	Ala	Ala	Thr	Ser	Leu	Val	Asn	Arg	Thr	
				215						220						225
	Lys	Gln	Gly	Ser	Ala	Ser	Ser	Gly	Ser	Ser	Gly	Ser	Ser	Ala	Pro	
20				230						235						240
	Pro	Ser	Ile	Lys	Arg	Ile	Thr	Pro	His	Leu	Thr	Ala	Ser	Ala	Ala	
				245						250						255
	Lys	Gln	Arg	Pro	Leu	Leu	Ala	Lys	Gln	Pro	Ser	Asn	Leu	Lys	Tyr	
				260						265						270
25	Ser	Glu	Leu	Ala	Asp	Ile	Ser	Ser	Ser	Glu	Thr	Ser	Ser	Gln	His	
				275						280						285
	Asn	Glu	Ser	Asp	Pro	Asp	Asp	Leu	Thr	Thr	Ala	Pro	Asp	Glu	Glu	
				290						295						300
	Tyr	Val	Ser	Asp	Leu	Glu	Met	Asp	Asp	Ala	Lys	Gln	Asp	Tyr	Lys	
30				305						310						315
	Val	Pro	Lys	Phe	Gly	Gly	Tyr	Ser	Asn	Lys	Ser	Lys	Leu	Lys	Lys	
				320						325						330
	Tyr	Ala	Leu	Leu	Arg	Ser	Ser	Gln	Glu	Leu	Phe	Ser	Arg	Leu	Pro	
				335						340						345
35	Trp	Ser	Ile	Val	Pro	Ser	Ile	Lys	Gly	Asn	Gly	Ala	Met	Lys	Asn	
				350						355						360
	Ala	Ile	Asn	Thr	Ala	Val	Leu	Glu	Asn	Ile	Ile	Pro	His	Arg	His	
				365						370						375
	Val	Lys	Trp	Val	Gly	Thr	Val	Gly	Ile	Pro	Thr	Asp	Glu	Ile	Pro	
40				380						385						390
	Glu	Asn	Ile	Leu	Ala	Asn	Ile	Ser	Asp	Ser	Leu	Lys	Asp	Lys	Tyr	
				395						400						405
	Asp	Ser	Tyr	Pro	Val	Leu	Thr	Asp	Asp	Asp	Thr	Phe	Lys	Ala	Ala	
				410						415						420
45	Tyr	Lys	Asn	Tyr	Cys	Lys	Gln	Ile	Leu	Trp	Pro	Thr	Leu	His	Tyr	
				425						430						435
	Gln	Ile	Pro	Asp	Asn	Pro	Asn	Ser	Lys	Ala	Phe	Glu	Asp	His	Ser	
				440						445						450
	Trp	Lys	Phe	Tyr	Arg	Asn	Leu	Asn	Gln	Arg	Phe	Ala	Asp	Ala	Ile	
50				455						460						465
	Val	Lys	Ile	Tyr	Lys	Lys	Gly	Asp	Thr	Ile	Trp	Ile	His	Asp	Tyr	
				470						475						480
	His	Leu	Met	Leu	Val	Pro	Gln	Met	Val	Arg	Asp	Val	Leu	Pro	Phe	
				485						490						495
55	Ala	Lys	Ile	Gly	Phe	Thr	Leu	His	Val	Ser	Phe	Pro	Ser	Ser	Glu	
				500						505						510

	Val	Phe	Arg	Cys	Leu	Ala	Gln	Arg	Glu	Lys	Ile	Leu	Glu	Gly	Leu	
					515					520						525
	Thr	Gly	Ala	Asp	Phe	Val	Gly	Phe	Gln	Thr	Arg	Glu	Tyr	Ala	Arg	
					530					535						540
5	His	Phe	Leu	Gln	Thr	Ser	Asn	Arg	Leu	Leu	Met	Ala	Asp	Val	Val	
					545					550						555
	His	Asp	Glu	Glu	Leu	Lys	Tyr	Asn	Gly	Arg	Val	Val	Ser	Val	Arg	
					560					565						570
10	Phe	Thr	Pro	Val	Gly	Ile	Asp	Ala	Phe	Asp	Leu	Gln	Ser	Gln	Leu	
					575					580						585
	Lys	Asp	Gly	Ser	Val	Met	Gln	Trp	Arg	Gln	Leu	Ile	Arg	Glu	Arg	
					590					595						600
	Trp	Gln	Gly	Lys	Lys	Leu	Ile	Val	Cys	Arg	Asp	Gln	Phe	Asp	Arg	
					605					610						615
15	Ile	Arg	Gly	Ile	His	Lys	Lys	Leu	Leu	Ala	Tyr	Glu	Lys	Phe	Leu	
					620					625						630
	Val	Glu	Asn	Pro	Glu	Tyr	Val	Glu	Lys	Ser	Thr	Leu	Ile	Gln	Ile	
					635					640						645
20	Cys	Ile	Gly	Ser	Ser	Lys	Asp	Val	Glu	Leu	Glu	Arg	Gln	Ile	Met	
					650					655						660
	Ile	Val	Val	Asp	Arg	Ile	Asn	Ser	Leu	Ser	Thr	Asn	Ile	Ser	Ile	
					665					670						675
	Ser	Gln	Pro	Val	Val	Phe	Leu	His	Gln	Asp	Leu	Asp	Phe	Ser	Gln	
					680					685						690
25	Tyr	Leu	Ala	Leu	Ser	Ser	Glu	Ala	Asp	Leu	Phe	Val	Val	Ser	Ser	
					695					700						705
	Leu	Arg	Glu	Gly	Met	Asn	Leu	Thr	Cys	His	Glu	Phe	Ile	Val	Cys	
					710					715						720
30	Ser	Glu	Asp	Lys	Asn	Ala	Pro	Leu	Leu	Leu	Ser	Glu	Phe	Thr	Gly	
					725					730						735
	Ser	Ala	Ser	Leu	Leu	Asn	Asp	Gly	Ala	Ile	Ile	Ile	Asn	Pro	Trp	
					740					745						750
	Asp	Thr	Lys	Asn	Phe	Ser	Gln	Ala	Ile	Leu	Lys	Gly	Leu	Glu	Met	
					755					760						765
35	Pro	Phe	Asp	Lys	Arg	Arg	Pro	Gln	Trp	Lys	Lys	Leu	Met	Lys	Asp	
					770					775						780
	Ile	Ile	Asn	Asn	Ser	Thr	Asn	Trp	Ile	Lys	Thr	Ser	Leu	Gln		
					785					790						795
40	Asp	Ile	His	Ile	Ser	Trp	Gln	Phe	Asn	Gln	Glu	Gly	Ser	Lys	Ile	
					800					805						810
	Phe	Lys	Leu	Asn	Thr	Lys	Thr	Leu	Met	Glu	Asp	Tyr	Gln	Ser	Ser	
					815					820						825
	Lys	Lys	Arg	Met	Phe	Val	Phe	Asn	Ile	Ala	Glu	Pro	Pro	Ser	Ser	
					830					835						840
45	Arg	Met	Ile	Ser	Ile	Leu	Asn	Asp	Met	Thr	Ser	Lys	Gly	Asn	Ile	
					845					850						855
	Val	Tyr	Ile	Met	Asn	Ser	Phe	Pro	Lys	Pro	Ile	Leu	Glu	Asn	Leu	
					860					865						870
50	Tyr	Ser	Arg	Val	Gln	Asn	Ile	Gly	Leu	Ile	Ala	Glu	Asn	Gly	Ala	
					875					880						885
	Tyr	Val	Ser	Leu	Asn	Gly	Val	Trp	Tyr	Asn	Ile	Val	Asp	Gln	Val	
					890					895						900
	Asp	Trp	Arg	Asn	Asp	Val	Ala	Lys	Ile	Leu	Glu	Asp	Lys	Val	Glu	
					905					910						915
55	Arg	Leu	Pro	Gly	Ser	Tyr	Tyr	Lys	Ile	Asn	Glu	Ser	Met	Ile	Lys	
					920					925						930

117

	Phe	His	Thr	Glu	Asn	Ala	Glu	Asp	Gln	Asp	Arg	Val	Ala	Ser	Val	
					935					940					945	
	Ile	Gly	Asp	Ala	Ile	Thr	His	Ile	Asn	Thr	Val	Phe	Asp	His	Arg	
					950					955					960	
5	Gly	Ile	His	Ala	Tyr	Val	Tyr	Lys	Asn	Val	Val	Ser	Val	Gln	Gln	
					965					970					975	
	Val	Gly	Leu	Ser	Leu	Ser	Ala	Ala	Gln	Phe	Leu	Phe	Arg	Phe	Tyr	
					980					985					990	
	Asn	Ser	Ala	Ser	Asp	Pro	Leu	Asp	Thr	Ser	Ser	Gly	Gln	Ile	Thr	
10					995					1000					1005	
	Asn	Ile	Gln	Thr	Pro	Ser	Gln	Gln	Asn	Pro	Ser	Asp	Gln	Glu	Gln	
					1010					1015					1020	
	Gln	Pro	Pro	Ala	Ser	Pro	Thr	Val	Ser	Met	Asn	His	Ile	Asp	Phe	
					1025					1030					1035	
15	Ala	Cys	Val	Ser	Gly	Ser	Ser	Ser	Pro	Val	Leu	Glu	Pro	Leu	Phe	
					1040					1045					1050	
	Lys	Leu	Val	Asn	Asp	Glu	Ala	Ser	Glu	Gly	Gln	Val	Lys	Ala	Gly	
					1055					1060					1065	
	His	Ala	Ile	Val	Tyr	Gly	Asp	Ala	Thr	Ser	Thr	Tyr	Ala	Lys	Glu	
20					1070					1075					1080	
	His	Val	Asn	Gly	Leu	Asn	Glu	Leu	Phe	Thr	Ile	Ile	Ser	Arg	Ile	
					1085					1090					1095	
	Ile	Glu	Asp													
					1098											

25

(84) INFORMATION FOR SEQ ID NO:83

(i) SEQUENCE CHARACTERISTICS

30

(A) LENGTH 5981 basepairs

(B) TYPE: Nucleotide

(C) STRANDEDNESS: Doublestranded

(D) TOPOLOGY: Linear

35

(ii) MOLECULAR TYPE: Genomic DNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

40

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Saccharomyces cerevisiae

(B) STRAIN: S288C

(C) HAPLOTYPE: Haploid

45

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: Genomic

(B) CLONES: 6 and 10

50

(viii) POSITION IN GENOME

(A) CHROMOSOME: 13

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83

	GGCTCACATT	CCAAAAAGAA	CAGTTCGAAC	GATAAAGCTT	TTCACCGCTG	50
	GTGGTGATAA	CAAGGTTAGG	ATATGGAAGT	TGAACAGAGA	TGAAAACGGA	100
	CAAAATGGGG	GGGTGCGTAA	GATTGAAAGC	CTTGACTTTC	TTGGCTCGTG	150
	ACGCATCACG	AACAGGCCAT	AAATGTAATC	CGATTCAACT	CGAAGGGTGA	200
5	CGTACTGGCG	TCTGCGGGCG	ATGACGGCCA	AGTGCTGCTA	TGGAAGCAAG	250
	AAGAACCAAA	TACACAGCAA	GAATCTGTGG	TCAGACCATT	CGGAATGGAT	300
	GCGGAGACTA	GTGAAGCAGA	CGAGAACAAG	GAGAAATGGG	TTGTGTGGAA	350
	ACGGCTGCGT	GGTGGTAGCG	GTGCTACTGC	GGCGGCAGAG	ATTTACGATC	400
	TAGCGTGGTC	ACCTGATAAC	AGGAACATAG	TGGTGGCATG	TATGGACAAT	450
10	TCGATACGAC	TGTTTCGATGT	TGGAGCTGGG	ATGCTGGTAT	GCGGCCAGTC	500
	GGATCATGGT	CACTACGTCC	AAGGTCTTGC	ATGGGACCCA	TTAAATCAGT	550
	TTATTCTCTC	ACAGTCTGCG	GACCGGTCTC	TGCATGTATA	TGGAGTCATT	600
	CTTTCATCTG	CAGGACTTAG	TTACAGGGCT	TGAAACTTTA	GAAGTAAGGT	650
	TGCCAAGGCA	GAAGTGCCTT	GTCCAGGTGA	TGTCCTGAGG	ACAAATTACT	700
15	TTTTCACAAC	GAGACGCTAC	CTTCATTCTT	TAGGCGATGC	AGCATATCGC	750
	CTTGTGGTGG	TTTGGTCGTA	ATTCCCAGTG	GTGTGTATAA	GGTGGCTGGT	800
	GATGAAGTCG	CGAACTGCGT	ATACGTGTAT	ACTAGATCTG	GAATACTGAA	850
	CAGCGCTGGT	GGCGTTAAAA	ACCGGCCTGC	GATTAGAATC	CCATCTTTGA	900
	AGAAACCAGC	GCTGATGGCG	GCTTCTCTCG	CCGTATTTTA	CGAAACGTGC	950
20	CAGAAGAGTG	TGCTTAAGCT	GCCCTATAAG	CTAGTATTTG	CCATAGCAAC	1000
	GAATAACGAA	GTAATCGTGT	ACGACACGGA	TGTATTGGAG	CCGTTATGCG	1050
	TTGTGGGAAA	TATACATTAC	TCACCCATAA	CTGATTTAGC	ATGGTCTGAG	1100
	GATGGCTCGA	CCCTACTAAT	CTCATCAACA	GACGGATTCT	GTTTCGTATGT	1150
	ATCGATCGAC	ACAGAAACGC	AATTCGGTTC	AAGGATAGAG	CCGCCAGCGA	1200
25	TGCATGCAGA	GCCACTAGAC	ACTGACGAGA	GCGCGGTAGC	GGCTAAGAAC	1250
	CAGCGCGAGG	CAGGTGGGAT	CGTGAACATG	CTGCCGGTGA	AGAAGATCCC	1300
	CTGCAATAGT	AGCGATAGTA	AAAAGAGGCG	CATACATCCT	ACGCCAGTCG	1350
	ATTTGTGATT	TTTAATATAT	TTAATGCGGT	ACATAAGAAT	GCCTAATCTA	1400
	GTTTGCCAGC	GAAGATATTT	TCCATTGTGT	GCTCAATGGA	CCCTGTGTTT	1450
30	CTGAGATCTT	GCACGACTTT	TTCCTGAGGC	ACATGTGGCG	CCATCGTCAT	1500
	CACGATTTCA	ACCATGTCAC	TATTAACGGC	TCTCTTTCGA	TCACTACCAT	1550
	GTCTGTTTAA	CCGAGCAACG	CGTTCCTCCG	GAGCCGATGG	TACTGGCTCC	1600
	GGAGAAGGGT	CGTTGGTGGC	GACCGGAGGC	GCCGGTTTGG	CATCCTGTAC	1650
	GGTCCGCAAG	GGTACTTGCT	TGGCGCCCTT	GTGTTTCACG	GTGTAAACAA	1700
35	ACAAGCACAC	CATCGTCAGT	ATAAAGCACT	ATAGTCGAAC	CATCCATTTT	1750
	TACTTTTGTG	CGCGTGGGTA	GCCGTGCCCT	GTCTGTGTGT	GTGGGAATGT	1800
	ATAAATGTGT	CCCGAGTTAT	TATTCTAAAG	CGGGCACCAT	TGTAGTAACT	1850
	TATTGCGAAA	TTTCTGCTCT	TCTCGTCTCG	CTCAAAAATC	GCGTTCAGGG	1900
	TAAAAGGGGC	GAAACAGAGG	GCCAGATAGA	AATTTTCGAGA	AAACGGGTCA	1950
40	CCCCGCCCCC	GCATTTTGAT	ATGGCGTATT	TGGGATTGCT	TGCTCGAAAG	2000
	TGTCTAAGTC	CGGCTGGCGG	GCCTGGCGCC	CTCGCCGAAG	GGAGATAGGA	2050
	AGGGGCGGGG	GTCCGGGCGC	CGGCTATGGT	GTCAGTTACC	TAGGGAAGGA	2100
	GAAGGGGGTA	GAACCAAGGG	GCTAGCACAC	TCACCCTGGG	GCCCCCGTCT	2150
	AGCCAAGCTT	AAATATAAAT	ACTAATGTAA	CTATAAATAT	AAGGATCTAC	2200
45	CGTGTCATTG	CACATCCACC	CACCCGTCTGA	TTAAAAAACC	AAACAAAGCA	2250
	AAGAATACAA	TAGCAACGCA	AGATCAACAC	AATGGCTCTC	ATCGTGGCAT	2300
	CTTTGTTTTT	GCCCTACCAA	CCACAATTCG	AGCTTGACAC	CTCTCTCCCT	2350
	GAGAACTCGC	AGGTGGACTC	ATCTCTCGTG	AACATCCAGG	CTATGGCCAA	2400
	TGACCAACAG	CAACAACGTG	CGCTTTCTAA	CAACATCTCA	CAGGAATCAT	2450
50	TGGTCGCGCC	AGCACCAGAA	CAAGGTGTCC	CCCCAGCAAT	CTCAAGGAGT	2500
	GCCACCAGGT	CACCCAGTGC	TTTCAACCGC	GCCTCGTCTA	CGACAAATAC	2550
	TGCCACTTTA	GATGATCTTG	TCTCTTCGGA	CATATTCATG	GAAAACTTGA	2600
	CTGCGAATGC	AACTACCTCA	CATACGCCAA	CAAGCAAGAC	TATGCTTAAA	2650
	CCCCGAAAAA	ATGGTTCCGT	GGAACGATTC	TTCTCCCCTT	CTTCCAATAT	2700
55	TCCCACGGAT	CGCATCGCAT	CGCCAATCCA	GCATGAGCAT	GACTCCGGTT	2750
	CGAGAATTGC	TTCGCCAATC	CAACAGCAAC	AGCAGGACCC	CACGACCAAC	2800

	TTATTAAGA	ACGTCAACAA	GTCATTGTTA	GTGCACTCAC	TGTTGAACAA	2850
	CACCTCACAA	ACTAGCCTAG	AAGGACCCAA	CAACCACATT	GTTACCCCGA	2900
	AATCGAGGGC	GGGCAACAGG	CCTACTTCGG	CGGCTACTTC	TTTAGTTAAT	2950
	AGGACCAAAC	AAGGTTCCGG	CTCCTCTGGA	TCTTCTGGGT	CTTCTGCGCC	3000
5	ACCTTCCATT	AAAAGGATTA	CGCCCCACTT	GACTGCGTCT	GCTGCAAAAC	3050
	AGCGTCCCTT	ATTGGCTAAA	CAGCCTTCTA	ATCTGAAATA	TTCGGAGTTA	3100
	GCAGATATTT	CGTCGAGTGA	GACGTCTTCG	CAGCATAATG	AGTCGGACCC	3150
	GGATGATCTA	ACTACTGCCC	CTGACGAGGA	ATATGTTTCT	GATTTGGAAA	3200
	TGGATGACGC	GAAGCAGGAC	TACAAGGTTT	CAAAGTTCGG	CGGCTATTCC	3250
10	AATAAATCTA	AACTTAAGAA	ATATGCGCTG	TTAAGGTCAT	CTCAGGAGCT	3300
	GTTTAGCCGT	CTTCCATGGT	CGATCGTTCC	CTCTATCAAA	GGTAATGGCG	3350
	CCATGAAGAA	CGCCATAAAC	ACTGCAGTCT	TGGAGAATAT	CATTCCGCAC	3400
	CGTCATGTTA	AGTGGGTCGG	TACCGTCGGA	ATCCCAACGG	ATGAGATTCC	3450
	GGAAAATATC	CTTGCGAACA	TCTCTGACTC	TTTAAAAGAC	AAGTACGACT	3500
15	CCTATCCTGT	CCTTACGGAC	GACGACACCT	TCAAAGCCGC	ATACAAAAAC	3550
	TACTGTAAAC	AAATCTTGTG	GCCTACGCTG	CATTACCAGA	TTCCAGACAA	3600
	TCCGAACCTG	AAGGCTTTTG	AAGATCACTC	TTGGAAGTTC	TATAGAAACT	3650
	TAAACCAAAG	GTTTGCGGAC	GCGATCGTTA	AAATCTATAA	GAAAGGTGAC	3700
	ACCATCTGGA	TTCATGATTA	CCATTTAATG	CTGGTTCGCG	AGATGGTGAG	3750
20	AGACGTCTTG	CCTTTTGCCA	AAATAGGATT	TACCTTACAT	GTCTCGTTCC	3800
	CCAGTAGTGA	AGTGTTTAGG	TGTCTGGCTC	AGCGTGAGAA	GATCTTAGAA	3850
	GGCTTGACCG	GTGCAGACTT	TGTCGGCTTC	CAGACGAGGG	AGTATGCAAG	3900
	ACATTTCTTA	CAGACGTCTA	ACCGTCTGCT	AATGGCGGAC	GTGGTACATG	3950
25	ATGAAGAGCT	AAAGTATAAC	GGCAGAGTCG	TTTCTGTGAG	GTTCAACCCA	4000
	GTTGGTATCG	ACGCCTTTGA	TTTGCAATCG	CAATTGAAGG	ATGGAAGTGT	4050
	CTGCAATGG	CGTCAATTGA	TTCGTGAAAG	ATGGCAAGGG	AAAAAACTAA	4100
	TTGTGTGTCG	TGATCAATTG	GATAGAATTA	GAGGTATTCA	CAAGAAATTG	4150
	TTGGCTTATG	AAAAATTCTT	GGTCGAAAAA	CCGGAATACG	TGGAAAAATC	4200
	GACTTTAATT	CAAAATCTGT	TTGGAAGCAG	TAAGGATGTA	GAAGTGGAGC	4250
30	GCCAGATCAT	GATTGTCTGT	GATAGAATCA	ACTCGCTATC	CACCAATATT	4300
	AGTATTTCTC	AACCTGTGGT	GTTTTTGCAT	CAAGATCTAG	ATTTTCTCTA	4350
	GTATTTAGCT	TTGAGTTCAG	AGGCAGATTT	GTTCTAGTCT	AGCTCTCTAA	4400
	GGGAAGGTAT	GAACCTGACA	TGTCACGAAT	TTATCGTTTG	TTCTGAGGAC	4450
	AAAAATGCTC	CCCTACTGTT	GTCAGAATTT	ACTGGTAGTG	CATCTTTTATT	4500
35	GAATGATGGC	GCTATAATAA	TTAACCCATG	GGATACCAAG	AACTTCTCAC	4550
	AAGCCATTCT	CAAGGGGTTG	GAGATGCCAT	TCGATAAGAG	AAGGCCACAG	4600
	TGGAAGAAAT	TGATGAAAGA	CATTATCAAC	AACGACTCTA	CAAACTGGAT	4650
	CAAGACTTCT	TTACAAGATA	TTCATATTTT	GTGGCAATTC	AATCAAGAAG	4700
	GTTCCAAGAT	CTTCAAATTG	AATACAAAAA	CACTGATGGA	AGATTACCAG	4750
40	TCATCTAAAA	AGCGTATGTT	TGTTTTCAAC	ATTGCTGAAC	CACCTTCATC	4800
	GAGAATGATT	TCCATACTGA	ATGACATGAC	TTCTAAGGGC	AATATCGTTT	4850
	ACATCATGAA	CTCATTTCCA	AAGCCCATTG	TGGAAAATCT	TTACAGTCGT	4900
	GTGCAAAACA	TTGGGTTGAT	TGCCGAGAAT	GGTGCATACG	TTAGTCTGAA	4950
45	CGGTGTATGG	TACAACATTG	TTGATCAAGT	CGATTGGCGT	AACGATGTAG	5000
	CCAAAATTCT	CGAGGACAAA	GTGGAGAGAT	TACCTGGCTC	GTAATAACAAG	5050
	ATAAATGAGT	CCATGATCAA	GTTCCACACT	GAAAATGCGG	AAGATCAAGA	5100
	TCGTGTAGCT	AGTGTTATCG	GTGATGCCAT	CACACATATC	AATACTGTTT	5150
	TTGACCACAG	AGGTATTTCAT	GCCTACGTTT	ACAAAAACGT	TGTTTCCGTA	5200
	CAACAAGTGG	GACTTTCCCT	ATCGGCAGCT	CAATTTCTTT	TCAGATTCTA	5250
50	TAATTCTGCT	TCGGATCCAC	TGGATACGAG	TTCCGGCCAA	ATCACAATAA	5300
	TTCAGACACC	ATCTCAACAA	AATCCTTCAG	ATCAAGAACA	ACAACCTCCA	5350
	GCCTCTCCCA	CTGTGTCGAT	GAACCATATT	GATTTGCGAT	GTGTCTCTGG	5400
	TTCATCGTCT	CCTGTGCTTG	AACCATTGTT	CAAATTGGTC	AATGATGAAG	5450
	CAAGTGAAGG	GCAAGTAAAA	GCCGGACACG	CCATTGTTTA	TGGTGTAGCT	5500
55	ACTTCTACTT	ATGCCAAAGA	ACATGTAAAT	GGGTAAACG	AACTTTTCAC	5550
	GATCATTTCA	AGAATCATTG	AAGATTAAAT	TTTACCATTT	TAAAATTTTA	5600

120

ATGTTCTTGG GTATGAACTT TTATTTTCAA CTGCTTATTA TATATCAATT 5650
 CTATAAATTT TTTTCTTCTC TCTAACGACC AATTATAAAA TTCATCCTCT 5700
 TATTTATTAC AGCATCTTAT ACATTATGTA TATGGGTAGC TATTATTCAT 5750
 TTTTGCTTCG TAAGGACTTT TTTTGTCAAC TTTTTCATCC TAAGCGGCTA 5800
 5 AAAGTGATTG GAGAGGAATG TCCAGGCGAC CAATGATAAA AACGCTTTCT 5850
 CTTGGAACAA GAAATAGGAG CAATTGACAG TTGTCGATGA ACAGCGAAAA 5900
 TAGTAAGATA ACCTTCAAGC CCAATATTCT AATTAAAGGC GTTTATATAT 5950
 TTGTACTTTA TGGTATGTGC ATATGTATTG T 5981

10

(85) INFORMATION FOR SEQ ID NO:84

(i) SEQUENCE CHARACTERISTICS

- 15 (A) LENGTH50 base pairs
 (B) TYPE: Nucleotide
 (C) STRANDEDNESS: Doublestranded
 (D) TOPOLOGY: Linear

20 (ii) MOLECULAR TYPE: Synthetic DNA

(iii) HYPOTHETICAL: No

(iv) ANTISENSE: No

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84

CGGGAAGACA TAGAACTATG ACTACGGATA ACGCTAAGGC GCAACTGACC 50

30

(86) INFORMATION FOR SEQ ID NO:85

(i) SEQUENCE CHARACTERISTICS

- 35 (A) LENGTH48 basepairs
 (B) TYPE: Nucleotide
 (C) STRANDEDNESS: Doublestranded
 (D) TOPOLOGY: Linear

40 (ii) MOLECULAR TYPE: Synthetic DNA

(iii) HYPOTHETICAL: No

(iv) ANTISENSE: No

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85


GGGCCCAACA ACACAATGGT TACCCCGAAA TCGAGGGCGG GCAACAGG 48

50

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>25</u> , line <u>16</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DSM-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1 B, D-3300 Braunschweig, Federal Republic of Germany	
Date of deposit 18 February 1992	Accession Number DSM 6928
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC) until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or is deemed to be withdrawn.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	


For receiving Office use only	
<input checked="" type="checkbox"/> This sheet was received with the international application	
Authorized officer 	

For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>25</u> , line <u>28</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution DSM-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1 B, D-3300 Braunschweig, Federal Republic of Germany	
Date of deposit 25 January 1993	Accession Number DSM 7425
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC) until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or is deemed to be withdrawn.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application. Authorized officer 	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
--	--

CLAIMS:

1. Genes, which comprise at least one of the isolated and purified DNA sequences coding for the short chain of about 57 kDa and the long chains of about 99 kDa and about 123 kDa of trehalose synthase and functional equivalents thereof.
2. The genes of claim 1, wherein the isolated and purified DNA sequence encodes the amino acid sequences of the short chain of about 57 kDa having the SEQ ID NO: 2 or functional equivalents thereof.
3. The genes of claim 1 wherein the isolated and purified DNA sequence encodes the amino acid sequences of the long chain of about 123 kDa comprising the SEQ ID NO: 4 or functional equivalents thereof.
4. The genes of claim 1 wherein the isolated and purified DNA sequence encodes the amino acid sequences of the long chain of about 123 kDa comprising the SEQ ID NO: 82 or functional equivalents thereof.
5. The genes of claim 1 wherein the isolated and purified DNA sequence encodes the amino acid sequences of the long chain of about 99 kDa having the SEQ ID NO: 29 - 38 and 44 - 49 or functional equivalents thereof.
6. The genes of claim 1, which are selected from the group consisting of TSS1, TSL1 and TSL2 and functional equivalents thereof.
7. The genes of claim 6, wherein TSS1 comprises the open reading frame of SEQ ID NO: 1 or functional equivalents thereof.
8. The genes of claim 6, wherein TSL1 comprises the open reading frame of SEQ ID NO: 3 or functional equivalents thereof.

9. The genes of claim 6, wherein TSL1 comprises the open reading frame SEQ ID NO: 83 or functional equivalents thereof.
10. The genes of claim 6, wherein TSL2 comprises the DNA sequences inserted into pALK756 (DSM7425) or functional equivalents thereof.
11. A truncated TSL1 gene encoding a truncated form of the 123 kDa long chain of trehalose synthase lacking up to 600 amino acids from one end preferably the N-terminus.
12. The truncated TSL1 gene of claim 11, wherein the long chain lacks up to 330 amino acids from the N-terminus end.
13. The truncated TSL1 gene of claim 11, wherein the long chain lacks 250 - 450 amino acids from the N-terminus end.
14. The truncated TSL1 gene of claim 11, wherein the long chain lacks 250 - 450, preferably about 325 amino acids from the N-terminus end.
15. The truncated TSL1 gene of claim 11, wherein the long chain lacks 209 amino acids from the N-terminus end.
16. A vector which comprises at least one of the genes of claims 1 - 15.
17. A DNA construct which comprises at least one of the genes of claims 1 - 15.
18. Host cells or organisms transformed with at least one of the vectors of claim 16.
19. Host cells or organisms transformed with at least one of DNA constructs of claim 17.
20. Host cells or organisms transformed with the truncated

TSL1 gene of claims 10 - 15.

21. The transformed host cells or organisms of claims 18 or 19, which express a trehalose synthase which exhibits trehalose-6-phosphate synthase activity activatable by fructose-6-phosphate and also trehalose-6-phosphatase activity.

22. The transformed host cells or organisms of claim 20, which express a trehalose synthase that is less inhibited by phosphate than is the intact trehalose synthase.

23. The transformed host cells or organisms of any of claims 18 to 22, which are selected from a group consisting of plants, fungi, yeasts or bacteria.

24. The transformed host cells or organisms of claims 23, wherein the yeast is Saccharomyces cerevisiae.

25. The transformed host cells or organisms of any of claims 18 to 22, wherein parts of the organism have increased trehalose content as compared to the corresponding parts of the parent cell or organism when grown under the same conditions.

26. The transformed host cells or organisms of any of claims 18 to 22, wherein said cells or organisms produce a higher yield of ethanol from carbohydrate than the parent cell or organism.

27. The transformed host cells or organisms of any of claims 18 to 22, wherein said cells or organisms are more resistant to heat, cold and water deprivation than are the parent cell or organism.

28. A trehalose synthase produced by recombinant DNA techniques using at least one of the genes of claims 1 to 15.

29. A substantially purified trehalose synthase, which exhibits trehalose-6-phosphate synthase activity activatable by

fructose-6-phosphate and also trehalose-6-phosphatase activity.

30. A substantially purified trehalose synthase, which exhibits trehalose-synthase activity less sensitive to inhibition by phosphate.

31. The trehalose synthase of claims 28 to 30, which comprises one short chain of about 57 kDa and at least one of two long chains of about 99 kDa and 123 kDa or truncated forms of the 123 kDa chain.

32. The trehalose synthase of claim 31, wherein the short chain comprises the amino acid sequence of SEQ ID NO: 2 or functional equivalents thereof.

33. The trehalose synthase of claim 31, wherein the 123 kDa long chain comprises the amino acid sequence of SEQ ID NO: 4 or functional equivalents thereof.

34. The trehalose synthase of claim 31, wherein the 123 kDa long chain comprises the amino acid sequence of SEQ ID NO: 82 or functional equivalents thereof.

35. The trehalose synthase of claim 31, wherein the 99 kDa long chain comprises a majority, preferably at least ten of the amino acid sequences SEQ ID NO:s 29 to 38 and 44 to 49 or functional equivalents thereof.

36. The trehalose synthase of claim 31, wherein the 99 kDa long chain comprises the amino acid sequences encoded by the DNA sequence inserted into pALK756 (DSM7425) or functional equivalents thereof.

37. A trehalose-6-phosphate synthase, which comprises the 57 kDa polypeptide corresponding to the short chain of claim 31 and having the amino acid sequence of SEQ ID. NO: 2 or functional equivalents thereof.

38. A trehalose-6-phosphate phosphatase, which comprises an about 99 kDa polypeptide corresponding to the long chain of claims 33 - 34.

5 39. A process for producing ethanol by using the host cells or organisms of claims 22 or 23, wherein the yield of ethanol or its rate of production is greater than by using the untransformed cell or organism.

10 40. The process of claim 39, wherein the organism is distiller's yeast.

41. The process of claim 39, wherein at least one of the DNA sequences of claims 1 - 15 are functionally combined with
15 promoters active under fermentative conditions.

42. A process for producing a crop plant which has increased resistance to water deprivation, heat and cold, comprising transforming the plant by introducing at least one of the genes
20 of claims 1 - 15 into said plant's tissue.

43. A process for producing trehalose by cultivating a host or organism which has been transformed with at least one of the genes of claims 1 - 15.

25 44. The process according to claim 43, wherein the transformed host cell or organism is a fungus, yeast or plant.

45. The process according to claim 44, wherein the yeast is
30 Saccharomyces cerevisiae.

46. A process for producing trehalose enriched food products from plants by introducing at least one of the genes of claims 1 - 15 and allowing said genes to express the trehalose
35 synthase in the edible tissues of the plant.

47. The process of claim 46, wherein the trehalose is purified

by conventional methods.

48. The process of claim 46, wherein the trehalose is used as such or as an unpurified homogenate.

5

49. A method for selecting strains which have been transformed with at least one of the genes of claims 1 - 15, wherein the selection medium comprises galactose as the main carbon source.




FIG. 2




FIG. 1

2/26

Promoter

TTGTTGCGAT TGTTCCTGTTT CATCTGCACC AGAACAAAGA ACAAAGAAG -396
AAGGAACAAA GTCCAAGCAC GTCAGCGCTG TTTATAAGGG GATTGACGAG -346
GGATCGGGCC TAGAGTGCCA GCGCGCCAGG GAGAGGGAGC CCCCTGGGCC -296
CTCATCCGCA GGCTGATAGG GGTCA~~CCCCG~~ CTGGGCAGGT CAGGGCAGGG -246
GCTCTCAGGG GGGCGCCATG GACAACTGC ACTGAGGTTT TAAGACACAT -196
GTATTATTGT GAGTATGTAT ATATAGAGAG AGATTAAGGC GTACAGCCGG -146
GTGGTAGAGA TTGATTAACT TGGTAGTCTT ATCTTGTCAA TTGAGTTTCT -96
GTCAGTTTCT TCTTGAACAA GCACGCAGCT AAGTAAGCAA CAAAGCAGGC -46
TAACAAACTA GGTACTCACA TACAGACTTA TTAAGACATA GAACT ATG +3

Terminator

ACC AAA AAC TGA TGA ACCCGATGCA AATGAGACGA TCGTCTATTC +1521
CTGGTCCGGT TTTCTCTGCC CTCTCTTCTA TTCACTTTTT TTATACTTTA +1571
TATAAAATTA TATAAATGAC ATAAGTAAA CGCCACACGT CCTCTCCTAT +1621
TCGTTAACGC CTGTCTGTAG CGCTGTTACT GAAGCTGCGC AAGTAGTTTT +1671
TTCACCGTAT AGGCC +1686

FIG. 3A

3/26

10 20 30
M T T D N A K A Q L T S S S G G N I I V V S N R L P V T I T

40 50 60
K N S S T G Q Y E Y A M S S G G L V T A L E G L K K T Y T F

70 80 90
K W F G W P G L E I P D D E K D Q V R K D L L E K F N A V P

100 110 120
I F L S D E I A D L H Y N G F S N S I L W P L F H Y H P G E

130 140 150
I N F D E N A W F G Y N E A N Q T F T N E I A K T M N H N D

160 170 180
L I W V H D Y H L M L V P E M L R V K I H E K Q L Q N V K V

190 200 210
G W F L H T P F P S S E I Y R I L P V R Q E I L K G V L S C

220 230 240
D L V G F H T Y D Y A R H F L S S V O R V L N V N T L P N G

250 260 270
V E Y Q G R F V N V G A F P I G I D V D K F T D G L K K E S

280 290 300
V Q K R I Q Q L K E T F K G C K I I V G V D R L D Y I K G V

310 320 330
P Q K L H A M E V F L N E H P E W R G K V V L V Q V A V P S

340 350 360
R G D V E E Y Q Y L R S V V N E L V G R I N G Q F G T V E F

370 380 390
V P I H F M H K S I P F E E L I S L Y A V S D V C L V S S T

400 410 420
R D G M N L V S Y E Y I A C Q E E K K G S L I L S E F T G A

430 440 450
A Q S L N G A I I V N P W N T D D L S D A I N E A L T L P D

460 470 480
V K K E V N W E K L Y K Y I S K Y T S A F W G E N F V H E L

490 494
Y S T S S S S T S S S A T K N

FIG. 3B

4/26

Promoter

TGTAGTAACT TATTGCGAAA TTTCTGCTCT TCTCGTCTCG CTCAAAAATC -392
CGGTTTCAGGG TAAAAGGGGC GAAACAGAGG GCCAGATAGA AATTTGAGA -342
AAACGGGTCA CCCC GCCCCT GCATTTTGAT ATGGCGTATT TGGGATTGCT -292
TGCTCGAAAG TGTCTAAGTC CGGCTGGCGG GCCTGGCGCC CTCGCCGAAG -242
GGAGATAGGA AGGGGCGGG GTCCGGGCAG CGGCTATGGT GTCAGTTACC -192
TAGGGAAGGA GAAGGGGTA GAACCAAGGG GCTAGCACAC TCACCCTGGG -142
GCCCCCGTCT AGCCAAGCTT AAATATAAAT ACTAATGTAA CTATAAATAT -92
AAGGATCTAC CGTGTCATTG CACATCCACC CACCCGTCGA TTAAAAAACC -42
AAACAAAGCA AAGAATACAA TAGCAACGCA AGATCAACAC A ATG GCT +6

Terminator

TTC ACG ATC ATT TCA AGA ATC ATT GAA GAT TAA ATTTTACCAT +3307
TTTAAAATTT TAATGTTCTT GGGTATGAAC TTTTATTTTC AACTGCTTAT +3357
TATATATCAA TTCTATAAAT TTTTTTCTTC TCTCTAACGA CCAATTATAA +3407
AATTCATCCT CTTATTTATT ACAGCATCTT ATACATTATG TATATGGGTA +3457
GCTATTATTC ATTTTGTCTT CGTAAGGACT TTTTTTGTCA ACTTTTTCAT +3507
CCTAAGCGGC TAAAAGTGAT TGGAGAGGAA Tgtccaggcg accaatgata +3557
aaaacgcttt ctcttggaac aagaaatagg agcaattgac agttgtcgat +3607

FIG. 4A

10 20 30
 M A L I V A S L F L P Y Q P Q F E L D T S L P E N S Q V D S
 40 50 60
 S L V N I Q A M A N D Q Q Q Q R A L S N N I S Q E S L V A P
 70 80 90
A P E Q G V P P A I S R S A T R S P S A F N R A S S T T N T
 100 110 120
A T L D D L V S S D I F M E N L T A N A T T S H T P T S K T
 130 140 150
M L K P R K N G S V E R F F S P S S N I P T D R I A S P I O
 160 170 180
H E H D S G S R I A S P I O Q Q Q Q O D P T T N L L K N V N K
 190 200 210
S L L V H S L L N N T S O T S L E G P N N H I V T P K S R A
 220 230 240
G N R P T S A A T S L V N R T K Q G S A S S G S S G S S A P
 250 260 270
P S I K R I T P H L T A S A A K Q R P L L A K Q P S N L K Y
 280 290 300
 S E L A D I S S S E T S S Q H N E S D P D D L T T A P D E E
 310 320 330
 Y V S D L E M D D A K Q D Y K V P K F G G Y S N K S K L K K
 340 350 360
Y A L L R S S Q E L F S R L P W S I V P S I K G N G A M K N
 370 380 390
A I N T A V L E N I I P H R H V K W V G T V G I P T D E I P
 400 410 420
E N I L A N I S D S L K D K Y D S Y P V L T D D D T F K A A
 430 440 450
 Y K N Y C K Q I L W P T L H Y O I P D N P N S K A F E D H S
 460 470 480
W K F Y R N L N O R F A D A I V K I Y K K G D T I W I H D Y
 490 500 510
 H L M L V P Q M V R D V L P F A K I G F T L H V S F P S S E
 520 530 540
 V F R C L A Q R E K I L E G L T G A D F V G F O T R E Y A R

FIG. 4B

4/26

Promoter

TGTAGTAACT TATTGCGAAA TTTCTGCTCT TCTCGTCTCG CTCAAAAATC -392
 GCGTTCAGGG TAAAAGGGGC GAAACAGAGG GCCAGATAGA AATTTGAGA -342
 AAACGGGTCA CCCCCTCTGCATTTGAT ATGGCGTATT TGGGATTGCT -292
 TGCTCGAAAG TGTCTAAGTC CGGCTGGCGG GCCTGGCGCC CTCGCCGAAG -242
 GGAGATAGGA AGGGGCGGGG GTCCGGGCAG CGGCTATGGT GTCAGTTACC -192
 TAGGGAAGGA GAAGGGGGTA GAACCAAGGG GCTAGCACAC TCACCCTGGG -142
 GCCCCGTCT AGCCAAGCTT AAATATAAAT ACTAATGTAA CTATAAATAT -92
 AAGGATCTAC CGTGTCATTG CACATCCACC CACCCGTCGA TTAATAAAC -42
 AAACAAAGCA AAGAATACAA TAGCAACGCA AGATCAACAC A ATG GCT +6

Terminator

TTC ACG ATC ATT TCA AGA ATC ATT GAA GAT TAA ATTTTACCAT +3307
 TTTAAAATTT TAATGTTCTT GGGTATGAAC TTTTATTTTC AACTGCTTAT +3357
 TATATATCAA TTCTATAAAT TTTTCTTCTC TCTCTAACGA CCAATTATAA +3407
 AATTCATCCT CTTATTTATT ACAGCATCTT ATACATTATG TATATGGGTA +3457
 GCTATTATTC ATTTTGTCTT CGTAAGGACT TTTTGTGCA ACTTTTTCAT +3507
 CCTAAGCGGC TAAAAGTGAT TGGAGAGGAA TGtccaggcg accaatgata +3557
 aaaacgcttt ctcttggaac aagaaatagg agcaattgac agttgtcgat +3607

FIG. 4A

10 20 30
 M A L I V A S L F L P Y Q P Q F E L D T S L P E N S Q V D S
 40 50 60
 S L V N I Q A M A N D Q Q Q Q R A L S N N I S O E S L V A P
 70 80 90
 A P E Q G V P P A I S R S A T R S P S A F N R A S S T T N T
 100 110 120
 A T L D D L V S S D I F M E N L T A N A T T S H T P T S K T
 130 140 150
 M L K P R K N G S V E R F F S P S S N I P T D R I A S P I Q
 160 170 180
 H E H D S G S R I A S P I O O O O O D P T T N L L K N V N K
 190 200 210
 S L L V H S L L N N T S O T S L E G P N N H I V T P K S R A
 220 230 240
 G N R P T S A A T S L V N R T K Q G S A S S G S S G S S A P
 250 260 270
 P S I K R I T P H L T A S A A K O R P L L A K Q P S N L K Y
 280 290 300
 S E L A D I S S S E T S S Q H N E S D P D D L T T A P D E E
 310 320 330
 Y V S D L E M D D A K Q D Y K V P K F G G Y S N K S K L K K
 340 350 360
 Y A L L R S S Q E L F S R L P W S I V P S I K G N G A M K N
 370 380 390
 A I N T A V L E N I I P H R H V K W V G T V G I P T D E I P
 400 410 420
 E N I L A N I S D S L K D K Y D S Y P V L T D D D T F K A A
 430 440 450
 Y K N Y C K Q I L W P T L H Y O I P D N P N S K A F E D H S
 460 470 480
 W K F Y R N L N O R F A D A I V K I Y K K G D T I W I H D Y
 490 500 510
 H L M L V P Q M V R D V L P F A K I G F T L H V S F P S S E
 520 530 540
 V F R C L A Q R E K I L E G L T G A D F V G F O T R E Y A R

FIG. 4B

550 560 570
H F L Q T S N R L L M A D V V H D E E L K Y N G R V V S V R

580 590 600
F T P V G I D A F D L Q S Q L K D G S V M Q W R Q L I R E R

610 620 630
W Q G K K L I V C R D Q F D R I R G I H K K L L A Y E K F L

640 650 660
V E N P E Y V E K S T L I Q I C I G S S K D V E L E R Q I M

670 680 690
I V V D R I N S L S T N I S I S Q P V V F L H Q D L D F S Q

700 710 720
Y L A L S S E A D L F V V S S L R E G M N L T C H E F I V C

730 740 750
S E D K N A P L L L S E F T G S A S L L N D G A I I I N P W

760 770 780
D T K N F S Q A I L K G L E M P F D K R R P O W K K L M K D

790 800 810
I I N N D S T N W I K T S L Q D I H I S W Q F N Q E G S K I

820 830 840
F K L N T K T L M E D Y O S S K K R M F V F N I A E P P S S

850 860 870
R M I S I L N D M T S K G N I V Y I M N S F P K P I L E N L

880 890 900
Y S R V Q N I G L I A E N G A Y V S L N G V W Y N I V D Q V

910 920 930
D W R N D V A K I L E D K V E R L P G S Y Y K I N E S M I K

940 950 960
F H T E N A E D O D R V A S V I G D A I T H I N T V F D H R

970 980 990
G I H A Y V Y K N V V S V Q Q V G L S L S A A Q F L F R F Y

1000 1010 1020
N S A S D P L D T S S G Q I T N I Q T P S Q Q N P S D Q E Q

1030 1040 1050
Q P P A S P T V S M N H I D F A C V S G S S S P V L E P L F

1060 1070 1080
K L V N D E A S E G O V K A G H A I V Y G D A T S T Y A K E

1090 1098
H V N G L N E L F T I I S R I I E D

FIG. 4C

1	M T T D N	A K A Q	L T S S S G G N I I
320	G G Y S N K S K L K	K Y A L L R S S Q E	
20	V V S N R L P V T I	T K N S S T G Q Y E	
340	L F S R L P W S I	V P S I K G N	
40	Y A M S S G G L V T	A L E G L K K T Y	
356	G A M K N A I N T	A V L E N I I P H R	
59	T F K W F G W	P G L E I P D D E K	
375	H V K W V G T V G I	P T D E I P E N I L	
76	D Q V R K D L L E K	F N A V P I F L S D	
395	A N I S D S L K D K	Y D S Y P V L T D D	
96	E I A D L H Y N G F	S N S I L W P L F H	
415	D T F K A A Y K N Y	C K Q I L W P T L H	
116	Y H P G E I N	F D E N A W F G Y	
435	Y Q I P D N P N S K	A F E D H S W K F Y	
132	N E A N Q T F T N E	I A K T M N H N D L	
455	R N L N Q R F A D A	I V K I Y K K G D T	
152	I W V H D Y H L M L	V P E M L R V K I H	
475	I W I H D Y H L M L	V P Q M V R	
172	E K Q L Q N V K V G	W F L H T P F P S S	
491	D V L P F A K I G	F T L H V S F P S S	

FIG. 5A

192	E I Y R I L P V R Q	E I L K G V L S C D
	: : : :	: : : :
510	E V F R C L A Q R E	K I L E G L T G A D
	: : : :	: : : :
212	L V G F H T Y D Y A	R H F L S S V Q R V
	: : : :	: : : :
530	F V G F Q T R E Y A	R H F L Q T S N R L
	: : : :	: : : :
232	L N V N T L P N G	V E Y Q G R F V N V
	: : : :	: : : :
550	L M A D V V H D E E	L K Y N G R V V S V
	: : : :	: : : :
251	G A F P I G I D V D	K F T D G L K K E S
	: : : :	: : : :
570	R F T P V G I D A F	D L Q S Q L K D G S
	: : : :	: : : :
271	V Q K R I Q Q L K	E T F K G C K I I V
	: : : :	: : : :
590	V M Q W R Q L I R	E R W Q G K K L I V
	: : : :	: : : :
290	G V D R L D Y I K G	V P Q K L H A M E V
	: : : :	: : : :
609	C R D Q F D R I R G	I H K K L L A Y E K
	: : : :	: : : :
310	F L N E H P E W R G	K V V L V Q V A V P
	: : : :	: : : :
629	F L V E N P E Y V E	K S T L I Q I C I G
	: : : :	: : : :
330	S R G D V E E Y Q	Y L R S V V N E L V
	: : : :	: : : :
649	S S K D V E L E R Q	I M I V V
	: : : :	: : : :
349	G R I N G Q F G T	V E F V P I H F M H
	: : : :	: : : :
664	D R I N S L S T N I	S I S Q P V V F L H
	: : : :	: : : :
368	K S I P F E E L I S	L Y A V S D V C L V
	: : : :	: : : :
629	Q D L D F S Q Y L A	L S S E A D L F V V
	: : : :	: : : :

FIG. 5B

```

388      S S T R D G M N L V   S Y E Y I A C Q E E
      | | | | : | | | |
684      S S L R E G M N L T   C H E F I V C S E D
      | | | | : | | | |

408      K K G S L I L S E F   T G A A Q S L N   G
      | | | | : | | | |
724      K N A P L L L S E F   T G S A S L L N D G
      | | | | : | | | |

427      A I I V N P W N T D   D L S D A I N E A L
      | | | | : | | | |
744      A I I I N P W D T K   N F S Q A I L K G L
      | | | | : | | | |

447      T L P D V K K E V N   W E K L Y K Y I S K
      : | | | : | |
764      E M P F D K R R P Q   W K K L M K D I I N
      | | | | : | | | |

467      Y T S A F W   G E N   F V H E L Y S T S S
      | | | | : | | | |
784      N D S T N W I K T S   L Q D I H I S W Q F
      | | | | : | | | |

486      S S T S S S A T K   N
      | | | | : | |
804      N Q E G S K I F K L   N
      | | | | : | |

```

Length = 511 Identities = 188 Gaps = 32

Identities/Length = 36.8 %

FIG. 5C

TSL1




FIG. 6A

TSS1




FIG. 6B




FIG. 7

12/26




FIG. 8




FIG. 10




FIG. 9





FIG. 11

FIG. 12








FIG. 13


17/26



18/26



19/26



20/26




FIG. 17

21/26




FIG. 18

22/26




FIG. 19A




FIG. 19B

23/26




FIG. 20A

24/26




FIG. 20B

25/26




FIG. 20C




FIG. 21